


































Submitted in partial fulfillment of the 
requirements for the degree of 
Doctor of Philosophy 
under the Executive Committee 





















































All rights reserved  
ABSTRACT 
Heterogeneity and Context-Specificity in Biological Systems 
Oren Litvin 
 
High throughput technologies and statistical analyses have transformed the way biological 
research is performed. These technologies accomplish tasks that were labeled as science fiction 
only 20 years ago – identifying millions of genetic variations in a genome, a chip that measures 
expression levels of all genes, quantifying the concentration of dozens of proteins at a single cell 
resolution. High-throughput genome-wide approaches allowed us, for the first time, to perform 
unbiased research that doesn’t depend on existing knowledge. Thanks to these new 
technologies, we now have a much better understanding on what goes awry in cancer, what are 
the genetic predispositions for numerous diseases, and how to select the best available treatment 
for each patient based on his/her genetic and genomic features.  
 
The emergence of new technologies, however, also introduced many new problems that need 
to be addressed in order to fully exploit the information within the data. Tasks start with data 
normalization and artifact identification, continue with how to properly model the data using 
statistical tools, and end with the suitable ways to translate those statistical results into 
informative and correct biological insights. A new field – computational biology – was emerged to 
address those problems and bridge the gap between statistics and biology.   
 
Here I present 3 studies on computational modeling of heterogeneity and context-specificity in 
biological systems. My work focused on the identification of genomic features that can predict or 
explain a phenotype. In my studies of both yeast and cancer, I found vast heterogeneity between 
individuals that hampers the prediction power of many statistical models. I developed novel 
computational models that account for the heterogeneity and discovered that, in most cases, the 
relationship between the genomic feature and the phenotype is context-specific – genomic 
features explain, predict or exert influence on the phenotype in only a subset of cases.  
In the first project I studied the landscape of genetic interactions in yeast using gene 
expression data. I found that roughly 80% of interactions are context-specific, where genetic 
mutations influence expression levels only in the context of other mutations. In the second project 
I used gene expression and copy number data to identify drivers of oncogenesis. By using gene 
expression as a phenotype, and by accounting for context-specificity, I identified two novel copy 
number drivers that were validated experimentally. In the third project I studied the transcriptional 
and phenotypic effects of MAPK pathway inhibition in melanoma. I show that most MAPK targets 
are context-specific – under the control of the pathway only in a subset of cell lines. A 
computational model I designed to detect context-specific interactions of the MAPK pathway 
identified the interferon pathway as a major player in the cytotoxic response of MAPK inhibition.  
 
Taken together, my research demonstrates the importance of context-specificity in the 
analysis of biological systems. Context-specific computational modeling, combined with high-
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Biological systems are of vast complexity, with tens of thousands of molecules participating in 
a large network to determine the behavior, response and traits of a cell. Pharmacological 
inhibition of a pathway, changes in cell environment, and even small changes in the concentration 
of just one protein can trigger a cascade of events that affects the most fundamental cellular 
features, such as differentiation, metabolism, and cell growth and death. It is therefore not 
surprising that even closely related systems, such as tumors from the same patient but from 
different sites, show substantial genomic and phenotypic heterogeneity. My work aims at using 
genomic features to predict and explain the phenotypic heterogeneity of various biological 
systems. 
Explaining and predicting phenotypes are at the heart of biology research. Phenotypic 
heterogeneity can be observed across all systems and conditions. For example, some individuals 
are more susceptible to a specific disease than others; tumors respond differently to treatment, 
and their metastasis patterns vary between patients; certain cells can adapt to environmental 
changes, proliferate and differentiate, while other cells are in a terminal fixed state. 
Understanding the underlying mechanisms of phenotypic heterogeneity is necessary in order to 
control and influence the phenotypes, develop new treatments, and choose the best treatment for 
individuals.  
 
Gene	  expression	  -­‐	  predictor	  of	  phenotype	  and	  phenotype	  to	  predict	  
Many studies focus on the prediction of a phenotype by genotype1 (figure 1A). These studies 
aim to identify genetic features - Single Nucleotide Polymorphism (SNP), Copy number variations 
(CNV) or somatic mutations - that cause or correlate with a phenotypic outcome2,3. In other 
words, is the phenotype a function of a genotype (P=f(G))?  
The scoop of these studies is very wide. Genome Wide Association Studies (GWAS) use 
statistical tests to scan the genome for genetic features, usually SNPs or CNVs, which explain a 
trait or disease, such as blood pressure4, schizophrenia5 and others. In the cancer field, studies 
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aim to identify germ-line or somatic genetic features that can predict and/or explain tumor 
progression or response to treatment.  
However, the genetic makeup is not always the best predictor of a trait. Additional factors, 
such as chromatin modifications, inherited cell 
state (e.g. cell type) and environmental 
conditions, affect cellular state and can 
influence the phenotypic outcome6 (figure 1B). 
Therefore, genetic features alone typically fail 
to fully explain the phenotypic variance, and 
the so-called “missing heritability”, the 
phenotypic variance that is not explained 
using genetic feature alone, remains the 
biggest hurdle in genotype to phenotype 
studies7-9. To identify the “missing heritability“, 
and to better predict and explain phenotypic 
variance, one has to take into account these 
additional epigenetic factors. However, it is 
infeasible, and for some features impossible, 
to measure them for all individuals.  
Another approach, instead of measuring 
each and every epigenetic and environmental 
feature, is using gene expression as a proxy to 
them. Epigenetic factors, together with the 
genetic background, influence the expression 
of many genes10,11. Therefore, gene expression can be viewed as an “integrator” of several 
factors, and can therefore “represent” them. Taken together, gene expression can be used as a 
predictor of phenotypes in association studies12 (figure 1C).  
 
Figure 1 – Gene expression as a phenotype 
and a predictor of a phenotype 
Gene expression integrates the effect of multiple 
genetic and epigenetic factors, and is a proxy to 
cellular state. A. Classic genotype to phenotype 
association, where a genetic allele is used to 
predict phenotype. B. Other factors, including 
epigenetics and environmental cues, also 
influence the phenotype. C. Expression of a gene 
is used to predict a phenotype. D. Gene 
expression cluster serves as a phenotype to be 
predicted. E. Gene expression is used both as a 
predictor and as a phenotype - expression of one 
gene predicts the expression of others.  
	  
 3	  
The use of gene expression has several advantages. First, high-throughput technologies to 
measure gene expression levels, such as microarrays or RNA-sequencing, are relatively cheap, 
and provide information on tens of thousands of transcripts at once. Second, expression of genes 
behaves in concert, and genes are highly correlated with each other. By clustering genes based 
on their expression, noise of both the biological system and the measurement decreases, while 
statistical power increases. Third, used as a proxy, gene expression significantly shrinks the 
feature space from millions of SNPs and complex epigenetic profiles to just ~30000 gene 
expression patterns, drastically relieving statistical burden. Fourth, gene expression can be linked 
to protein activity, which can be critical for the mechanistic understanding of a response13, but is 
much harder to measure with high-throughput methods.  
While expression patterns can be used to predict phenotypes, they can also be considered as 
the phenotype itself. Expression levels reflect cellular states and can inform us on the activity of 
various pathways and cellular functions that we wish to predict and explain13. For example, 
oncogenic activation of a pathway alters the expression of its downstream genes14. We can use 
expression patterns as cellular phenotypes, and associated them with the genetic background15 
(figure 1D). Genetic features that influence expression levels are also called eQTLs (expression 
quantitative expression loci)16. 
Finally, as gene expression can be used as phenotypes themselves and predictors of 
phenotype, one can design a study that uses gene expression for both (figure 1E). However, 
such studies have several drawbacks. Specifically, the high correlation between gene expression 
profiles makes it difficult to identify the best predictive feature, and unlike DNA features, gene 
expression can be both the cause and the effect. By addressing these pitfalls via the integration 
of DNA based data, expression-to-expression association studies, such as CONEXIC (described 
in chapter III), provide an important framework for identifying both important features and 
unknown phenotypes.  
 
Taken together, gene expression is a powerful resource that can be used in many applications 
of biological research. In my work, I use gene expression patterns as both the phenotypes and 
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the predictors of phenotypes. My results demonstrate that gene expression is a versatile feature - 
it is a proxy to the metabolic state of the cells, it can be used to identify driver oncogenes, and in 
some case it is associated with resistance and sensitivity to targeted therapy.   
 
Context-­‐specificity	  of	  biological	  systems	  
Genotype-to-Phenotype association studies aim at identifying a genetic (or genomic) feature 
that predicts the phenotype. In other 
words, the goal is to represent a 
phenotype P as a function of a 
genomic feature G: P ≅ f(G).  
In most cases, however, multiple 
features influence the phenotype17: 
P ≅ f(G1, G2, …,Gn). To estimate the 
influence of multiple features, most 
association studies use additive 
models, in which the phenotype is a 
linear combination of the features: P 
≅ aG1 + bG218. The underlying 
assumption of additive models is 
that all features exert influence in all 
individuals.  
 Using examples from three biological systems, my results demonstrate that in many cases 
the relationship between the genomic features is context-specific. In these cases, the predictive 
model can be viewed as a tree (figure 2). First, the value of the main feature is examined, and 
only in specific contexts, i.e. the individual has a specific allele of a gene, the second genetic 
feature exerts an influence.  
The concept of context-specificity is by no means novel in biological research. For example, 
PTEN mutations only arise in the context of BRAF mutations in melanoma19. However, my work 
 
Figure 2 – interactions between genetic features 
In an additive model, the phenotype is a linear combination of 
two genetic features – P = aG1 + bG2. The effect of each 
feature is similar, regardless of the context of the other 
feature. In the context-specific model the second feature only 
affects when the first feature is of a specific allele. When the 
first feature is of the other allele, the second feature bares no 
influence (grayed out), and the phenotype depends only on 
the first feature.  
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demonstrates how prevalent these types of interactions are. For example, by using context-
specific models, I was able to identify 5 times more interacting eQTLs than with additive models 
(chapter II).  
Importantly, these tree-based models can’t be mathematically represented by an additive 
function. Moreover, such relationships add another layer of complexity to the model – not only 
that we need to identify the most predictive features, we also need to identify the contexts in 
which they exert influence. In this thesis I present three computational models, GOPLH, 
CONEXIC and COSPER, each taking a different approaches to identify the contexts and the 
features. By applying my novel methods to data of several types and sources, I was able to 
identify key genomic features, such as driver genes in cancer and genetic mutations that are 
associated with resistance to treatment. 
 
Context-­‐specific	  eQTLs	  
In chapter II, I explore the landscape of genetic interactions in S. cerevisiae using gene 
expression as a phenotype. My results show that roughly 80% of genetic interactions are context-
specific. 
 Yeast is used as a model organism to better understand association between genotype and 
phenotype. The readily available genetic and genomic data of a panel of related individuals 
(strains) provides a testing ground for hypotheses and the design of mathematical models for 
linkage and association studies. Here, I use genetic loci and associate them with gene expression 
clusters to identify eQTLs.  
Previous work on eQTLs in this data searched for one locus-one gene pairs. However, it was 
demonstrated that one locus does not fully explain the expression variance of a gene. Therefore, 
Brem et al.17 expanded their search for multiple loci (two in their study) using the additive model 
(P ≅ aG1 + bG2, figure 2). However, this model could only explain a fraction of the variance in 
gene expression.  
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In search of the missing heritability, I developed GOLPH, a non-additive statistical model, to 
characterize the landscape of interacting eQTLs. GOLPH introduces two novel concepts that 
greatly improve prediction: 
1. Instead of associating only one gene as a time, GOLPH uses clusters of co-expressed 
genes. This approach greatly reduces the statistical burden of the model, while also 
reducing biological and measurement noise.  
2. To examine the effect of multiple loci, GOLPH uses a tree-based model, which includes 
both additive and context-specific interactions (figure 2). 
 
Using GOLPH, I was able to identify 5 times more interactions than previously published 
methods, mostly due to the incorporation of context-specific models. I later expanded GOLPH, in 
collaboration with Anat Kremer and Itsik Pe’er, to work on human data20. These results 
demonstrate the prevalence of context-specific interactions across biological systems.  
 
Identifying	  context-­‐specific	  drivers	  in	  melanoma	  
In chapter III I present a work on driver mutations in melanoma. It serves as a logical 
extension of my finding in chapter I, while introducing new concepts specific to cancer biology. 
The work, which was done jointly with Dr. Akavia, aims at identifying DNA copy number drivers in 
cancer.  
During tumorigenesis, due to genomic instability, the DNA accumulates dozens of aberrations, 
including point mutations, amplifications, deletions, translocations and others. Each aberration 
can lead to activation of oncogenes or repression of tumor suppressors in different ways. Point 
mutations, for example, can lead to a loss-of-function of a tumor suppressor or gain-of-function of 
an oncogene21. DNA amplifications lead to overexpression of the genes in the amplified region, 
which in turn can over-activate an oncogene22. However, only a small percentage of those 
aberrations, i.e. driver mutations, contribute to the fitness of the tumor. Other mutations are fixed 
in the tumor’s DNA but don’t provide any fitness advantage (i.e. passenger mutations). 
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Identification of driver aberrations, i.e. distinguishing them from passengers, is essential for the 
development of new treatments and treatment regimens.   
Large projects, such as The Cancer Genome Atlas, use high-throughput technologies to 
quickly identify all DNA aberrations in large panel of tumors. However, as each tumor harbors 
dozens to hundreds of aberrations23,24, distinguishing drivers from passengers requires additional 
computation, data or knowledge and remains a major hurdle in putting these large datasets in 
use.  
Typically, identification of drivers is based on their frequencies in a panel of tumors. Since the 
likelihood of a specific locus to mutate during tumorigenesis is very low, an aberration that recurs 
in many tumors is likely to be a driver mutation. Methods based on aberration frequencies, such 
as GISTIC25, have proven to be successful and identified dozens of oncogenes and tumor 
suppressors26,27. However, not all driver mutations are overrepresented in the tumor panel, and 
approaches based solely on frequencies tend miss them.  
Frequency based method fail for two reasons, context specificity and low penetrance. Certain 
genes are drivers only in a specific context. For example, PTEN is only deleted in BRAF-mutated 
melanomas. Therefore, PTEN might be deleted in 60% of BRAF tumors, but its overall deletion 
frequency in melanoma is only 30%. By assessing the significance threshold for all tumors 
combined, PTEN might fall below threshold and be classified as a passenger. In order to define 
true significance thresholds of driver aberrations, one must first define the context in which the 
driver is essential. The problem of low penetrance arises for a different reason – certain 
aberrations drive a malignant phenotype, but do so in a small subset of tumors. To identify such 
driver, one can identify a malignant phenotype that exists in a subset of tumors, and associate 
genetic aberrations with it.   
Copy number aberrations present an additional hurdle. Unlike point mutations that are specific 
for a gene, copy number aberrations affect dozens of genes at once, amplifying or deleting large 
genomic regions. Therefore, even after identifying “driver” aberrant regions, one still has to 
identify the driver gene within a large region (on average, a copy number aberrant region in 
melanoma contains 23 genes).  
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In our work, we aimed at identifying copy number based drivers. We designed a computational 
method - CONEXIC - that attempts to overcome the three pitfalls of frequency-based driver 
identification approaches – low penetrance, context-specificity and large aberrant regions. In 
short, CONEXIC starts with a very 
permissive frequency threshold and 
tests many putative genes as 
drivers. Then, to assess the 
contribution of each putative driver 
to a malignant phenotype, we 
associate the gene expression 
pattern of the gene with a malignant 
phenotype defined by a gene 
expression cluster. Additionally, to 
account for context-specific drivers, 
we define contexts based on gene 
expression patterns, and test each 
putative driver in each of the 
contexts.  
CONEXIC was the first method to combine gene expression patterns and genetic information 
to distinguish drivers from passengers. Additionally, CONEXIC includes three major 
advancements over the current paradigms and methods in the field (figure 3):  
1. The gene expression of a gene, and not its copy number profile, is used to assess its 
contribution to the malignant phenotype. Figure 3A demonstrates that the expression of 
MITF, and not its copy number profile, is correlated with the expression of MITF’s known 
targets. If a gene is important for tumorigenesis, cells will find various ways to over-
activate it, and copy number is just one of those ways. By using expression and not 
copy number, CONEXIC integrates the effects of various aberrations that lead to over-
activation of the driver.   
 
Figure 3 – Identifying CNA drivers in melanoma 
Our computational model - CONEXIC – identifies copy 
number drivers. A. CONEXIC identifies the driver genes 
within aberrant regions using their gene expression profile. 
Here a known oncogene, MITF, and its targets are shown. 
The expression of the oncogene, and not its copy number 
profile, predicts the expression levels of its targets. B. 
CONEXIC also identifies the context in which a driver exerts 
an influence. In this case, RAB27A only influence its putative 
targets when TBC1D16 is highly expressed.  
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2. The malignant phenotypes are represented by gene expression clusters, which are 
used to evaluate the contribution of the driver genes. By identifying putative drivers 
whose gene expression correlate with the phenotypes, CONEXIC can distinguish 
between drivers and passenger that share the same aberration profile.  
3. The effect of driver aberration is assessed in the context of other drivers, under the 
assumption that not all drivers are important in all tumors. This leads to the identification 
of context-specific interactions between drivers.  
 
Using CONEXIC we identified two novel drivers, RAB27A and TBC1D16, both involved in 
protein trafficking, and experimentally validated tumors’ context-specific dependency of them.  
	  
Context-­‐specific	  interactions	  of	  the	  MAPK	  pathway	  in	  melanoma	  
In the fourth chapter I present my work on phenotypic heterogeneity of drug response in 
melanoma. While CONEXIC aimed at identifying drivers, here I investigated how genetic 
aberrations alter the response of melanoma to inhibition of a key oncogenic signaling pathway.  
The RAS-dependent extracellular signal-regulated kinase (ERK1/2) Mitogen Activated Protein 
Kinase (MAPK) pathway transmits signals from growth factor receptors to the nucleus, and plays 
crucial role in various cellular functions such as proliferation, apoptosis, differentiation and more. 
In melanoma, the pathway is constitutively active by mutations in 70-90% of tumors. Inhibition of 
the pathway leads to a dramatic decrease in proliferation and an increase in cell death, both in 
vitro and in patients. Recently, several highly potent and specific drugs that inhibit the pathway 
have been approved for clinical use 28,29. However, not all patients respond to the drugs, and the 
responses in patients that do show some response are heterogeneous30. The molecular 
mechanisms that underlie this phenotypic heterogeneity are still not well understood. In this work 
I investigated context-specific interactions of the MAPK pathway in order to pinpoint the molecular 
mechanisms underlying phenotypic heterogeneity. 
	  
 10	  
The	  MAPK	  pathway	  in	  melanoma	  
The ERK-MAPK signaling pathway transmits signals through a cascade of kinases – RAF-
>MEK1/2->ERK1/2. RAS, a small GTPase, is required for the physiological activation of the 
kinase cascade and is considered a member of the pathway (figure 4A). Upon activation of 
several growth receptors, the pathway, and most importantly ERK1/2, undergoes a rapid and 
strong burst of activation that triggers cell division and suppresses cell death31.  
The MAPK pathway is deregulated by various molecular mechanisms in about a third of all 
human cancers, including breast, pancreas, lung, melanoma and others32. In melanoma, the 
pathway is constitutively active in 70-90% of tumors, by point mutations in NRAS (~20%) or 
BRAF (~50%), or by NF1 loss (~20%), although the latter has yet to be directly implicated in 
MAPK-dependent melanogenesis33 (figure 4B).  
The list of reported direct and indirect ERK targets is very long and involves almost every 
cellular pathway and process, but varies significantly depending on the context and conditions 
tested34-37. To further complicate things, ERK acts both as a kinase that directly alters activation 
of its targets, and as a transcription co-factor to induce or repress transcription of genes38. 
Deciphering the complex network of MAPK targets and the contexts in which they are regulated is 
necessary for the development of new drugs and treatments for melanoma patients. 
Phenotypic	  heterogeneity	  in	  response	  to	  MAPK	  pathway	  inhibition	  
In recent years, several highly specific and potent small molecule inhibitors of BRAF, MEK 
and ERK were developed39-41. This extended panel of drugs significantly enhanced our ability to 




The first potent and specific drugs to be developed were MEK inhibitors, and therefore most of 
the published literature examines 
the effects of MEK inhibition. In vitro 
studies using melanoma cell lines 
show a dramatic growth inhibition 
following MEK inhibition in almost all 
MAPK-activated melanomas42. 
However, cytotoxic (i.e. cell death) 
response varies significantly 
between cell lines and conditions, 
some cell lines show almost no 
cytotoxic response, while others 
undergo massive cell death42. The 
mechanisms by which MAPK 
activity suppresses apoptosis, and 
the molecular consequences of MAPK inhibition that lead to cell death are still not fully 
understood and contradictory explanations exist42-44.  
Clinical results also demonstrate response heterogeneity. The drug that attracted the most 
interest is vemurafenib30 (PLX4720), a highly specific molecule that targets the BRAF-V600 
mutation that exists in ~50% of melanoma patients. Compared with other available melanoma 
treatments, the drug showed remarkable clinical results and was quickly approved for clinical use, 
but not all BRAF-mutant patients respond to the drug30 (figure 4C). However, the reasons for 
clinical heterogeneity can be far more complex than the in vitro models, and can include 
interactions with the immune system, genetically heterogeneous tumors, drug delivery and more.  
Context-­‐specific	  interactions	  of	  MAPK	  in	  melanoma	  
My project addressed the response heterogeneity of MAPK-activated melanoma to MEK 
inhibition in vitro. By studying the underlying mechanisms of cytotoxic and cytostatic responses, I 
 
Figure 4 – MAPK pathway in melanoma 
A. The ERK-MAPK pathway transmits signals from growth 
receptors via a cascade of kinases.  Numbers show approx. 
percentage of mutations in melanoma tumors. B. Mutation 
and copy number data from the TCGA project (source: 
bioportal, MSKCC). Each column represents one tumor. C. 
Clinical results of the Vemurafenib clinical trial. Each bar 
represents the maximal volume change of one lesion in one 
patient. Source: Sosman et al. NEJM 2012  
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hoped to identify some of the reasons for the varied clinical response, and suggest new targets 
and treatments that will improve clinical outcome.   
Many computational-based studies have attempted to identify genetic and genomic features 
that can explain and predict response to drugs45,46. These association studies use high-
throughput data, such as gene expression and mutations, and correlate them with a quantitative 
phenotype, such as growth rate. Thus far, this approach has failed to identify good predictors of 
cytotoxic and cytostatic responses for several reasons. First, growth-based phenotype is a result 
of several independent cellular phenotypes (growth arrest, death), and models aiming to predict a 
response ought to predict each cellular response independently of others. Furthermore, these 
studies use mathematical models that assume that the same molecular mechanism underlies a 
cellular response in all individuals, typically even across different cancers, which is unlikely to be 
the case (see Discussion for a full comparison of the methods).  
I took a different approach. I hypothesized that context-specific targets and interactions of the 
MAPK pathway underlie the heterogeneous responses to MAPK inhibition. Therefore, a better, 
context-specific, characterization of the network regulated by the MAPK pathway will help identify 
the reasons underlying phenotypic heterogeneity. 
To allow better inference of the network, I used both pre- and post- inhibition data. Most 
association studies only use steady state expression data and rely solely on correlation to identify 
MAPK targets. I assumed that supplementing the data with post-inhibition expression profiles 
would greatly enhance my ability to identify targets. Not only can perturbations change cell state 
and expose hidden interactions47, by perturbing the network I am able to infer causality and 
directionality of the interactions. Therefore, I measured changes in gene expression following 
MEK inhibition in a panel of MAPK-activated melanoma cell lines, since MEK inhibition fully 
inhibits the MAPK pathway both in NRAS- and BRAF-mutated cells.  
Notably, I found that although all cell lines harbor a MAPK activating mutations, most targets 
of the pathway are context specific – under the control of the pathway in only a subset of cell 
lines. To identify these context specific targets, and to assess their contribution to the phenotypic 
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variance, I developed computational tools that analyze pre- and post- perturbation gene 
expression data. 
Using the computational methods, I identified that the interferon pathway has a key role in the 
cytotoxic response to MEK inhibition. The computational analysis found that the interferon 
pathway is either on or off in different cell lines, and identified an interaction between the 
interferon and the MAPK pathways. An experimental validation showed a synergy between two 
unrelated drugs for melanoma – Type-I Interferon (IFNα/β) and MEK inhibitor. Moreover, copy 
number analysis identified that a deletion of the interferon genes predicts sensitivity to MEK 
inhibition. Taken together, my results showed that the interferon pathway plays an important role 
in melanoma.  
 
Summary	  
Context-specificity proved to be the key feature in all my projects. While the biological systems 
and the questions asked in each project were different, models that account for heterogeneity of 
the underlying molecular networks were essential to understand phenotypic variance. Analysis of 
each of the cases above found vast differences in the interactions and dependencies of genes 
and proteins between individuals (cell lines, yeast strains). Since our goal is to explain and 
understand human disease in different individuals, such differences must be identified and 
understood. I believe that a better understanding of context-specific interactions and 
heterogeneity would enable clinicians to tailor new and unexpected drug combinations to 





Chapter	  I –	   Review:	   Genetic	   and	   genomics	   of	  
melanoma	  
Melanoma	  –	  an	  aggressive	  form	  of	  skin	  cancer	  
Metastatic melanoma is an incurable disease, with only 14% of patients with survive for five 
years48. Roughly 80000 people are diagnosed with melanoma annually, of which 10000 are 
metastatic.  
Melanocytes, the pre-cursors of melanoma, are derived from the neural-crest cell layer. During 
tumorigenesis they develop and form nevi, and the subsequent development of dysplasia, 
hyperplasia, invasion, and metastasis49.  
Cancer can be seen as a Darwinian evolutionary process, with genetic and epigenetic 
changes providing cells a fitness advantage to proliferate, survive and metastasize. All cancers, 
including melanoma, share a common pathogenesis. A premalignant cell gradually transforms, 
through the acquisition of oncogenic aberrations, into a malignant tumor with the ability to 
metastize50 . In melanoma, UV radiation is the major cause for the accumulation of DNA 
mutations51. 
Recent studies portrayed the landscape of genetic alterations in melanoma and helped 
identify several key oncogenes and tumor suppressors52. Of main interest are mutations in NRAS 
and BRAF that activate the MAPK pathway in more than 70% of tumors. Drugs that target the 
pathway have been recently approved for clinical use and show exciting clinical results. However, 
clinical results vary significantly between patients, and our limited understanding of melanoma’s 
molecular biology hampers our ability to design new drugs and treatments.  
In this chapter I review our current understanding of molecular biology of cancer in general 
and of melanoma specifically. I start with the description of the process that drives cancer – 
mutagenesis, and summarizes the molecular events underlying it. Then I discuss how 
mutagenesis, by altering the activity of “driver” genes, leads to tumorigenesis. I then review the 
different computational and biological methods to identify these keys drivers. Finally, I provide a 
brief review of melanoma drivers.  
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DNA	  integrity	  and	  mutagenesis	  
Cancer is a rapid evolutionary process, driven by accumulation of mutations and aberrations 
in DNA. Those aberrations are caused by several mechanisms, including error-prone DNA 
synthesis, external carcinogens such as tobacco and UV radiation, internal carcinogens such as 
reactive oxygen species, loss of DNA integrity checkpoints and others.  
Mutations that contribute to proliferation and fitness of a cell are selected during the 
evolutionary process. These mutations support numerous processes, including proliferation, 
overcoming cell death, angiogenesis, rapid metabolism and more53. While we still do not have the 
tools to identify all key aberrations, we do have the molecular understanding of how certain 
aberrations support ontogenesis.  
Type	  of	  aberrations	  
Genetic instabilities and lack of genetic integrity, together with the effects of carcinogens, lead 
to the accumulation of genetic aberrations. There are several categories of genetic aberrations, 
and while their mechanisms of action is different, they all lead to the activation of oncogenes or 
repression of tumor suppressors: 
 
Point mutations – single DNA base mutations account for most DNA aberrations in cancer. 
The most prevalent aberration is base substitution, which account for 95% of these mutations54. 
The others, accounting for 5% of point mutations, are single nucleotide insertion and deletion. In 
melanoma, initial reports based on whole-genome sequencing identified roughly 10000-80000  
mutations per cancer genome51,52.  
While most point mutations are in “gene-deserts” and have no phenotypic effects, others can 
lead to several molecular effects: 
• Oncogene activation – the first point mutation that was shown to have oncogenic activity 
was identified in the gene HRAS. The mutation, a substitution of G>T in codon 12 of the 
gene55, leads to constitutive activation the MAPK pathway. Since then, additional point 
mutations that lead to constitutive activation of oncogenic proteins were identified, such 
as BRAF56 and PIKC3A57. 
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• Loss of function – point mutations can lead to nonsense mutations or amino acid 
substitution that inhibit the expression or activity of a gene. An example is TP53, a tumor 
suppressor mutated in ~40% of human cancers58. 
• Splicing – point mutations in splicing sites can lead to both loss- and gain- of function in 
proteins59,60. However, since our understanding of splicing mechanisms is still limited, it is 
hard to identify such mutations and understand their molecular consequences.  
 
Copy number aberrations – tumors often display gain or loss of chromosomal regions61. In 
some cases, entire chromosomes are lost or gained (aneuploidy62), for example, gain of 
chromosome 8 in 20% of acute myeloid leukemia63. Other cases show a focal deletion or focal 
amplification of a chromosomal region or a specific gene, for example, amplification of HER2 in 
breast cancer64.  Copy number aberrations (CNA) lead to under- and over- expression of genes, 
and alter their activity levels.  
 
Translocations and fusion genes – chromosomal translocation is caused by fusion of 
subparts of chromosomes. While the definition usually refers to a fusion of nonhomologous 
chromosomes, for example, fusion of chromosomes 14 and 8 in Burkitt’s lymphoma65, 
chromosomal deletions that lead to a fusion of two genes on the same chromosomes are also 
characterized as translocations66. Oncogenic translocations usually fuse a promoter of a gene 
that is highly expressed in the cancer’s cell lineage to an oncogene. Increased expression of the 
oncogene leads to constitutive activation of its pathway. The first genetic aberration that was ever 
identified in cancer was the “Philadelphia chromosome” - a translocation that fuses BCR to ABL 
in chronic myelogenous leukemia67.  
 
Short insertions and deletions (indels) - insertion or deletion of a small number of 
nucleotides. If the resulting change in number of nucleotides is not a multiple of 3, it will results in 
a frameshift mutation that is likely to cause an early stop codon and a truncated protein. As an 




DNA	  instability	  crisis	  
It has been argued that a global event of “genomic instability”, which leads to a rapid 
accumulation of mutations, is required for the generation of sufficient number of oncogenic 
mutations69,70. However, others have disputed this claim, demonstrating that some tumors have a 
normal rate of mutagenesis71.  
 
Global and catastrophic genetic instability can arise by several mechanisms. Hereditary 
defects in genes controlling the mismatch repair mechanism, such as MLH1 and MSH2, lead to 
rapid accumulation of point mutations in colon cancer72,73. Defects in the identification and repair 
of double-stranded DNA breaks, commonly caused by hereditary mutations in BRCA1 and 
BRCA2, also lead genetic instability and account for 5-10% of breast cancer74,75. A chromosomal 
“crisis”, caused by shortening of telomeres of aging cells, is another major source of genetic 
instability and can lead to a rapid accumulation of drastic aberrations of the DNA76. 
 
Molecular	  basis	  of	  genetic	  alterations	  
The molecular basis of genetic aberrations in cancer can be roughly divided into 3 categories: 
1. Sporadic and random aberrations caused by imperfections in the synthesis and mitosis cellular 
mechanisms; 2. Carcinogen-induced mutations, such tobacco and UV; 3. Systematic mutation 
accumulation due to catastrophic failures of the mechanism responsible for genomic integrity.  
The second and third categories are of the most interest. A better understanding of 
carcinogen-induced mutations will help to direct prevention guidelines, such as sunscreen to 
reduce exposure to UV radiation. For example, recent studies show a high rate of TC>TG 
mutations in breast cancer, but the carcinogen or molecular mechanism responsible for these 
mutations hasn’t been found77.  
Errors in mechanisms that maintain genetic integrity are also of interest. First, tumors acquire 
resistance to treatment by further accumulation of mutations. Identifying the molecular 
mechanisms of systematic mutagenesis will allow development of drugs that will prevent or slow 
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down mutation rate. Second, familial cancers are often caused by heredity mutations in genes 
involved in genetic integrity, such as MSH2, a gene involved in the mismatch repair mechanism. 
Pinpointing such heredity mutations will allow identifying the population at risk and will guide early 
detection and prevention efforts.  
While some mutagenic mechanisms are well described, such as UV-induced mutations, 
others, such as focal amplifications, are not understood as well. Here I give a brief overview of 
the different molecular mechanisms underlying mutagenesis: 
 
UV- and carcinogen-induced point mutations – Carcinogens and ultra-violet radiation lead 
to DNA damage by specific molecular changes of nucleotides. Ultra-violet, for example, leads to 
two types of lesions - cyclobutane pyrimidine dimers and 6-4 photoproducts78. Acrolein, a 
carcinogen found in cigarettes, irreversibly binds to DNA and interferes with new strand 
synthesis79. These DNA aberrations are repairable. Two DNA repair mechanisms - nucleotide 
excision repair (NER) and base excision repair (BER) – are responsible to the identification and 
repair of these lesions80,81. However, when these repair mechanisms fail to identify and/or repair 
the lesions, the mutations persist and interfere both with the synthesis of a new strand and with 
RNA expression.   
Different organs are exposed to different carcinogens, which influences the type of mutations 
in tumors of those cell linages. For example, 60% of point mutations in melanoma are C>T, a 
result of failed repairs of UV-induced lesions51.  
 
Replication-based point mutations and Microsatellite instability – DNA synthesis is an 
error prone mechanism. Although the process is characterized by high fidelity, most mismatch 
base errors repaired during synthesis, some bypass the multiple mismatch repair mechanisms 
and are fixed in the nascent strand82,83. However, events that alter the activity of the repair 
mechanisms, such as downregulation or mutations in proteins that form complexes that identify 
mismatches, can significantly increase synthesis mutation rate. For example, 15% of sporadic 
colon cancers display downregulation of genes in the MSH family, which leads to accumulation of 
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small indels in highly repetitive sequences, also known as microsatellite instability84. Importantly, 
patients with microsatellite instability show distinct clinical responses85.  
 
Aneuploidy – Gain and loss of whole chromosomes occur in all human cancers86. It is 
possible that the rate of aneuploidy is higher than currently estimated , as techniques that 
estimate aneuploidy miss loss-of-heterozygosity and whole chromosome duplication events, 
which are prevalent in some cancer types87. The molecular mechanisms underlying aneuploidy 
are not well understood, but it is hypothesized that they arise due to improper monitoring of cell 
cycle progression and errors in centrosome/microtubule formation62. Mutations in mitotic 
checkpoint genes have also been identified88.  
 
Focal copy number aberrations – although somatic focal copy number aberrations are 
frequent in cancer61, the underlying molecular processes that lead to these aberrations are not 
well characterized89. It is currently thought that double-stranded breaks, together with the lack of 
robust genomic checkpoints, lead to focal DNA amplification90.  
 
From	  mutations	  to	  oncogenes	  
In the early days of cancer research, before cloning, sequencing and high-throughput 
technologies, epidemiologic studies of carcinogenesis suggested that mutations in the genome 
are responsible, involved or essential for the initiation and progression of cancer91, but direct 
evidence was missing.  In his seminal study on familial retinoblastoma, Knudson has laid down 
the statistical framework that demonstrated the “two-hit” hypothesis, suggesting that tumors arise 
after the loss of two copies of a “tumor-supprosser”92. The genomic location of the retinoblastoma 
gene, Rb1, was only identified 7 years later, using karyotyping techniques on just two patients93.  
Many other tumor suppressors and oncogenes were discovered prior to the use of high 
throughput technologies. In 1973 Rowley has identified a chromosomal aberration in 9 leukemia 
tumors, which is now known as the Philadelphia chromosome67 using karyotyping. The discovery 
of oncogenic viruses and the research on the molecular biology underlying virus-induced 
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tumorigenesis demonstrated that the human genome harbors several pre-oncogenes. Later, by 
comparing viral oncogenes with human pre-oncogenes, the first single nucleotide oncogenic 
mutation was characterized in the gene HRAS94. Linkage analysis was also used to identify 
oncogenes and tumor suppressors in familiar cases of cancer. For example, studies on the 
autosomal recessive disease Xeroderma pigmentosum identified 7 DNA repair genes responsible 
for its manifestation, correspond to 7 disease groups95.  
Prior to  high-throughput technologies, identifying oncogenes and tumor suppressors involved 
linkage analysis, molecular biology studies and a great deal of luck. In the era of high-throughput 
technologies, it is possible to identify all genetic and epigenetic alterations in hundreds of tumors. 
However, while these technologies solve one problem – identifying mutations, they create a new 
one – identifying which of the tens of thousands of mutations each tumor harbors are oncogenic.  
 
Drivers	  and	  passengers	  
Cancer is a result of somatic genetic and epigenetic aberrations that provide the cell with the 
oncogenic phenotypes required for proliferation and survival. Although the exact number of 
mutations required for tumorigenesis is still disputed, the numbers range between 4 and 3091,96,97. 
Mutagenesis is a random process, and pre-malignant cells acquire many mutations until genes 
that support transformation are hit. Moreover, since tumors often lack mechanisms that maintain 
DNA integrity, they continue to acquire additional mutations98.  
We can therefore classify mutations into two categories – “drivers” and “passengers”. Drivers 
are genes and mutations that support the tumor, while passengers are mutations that were “fixed” 
in the genome during tumorigenesis due to random mutagenesis.  
The definition of drivers, however, is very complex and needs some refinement: 
• Activity: many genes are required for tumor survival and proliferation, and most of them 
are needed for the physiologic operation of non-malignant cells as well. Therefore, the 
term “drivers” usually refers to genes with altered activity in tumors – mutated, over-
activated, under-expressed, etc.  
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• Timing: while some altered genes are required for transformation from pre-malignant to 
malignant cells, they might not be required for the survival of the tumor. Such genes can 
also be classified as drivers, although they have no functional activity in tumors.  
• Function: the range of functions oncogenes support is also very broad. While most 
studies identify drivers required for proliferation, mutations also support additional 
hallmarks of cancer, such as evading the immune system and inducing angiogenesis53.  
• Resistance: another class of “drivers” includes genes that play a role in drug resistance. 
While these genes do not support tumor survival in physiological conditions, they are 
required for survival under specific drug treatments, and are often acquired only after 
treatment. 
 
Due to the diverse functionality of drivers, it is hard to define one method that identifies all 
drivers in all contexts and tumor types. Therefore, there are several different methods to identify 
drivers, each of which define and identify drivers of different type.  
Methods	  to	  identify	  drivers	  
When sequencing first became available, studies used prior information and focused on likely 
oncogenes. For example, in 2004 a study that specifically sequenced genes in the PI3K family 
identified high frequency of activating point mutations in PIK3CA99. Another study focused on 
BRAF, the gene downstream of the then known RAS oncogenes, and identified the V600E 
mutation in various cancer types21, and was later shown to activate the MAPK pathway in 50% of 
melanoma tumors100.  
When studies switched from targeted sequencing to whole-genome technologies, like 
microarrays and DNA-sequencing, researchers have learnt that each tumor harbors thousands of 
aberrations. The focus, therefore, had to shift from identifying mutations to identifying driver 
mutations101. New experimental and statistical methods were developed to tackle the new 




Most driver identification methods assume that mutagenesis is a random process, and the 
likelihood of a specific gene to be mutated across many tumors is fairly low. However if a gene is 
a driver that is required for tumor survival, mutations in it will be repeatedly selected in many 
tumors. Therefore if a mutation is observed across several tumors, and the frequency of the 
aberration is more than expected by chance, the mutation is likely to be a driver that was selected 
for during the evolution of the tumor.  
One of the first and most surprising drivers identified by high-throughput sequencing was 
IDH1. Mutations in isocitrate dehydrogenase 1 (IDH1) were identified in 5 out of 22 glioblastoma 
tumors that underwent whole exome sequencing102. IDH1 participates in the oxidative 
phosphorylation cycle, and was the first metabolic driver to be identified. In an extended panel of 
glioblastoma tumors, IDH1 mutations were found in 12% of tumors, and its mutation predicts 
better overall survival102. Notably, since the gene and its family were never implicated in cancer, 
only when studies switched from targeted sequencing to unbiased whole genome approaches 
were the mutations were identified.  
Whole genome non-sequencing approaches were also found effective in driver identification. 
Garraway et al. used high-density SNP arrays to identify copy number aberrations in a panel of 
melanoma tumors103. They identified a focal amplification in chromosome 3, and together with 
gene expression levels, that pinpointed amplification and overexpression of MITF, a melanocyte-
specific transcription factor, which is now classified as a melanoma driver.  
Copy number aberrations, however, present a new statistical hurdle. While other types of 
mutations are specific to a small genomic location, copy number aberrations span genomic 
regions of various lengths. Some aberrations are focal, confined to an exon or a gene, while 
others include dozens to hundreds of genes. Therefore, statistical models that assess the 
significance of the aberration must define the aberrant region, test the likelihood that the 
aberration is not due to random chance and identify the target driver gene within that region. 
Several statistical frameworks were developed to address this problem, but most of them solve 
just half of the problem25,104. They identify genomic regions with high recurrence of amplification 
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or deletion, but those regions often contain dozens of genes. An analysis that integrates multiple 
data types is required to pinpoint the driver gene within those regions.  
The understanding that multiple data types are required for a comprehensive analysis of 
cancer genomics has led to the initiation of large-scale cancer genomic projects. Spearheading 
the effort is “The Cancer Genome Atlas” (TCGA) project24,105. The project consortium collects 
hundreds of tumor samples of each cancer type and measures their gene expression levels, copy 
number aberrations, mutations, translocation, epigenetic state and more. These large data sets 
give an extensive overview of the genetic landscape of cancer106. However, it is clear that these 
vast datasets will require the development of advanced bio-statistical methods that integrate 
different data types for the identification of driver mutations, pathway activation and other cellular 
aberrations that contribute to tumorigenesis.  
Association-­‐based	  methods	  
Another class to driver identification methods focuses on aberrations that contribute to a 
specific and known phenotype. The phenotype usually reflects clinically important characteristics, 
such as overall survival, response to treatment, and metastasis patterns107-111.  
In most studies, the outcome is overall survival and the predictors are either copy number 
aberrant regions or gene expression profiles. For example, Xie et al. found that gain of 
chromosome 20q predicts better overall survival in colorectal cancer110. Hicks et al. identified a 
gene expression profile comprised of 95 genes that predict response to tamoxifen in ER+ breast 
cancer112. 
Association based methods are also used in in vitro settings to identify mutations and other 
aberrations associated with response to treatment. A group led by Andy Minn at the University of 
Pennsylvania found an interferon-based gene expression signature that predicts response of 
breast cancer cell lines to radiation113.  
Large-scale association based efforts to identify genetic and genomic determinants of drug 
response in vitro are underway45,46. In these studies the growth response to dozens of drugs in 
hundreds of cancer cell lines is assessed, and then associated with whole genome features, such 
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as mutations, copy number aberrations and gene expression profiles. So far, however, these 
studies failed to provide fresh insights into the resistance mechanisms to targeted therapy. 
Functional	  assays	  	  
Another approach to identify drivers that contribute to fitness of cancer cells is based on 
unbiased functional screens using siRNA or shRNA114-116. In these assays, a large panel of small 
interfering RNAs is used to identify genes that are required for proliferation. These assays are 
performed either under normal growth conditions or under drug treatment. In the latter case, the 
results help identifying genes that confer resistance to treatment, and can therefore be used to 
suggest combinatorial treatments. In many cases, in order to gain statistical and biological power, 
a panel of cell lines is used.  
Prahallad et al. used such method to show that EGFR signaling confers resistance to MAPK 
pathway inhibition in colon cancer114. Cheung et al. started the Achilles project, a systemtic effort 
to identify genetic dependencies across cancer cell lines. Their initial screen identified PAX8 as a 
driver of ovarian cancer116.  
 
Tumors rely on numerous processes for their survival, from uncontrolled growth, through 
evading cytotoxic signals, to changing their microenvironment to support their growth. Driver 
genes, therefore, are selected to support these various functions. Studies that use one discovery 
approach or focus solely on growth phenotypes are likely to miss many important drivers. The 
frequency, association and functional approaches are not mutually exclusive, and approaches 
that integrate input and insights of all these methods are needed to create a comprehensive view 
of cancer aberrations.  
 
Drivers	  in	  melanoma	  
The use of sequencing and other high-throughput technologies drastically improved our 
understanding of melanoma genetics. Thus far, genomic and functional studies have implicated 
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several pathways in melanoma progression and survival, including MAPK100, PI3K117, KIT118, 
MITF119, TGFβ120, WNT121, CDKN2A122, JAK/STAT123 and several others124.  
Functional assays and clinical results, however, have focused most of the research on the 
MAPK pathway, which was shown to be a major driver of almost all melanomas. Here I give a 
brief introduction to the roles several major pathways play in melanoma progression, survival and 
drug resistance.  
MAPK	  
The ERK-MAPK (Extracellular Regulated Kinase – Mitogen Activated Protein Kinase) pathway 
is constitutively active in ~70% of tumors. NRAS is mutated in ~20% of tumors, and BRAF 
harbors a point mutation (V600) in ~50% of tumors125. Studies show that MAPK activation is an 
early event in melanoma progression, as it is observed at similar frequencies in benign nevi and 
metastatic melanomas56.  
MAPK-activated tumors are highly dependent on MAPK activity. Inhibition of the pathway 
induces cell cycle arrest and cell death in many of the melanoma models, including cell lines, 
xenografts and patients126,127.  
MAPK influences a number of key cellular processes by regulating numerous pathways. 
MAPK controls the transition of cell cycle between G1 to S phases by negative regulation of 
p27128, and positive regulation of both Myc129 and Cyclin D1130, among others. It inhibits cell death 
by inhibition of the pro-apoptotic protein BIM131, and regulates cell growth and metabolism 
through activation of mTOR132.  
Due to the dependency of many cancer types, including melanoma, on MAPK activity, several 
drugs that inhibit the pathway were developed. Of notice is PLX4032, a highly potent inhibitor 
specific to mutated BRAF133. The drug has been recently approved for melanoma treatment and 
shows good clinical results127. However, not all tumors respond to the drug, and the molecular 
mechanisms underlying response heterogeneity are still not understood. Dual inhibition of MEK 





Micropthalmia-associated transcription factor (MITF) is a master regulator of melanocyte 
development, function and survival119. It promotes melanocyte differentiation by regulating the 
expression of genes required for melanin production and melanocyte differentiation from neural-
crust pre-melanocyte cell to a differentiated and functional melanocyte.  
In 2004 MITF was found to be amplified and overexpressed in 10-20% of melanomas103. 
Further studies have revealed a higher frequency of MITF overexpression in nevi compared with 
metastatic lesions135. It was also shown to predict survival, with low MITF correlating with worse 
outcome136. Additionally, in vitro studies found the MITF expression correlates with cell lines’ 
response to MAPK inhibition137.  
Under physiological conditions MITF is regulated by α-MSH, a melanocyte-stimulating 
hormone. α-MSH binds to MC1R, and through the accumulation of cAMP they activate CREB. In 
turn, CREB stimulates the promoter of MITF-M, a lineage specific isoform of MITF119. 
Interestingly, germ-line mutation in MC1R are linked with higher incidence of melanoma138,139. 
Regulation of MITF in melanoma is more complicated. While MAPK and KIT can activate CREB 
and lead to MITF expression, they also negatively control production and accumulation of MITF 
protein140-142.  
Functional assays, unfortunately, do not help to clarify the role of MITF in melanoma. 
Knockdown of MITF in cell lines with high MITF expression leads to growth inhibition, while 
overexpression of MITF in other cell lines leads to terminal differentiation and lower 
tumoigeneicity135.  
Additional studies are required to understand the role of MITF in melanoma, and to determine 
whether it can be used as a biomarker or a target for therapy.  
p16	  and	  cell	  cycle	  proteins	  
CDKN2A, or p16, was first implicated in melanoma after identifying germ-line mutations in 
familial melanoma122,143. Mutations and loss of the gene locus were also described in sporadic 
	  
 27	  
cases and cell lines144,145. p16 deletion and mutation are now reported in ~50% of melanomas 
(TCGA, in press).  
p16 is a cyclin-dependent kinase inhibitor that blocks CyclinD to prevent G1 to S transition. It 
acts as a tumor suppressor and its loss disrupts cell cycle regulation. Other components of the 
cell cycle regulation are often deregulated in cancer. In melanoma these aberrations include loss 
of Rb1, Cyclin D1 overexpression or CDK4 amplification and overexpression146,147.  
Pharmaceutical inhibition of the cell cycle machinery is currently being tested. Although initial 
studies report low efficacy of CDK inhibitors, combinatorial treatments and second-generation 
inhibitors are still being tested148.  
PTEN	  and	  the	  PI3K	  pathway	  
The pro-growth anti-apoptosis PI3K-AKT pathway is activated in melanoma by PTEN loss or 
AKT3 amplification149-151. Among many of its targets are the growth regulator mTOR, CDK 
inhibitors, FOXO transcription factors, MDM2, the bcl-associated death promoter (BAD) and 
others152.  
PTEN loss was found by several independent studies to correlate with response to MAPK 
(MEK or BRAF) inhibition42,153. Supporting these studies are results that show that concurrent 
inhibition of the PI3K and MAPK pathways leads to stronger cytotoxic and cytostatic 
responses154-156. However, others have suggested that PTEN plays other roles in melanoma 
which are unrelated to proliferation and apoptosis157. Additionally, no correlation between PTEN 
status and response to treatment in patients has been reported, and the role of the PTEN-AKT 
pathway has yet to be fully determined.  
Open	  questions	  	  
High throughput technologies greatly advanced our understanding on tumorigenesis as a 
whole, and melanoma progression and survival specifically. More recently, several new drugs, 
both immuno-modulators and kinase inhibitors, have been approved for melanoma treatment. 
However, initial clinical results demonstrate response heterogeneity. The molecular reasons 
underlying response heterogeneity are still unknown.  
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A better understanding on the molecular biology of melanoma is likely to assist with the pursuit 
of better clinical results. Although several large-scale high throughput studies aimed to identify 
oncogenes and tumor suppressor have been conducted, our knowledge is still lacking: The 
drivers within many of the frequent copy number aberrant regions have not been identified; The 
genetic and molecular determinants of phenotypic response to MAPK inhibition are still unknown; 
Combinatorial treatments show good in vitro results, but toxicity issues thwart clinical use of the 





Chapter	  II -­‐	  Context-­‐Specific	  Interactions	  in	  the	  
Genetics	  of	  Gene	  Expression	  
This chapter was published under Litvin et al. PNAS 2009158 
Introduction	  
Understanding the effect of genetic sequence variation on phenotype is a major challenge that 
lies at the heart of genetics. Recent technological advances in genotyping have now made it 
possible to obtain a comprehensive view of genome-wide variation in a large number of 
individuals. However, studies that associate genetic polymorphisms with phenotypic properties 
(disease, height, etc.) involving tens of thousands of individuals159 have, for the most part, only 
been able to detect loci that collectively account for 3% of the heritable phenotype. This suggests 
that the connection between genotype and phenotype is more complex than previously assumed 
and that more sophisticated approaches are needed to interpret the data.  
The goal of this project is to elucidate the relationship between genotype and phenotype, and 
to map the landscape of genetic interactions. I use gene expression as a phenotype, and 
associates clusters of gene expression with genetic variance. Changes in cell state, such as 
metabolic state and growth rate, as well as activation of various pathways, are likely to affect the 
expression of many genes. In this approach, expression quantitative trait loci (eQTL), is based on 
the notion that gene expression reflects cellular state.  
Quantitative trait mapping of gene expression abundances has proved a powerful model 
system for studying genetic traits in a number of organisms15,160-162. I use gene expression and 
genotype data on segregants generated in a cross between a laboratory strain (BY) and a wild 
strain (RM) of Saccharomyces cerevisiae163,164.  
I developed GOLPH (GenOmic Linkage to PHenotype), a novel statistical algorithm to identify 
multiple genetic factors influencing gene expression abundance. GOLPH’s premise is that the 
modular organization of gene regulation can be used to enhance the statistical power of linkage 
to eQTLs, since clusters reduce the statistical burden of the test while also reducing the noise in 
the data.  
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GOLPH identifies an unprecedented number of linked regions for each gene. The results 
portray a complex picture in which multiple loci influence the expression of modules of co-
expressed genes that define coherent biological processes. The data show that genetic 
polymorphism can give rise to distinct cellular states in which entire metabolic pathways and 
biological processes are activated to different extents between individuals. In this regard, 
genotypic differences are similar to environmental perturbations in their effect on the internal state 
of the cell.  
Moreover, most interacting loci demonstrate allele-specific genetic interactions, in which the 
secondary locus exerts an influence only in a specific context of the primary locus. A possible 
explanation is that the primary locus switches the cell among states or predisposes it towards 
adopting a cellular state. The secondary locus only has an effect in one of these states. For 
example, I observe differences in the cellular state mediated by variation at the IRA2 locus. 
Genetic variation in IRA2, an inhibitor of RAS/PKA signaling, predisposes strains with the IRA2-
RM allele towards aerobic respiration164. Other loci containing genes with critical functions 
involved with mitochondria and respiration exhibit IRA2-RM specific influence on entire 
transcriptional programs.  
To support the biological and statistical analysis, I developed and used GENATOMY, a 
custom-built analysis tool, to visualize and analyze the resulting genetic interactions between 
quantitative trait loci. GENATOMY is available for download on the lab website.  
The data and results depict a complex relationship between genotype and phenotype resulting 
from the dynamic nature of genetic interaction networks that are responsive to both the 





I developed GOLPH, a new statistical approach to find multi-locus linkage or association to 
gene expression traits. It is based on the detection of iQTL (interacting Quantitative Trait Loci) 
that involve two or three loci. Each iQTL consists of a primary locus and up to two secondary 
interacting loci, which significantly link to the trait in a context-specific manner - only when the 
primary locus has a specific allele. GOLPH constructs iQTL modules consisting of the iQTL 
decision tree and all the genes that link to that combination of interacting loci (Figure II-1). These 
iQTL modules are further partitioned into subsets of co-expressed genes, referred to as 
expression patterns. 
 
Figure III-1 - Overview of GOLPH 
GOLPH takes as input gene expression and genotype data for a set of individuals.  Top panel: shows the 
computation occurring at each stage  and the resulting output (bottom panel).  Stage one - genes are linked 
to a primary locus; stage two - iQTL are constructed by partitioning the samples based on the primary locus 
and linkage to the secondary locus; stage three -, FDR is used to expand significant linkages.  Bottom 
panel: Once all iQTL modules have been constructed they are analyzed using GENATOMY, our interactive 
visualization and data analysis tool.  GENATOMY uses additional resources such as sequence, Gene 




I applied GOLPH to genotype and gene expression data obtained from 108 segregants and 
their parents15,163,164. GOLPH works in three stages, each increasing the number of detected 
linkages. Similar to previous studies17,165, GOLPH begins with a stepwise search. In the first 
stage, primary QTLs are detected for each trait, and in the second stage, secondary interacting 
loci are detected. In contrast to previous studies165, a secondary QTL is identified independently 
for every allele at the primary locus. In the final phase I exploit the modular organization of gene 
regulation to link genes that are not significant alone, but which share a pattern with significantly 
linked genes (see Figure II-1 and Methods). I analyzed the resulting linkages using GENATOMY, 
a purpose-built visualization tool, to gain insight into the architecture of interacting loci.  
 
The	  GOLPH	  algorithm	  significantly	  increases	  the	  number	  of	  linkages	  	  
Stage one of the analysis identified 44 hotspots including many previously reported regions 
(AMN1, GPA1, HAP1, IRA2, MKT1, PHO84)15,162,164,166,167. Using these hotspots, stage two 
identifies secondary loci that interact with each of the primary loci. 81 pairs of iQTL that link to 5 
 
Figure III-2 – The genetic landscape of eQTL 
The number of linked genes increases at each of the three stages, with the greatest expansion in module 
size occurring at stage 3. (a) Number of linkages at each locus color coded by stage 1 (blue), 2 (green) and 
3 (red). The x axis represents the location of the locus, each of the bold lines below the axis represent yeast 
chromosomes I to XVI. The y axis represents the number of genes linked to that locus. (b) Histogram 
representing the number of loci linking to each gene at each of the three stages. The color code is the same 
as in 2(a). (c) Plot showing the size of each iQTL at stages 2 (green) and 3 (red). The size of the circle is 
proportional to the number of genes linked to the iQTL). Both axes relate to chromosomal location with the 
position of the chromosome marked in bold.  
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or more genes were found, resulting in an increase in the number of multi-locus genes (Figure II-
2a,b). 
In stage three, GOLPH uses the modularity of gene expression to gain additional power. The 
premise is that gene regulatory networks are organized into modules of co-regulated genes168,169. 
For example, deletion studies have shown that when a regulator is deleted, the expression of 
hundreds of genes are influenced170. Therefore, weaker linkage of additional genes to the iQTL 
identified in stage two are more likely to be real. This leads to a dramatic increase in both the 
number of genes linked to each marker and the number of markers linked to each gene (Figure II-
2). After stage three, more than 2500 genes linked to two or more loci and more than 800 genes 
linked to five or more loci, matching previous analysis estimating that the expression of more than 
half the genes is likely influenced by at least five different loci163. To ensure GOLPH does not 
report spurious linkage, randomization testing for each step is performed, and indeed no signal is 
detected for the randomized data (see Methods). I conclude that GOLPH detects an 
unprecedented number of loci for each gene expression trait and demonstrates that genetic 
interactions between loci are more common than previously estimated166.  
Interacting	  QTLs	  generate	  coordinated	  biological	  programs	  of	  gene	  expression	  
Although genes were added to each iQTL module based on their linkage alone, the resulting 
sets of genes form tightly co-expressed clusters. Figure II-3 shows the set of genes that are 
added to an iQTL module involving IRA2 (Chromosome XV:170945-180961) and the 
chromosome VII locus (Chromosome VII:167587-192140) at each stage. The genes added in 
stage three have the same pattern of expression as the genes added during the more rigorous 
stage two. In addition, the genes added in stage three share Gene Ontology (GO) annotations 
and binding sites with those chosen in stages one and two, significantly improving the functional 
enrichment of the modules, and further supporting their linkage (see Methods). Examples of 
improved enrichment include ribosome biogenesis and assembly: 10-47 in stage two to 10-102 after 
stage 3, mitochondrion from 10-18 to 10-76, iron ion transport 10-4 to 10-10 and aerobic respiration 
10-3 to 10-12. We conclude that iQTL do not influence a single gene but rather entire biological 
processes and pathways.  
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Figure II-3 shows two distinct patterns of co-expressed genes that are inverted, i.e., down-
regulation on one side of the heat map is accompanied by up-regulation of equivalent magnitude 
on the other side and vice-versa. This is a widespread phenomenon involving 122 modules and 
3638 linked genes, resembling the response to environmental perturbation, in which entire 
processes are co-coordinately up- or down- regulated (see Methods). The existence of inverse 
expression patterns suggests that many 
iQTL not only regulate single pathways, 
but rather orchestrate entire cellular 
responses involving multiple biological 
processes.  
My results provide a view of genetic 
variation as an internal cue that 
predisposes the organism towards, or 
away from a cellular state. The presence 
of a single allele can tip the balance 
between one state and another. The 
most striking example is provided by the 
IRA2 locus which links to more than 
2000 genes. Ira2 is a GTPase-activating 
protein that negatively regulates RAS. 
The RAS/PKA pathway plays a central 
role in coordinating processes such as 
growth and stress tolerance in response 
to nutrient availability. The IRA2-RM 
sequence differs from BY by 87 non-
synonymous coding SNPs and 3 gaps. 
Segregants with the RM allele of IRA2 correspondingly inhibit Ras/PKA signaling better than 
segregants with the BY allele164. Although all of the segregants were grown in glucose (and might 
 
Figure III-3 - IRA2 module 
A heat map showing the IRA2–chrVII iQTL module and the 
expression of the genes linked at stages 2 and 3. Each 
row represents a gene and each column represents a 
strain. The module is organized as a decision tree based 
on the strain’s genotype and whether they inherited the BY 
(blue) or RM (purple) genotype for each of the interacting 
loci. (a) Top split based on the primary locus, chromosome 
XV:IRA2. The lower split is based on the secondary locus 
chromosome VII:167587-192140. (b) 80 genes linked in 
stage two. The columns represent strains and are 
arranged according to the tree, the vertical dotted yellow 
lines show the split point in the genotype. (c) 62 genes 
linked in stage 3. The variance in expression of these 
genes is >0.25 SD. These genes were considered in 
stages 1 and 2, but did not pass the higher threshold for 
significance. (d) An additional 88 genes are linked in stage 
3. These genes are not considered in stage two because 




be expected to undergo fermentative growth), the presence of the RM allele correlates with the 
up-regulation of genes annotated for mitochondria (10-14), aerobic respiration (10-9), response to 
stress (10-8) and the down-regulation of genes annotated for ribosome biogenesis and assembly 
(10-95), rRNA processing (10-57) and the nucleolus (10-56), suggesting a transcriptional response 
consistent with respiration.  
In contrast to IRA2, the phenotypic differences that link to the HAP4 (Chromosome XI: 
247944_247956) locus are likely to 
be driven by allelic differences in the 
promoter. Hap4 is part of a 
transcriptional activator complex that 
regulates the transcription of genes 
in response to heme/oxygen and/or 
growth on non-fermentable 
substrates 171 and the locus is linked 
to more than 200 genes. HAP4 is a 
cis-eQTL, i.e., a gene that links to its 
own locus, and the RM strain has 14 
promoter SNPs. Moreover, the 
presence of the HAP4-RM allele 
correspondingly correlates with the 
up-regulation of HAP4 along with 
genes it activates: Hap4 bound 
genes (10-19), those annotated for 
mitochondria (10-90), and aerobic 
respiration (10-13).  
 
Figure III-4 - Linear and Non-linear iQTLs 
(a) An example of an iQTL module with an additive interaction 
between the IRA2 primary locus and the HAP4 secondary 
locus. The colored number (red for positive and blue for 
negative) represents the difference in means of  gene 
expression between each side of the split.  We observe that the 
delta between HAP4-BY and HAP4-RM segregants is similar for 
both IRA2-BY and IRA2-RM ; hence the interaction between 
these loci is additive.  (b) An example of an iQTL module with 
an opposing interaction between the IRA2 primary locus and 
chromosome VI:70818-75460.  The delta between chrVI-BY 
and chrVI-RM is -0.59 in the context of IRA2-BY and reversed 
(0.64) in the context of IRA2-RM. 
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The	  landscape	  of	  genetic	  interactions	  	  
GOLPH detected 83 pairs of interacting loci in 205 
modules with 542 expression patterns. I used the 
multi-locus phenotypes to characterize the genetic 
interactions between QTLs. Most methods for multi-
locus traits assume an additive model, y~aX+bY. For 
example, the iQTL module involving the IRA2 and 
HAP4 loci influence different aspects of mitochondrial 
function. The IRA2-RM allele represses the PKA 
pathway, predisposing the strain towards respiratory 
growth. Hap4, an activator of aerobic respiration is 
upregulated in segregants with the HAP4-RM locus. 
Therefore, the presence of IRA2-RM and HAP4-RM 
each push the cell towards respiration through 
independent mechanisms and their joint influence is 
an additive combination of their individual influences 
(Figure II-4a).  
 
One of the most striking aspects of the data is the 
dominance of allele-specific interactions, i.e., 
situations in which the secondary locus exerts an 
influence on the phenotype only when the primary 
locus has a particular allele (and has little or no 
influence when the primary locus has another allele). 
GOLPH is able to detect allele-specific interactions 
because each primary allele is tested for linkage 
independently and the secondary locus need not link 
to both. One such example was presented in Figure 
 
Figure III-5 - The landscape of iQTLs 
(a) A pie chart representing the types of 
interactions between loci in our analysis. The 
outer circle represents genes and the inner 
circle represents modules. RM allele-specific 
interactions are orange, BY allele-specific 
interactions are brown. Blue represents 
situations in which the secondary allele links to 
both sides, additive interactions are dark blue 
and synergistic interactions are light blue. Green 
represents modules with two different allele-
specific interactions, one for each side. The 
dominance of allele-specific interactions is 
evident. (b) Histogram of correlation coefficients 
in allele-specific modules. The data show that 
the effect of the secondary locus on the non-
interacting allele is negligible. The x axis is the 
correlation coefficient between the secondary 
locus and the mean expression level for genes 
in the module. The y axis shows the number of 
modules. The blue bars represent data from the 
interacting primary allele and the red bars 
represent the other non-interacting allele. The 
green line shows that the distribution for 
randomly chosen pairs of loci is similar to the 
histogram in red demonstrating that the 
interactions are indeed with only one allele and 
not the other.   
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II-3 - the chromosome VII locus interacts with IRA2-RM only and has no influence on IRA2-BY. 
While 196 genes link to the chromosome VII locus in with the presence of IRA2-RM, none of 
these linkage signals were significant in stage one. To confirm that these interacting loci are 
indeed allele-specific and do not reflect borderline effects, I compared the regression coefficient 
of the linked versus non-linked alleles and found that coefficients for the non-linked alleles 
resemble a random distribution (Figure II-5b). GOLPH detected a remarkable number of allele-
specific genetic interactions. These involve 78 interacting loci, organized into 94 iQTL modules 
that contain 1856 unique genes and 2891 allele-specific interactions, 81% of the total interactions 
identified (Figure II-5a). I conclude that allele-specific genetic interactions are prevalent in our 
data.  
The same secondary locus was found to influence both primary alleles in 50 iQTL modules 
containing a total of 562 genes. I tested each of these for epistasis (see Methods), and in cases 
where the secondary locus links to both primary alleles, the majority of interactions (423/562) do 
not show a significant interaction term.  Since most other methods do not detect allele-specific 
interactions, this could explain why genetic interactions are typically assumed to be additive. 
While there are only a few epistatic modules, these can exhibit dramatic effects; a number of 
iQTL modules had secondary locus effects in opposing directions between the two primary 
alleles. For instance in the iQTL involving the IRA2 and chromosome VI:70818_75460, the effect 
of the chromosome VI locus depends on the IRA2 allele. The RM allele of chromosome 
VI:70818_75460 up-regulates the genes in the module in the presence of IRA2-BY and down-
regulates the genes in the presence of IRA2-RM (Figure II-4b). 
The	  prevalence	  of	  allele-­‐specific	  genetic	  interactions	  
To understand how allele-specificity might arise, I analyzed an iQTL module linked to IRA2-
RM and a locus on chromosome II: 334020_334022 (Figure II-6). The causal gene on 
chromosome II is likely to be TCM62, which encodes a protein that supports biogenesis of the 
mitochondrial succinate dehdrogenase complex by acting as a molecular chaperone 172. Strains 
deleted for TCM62 grow slowly on rich glycerol medium and are respiration deficient. TCM62-RM 
has 3 coding SNPs and 57 promoter SNPs compared with the BY sequence, including SNPs in 
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two Pho2 binding sites. One of these SNPs is predicted to increase the binding affinity of Pho2 
173; indeed, TCM62 is a strong cis-eQTL and is up-regulated in segregants bearing the TCM62-
RM allele.  
When segregants have both IRA2-RM and TCM62-RM, mitochondrial genes (10-7) and Skn7 
targets (10-5) are up-regulated, while ribosome biogenesis and assembly (10-63), nucleolar (10-37) 
and rRNA processing genes (10-32) are down-regulated. Figure II-6 shows the expression pattern 
of genes in the module and that the TCM62 locus has a strong influence in segregants with the 
IRA2-RM allele and negligible influence in segregants with the IRA2-BY allele. The PKA pathway 
is inhibited in segregants bearing the IRA2-RM allele and the balance is tipped towards the 
expression of genes associated with 
respiratory growth and the up-
regulated TCM62-RM allele likely 
further tips the cell towards respiratory 
growth.  
Previous work reports that linkage 
to a particular locus is often dependent 
on environment, the locus exerting an 
influence in one environment, but not 
in another164. Both external 
environmental signals and genetically 
driven internal cues can drive cells to 
switch between states, as reflected by 
different metabolic fluxes and stresses 
acting on the cell. I postulate that the 
allele-specific linkages we detect are 
largely due to such events. These switches can sometimes be subtle, such as a release of 
inhibition or a shift in bottlenecks, making certain genes more critical in some conditions than 
 
Figure III-6 - IRA2 module 
The IRA2–TCM62 iQTL module is graphically represented as 
described in Figure II-3. For compactness, representative 
genes were chosen for each pattern. The full list of genes for 
each pattern is provided in Supporting   (delta 0.11 is low 
even by random scales).  We manually added an additional 
partition using the chromosome VII locus from Figure 3 to 
TCM62-BY to demonstrate that the chromosome VII locus 




others. Thus genetic variation leads to internal change, altering interactions between genes 
through shutdown or activation of pathways, release of inhibition, or shifting of bottlenecks.  
The IRA2-RM allele plays a dominant role among the allele-specific iQTL modules 
accounting for 41% of the genes influenced by allele-specific interactions with RM; however, 
other loci also exhibit this phenomenon. Each of HAP1-RM and MKT1-RM has allele-specific 
effects on the expression of more than 200 genes. Although there are fewer allele-specific 
interactions with BY, 886 genes are affected by allele-specific interactions on the BY side. The 
loci that dominate BY allele-specific interactions include HAP1-BY and a locus on chromosome 
I:41483_42639, likely to be due to polymorphism in OAF1, an oleate-activated transcription factor 
involved in the beta-oxidation of fatty acids and peroxisome organization and biogenesis. 
Together there are more than 10 different hotspots that exert allele-specific influences over a 





Materials	  and	  Methods	  
Data	  
The strains, genotypes and gene expression measurements were those of 164. I merged 
adjacent, highly-correlated markers, to obtain a total of 526 markers 174. Expression data were 
normalized with mean of zero and variance one. For stages one and two of GOLPH, only 1733 
genes that showed significant variation (stdev>0.25) in their expression level were used. GO 
categories from http://www.yeastgenome.org/ with more than 5 genes were used for the 
evaluation of biological function. Putative transcription factor binding sites were obtained from the 
Fraenkel lab web site http://fraenkel.mit.edu/yeast_map_2006/.  
GOLPH	  algorithm	  
GOLPH aims to find multi-locus linkage or association to gene expression traits and is 
designed to find iQTL (interacting Quantitative Trail Loci) that involve two or three loci. Each iQTL 
consists of a primary locus that links to the trait and up to two secondary interacting loci. A 
secondary allele is included if it significantly links to the trait, conditioned on a specific allele for 
the primary locus. An iQTL can have a different secondary locus for each allele of the primary 
locus. The relationship between loci is represented as a decision tree with the primary locus set 
as the root node of the tree. GOLPH constructs iQTL modules consisting of the iQTL decision 
tree and all the genes that link to that combination of interacting loci. These iQTL modules are 
further portioned in subsets of co-expressed genes, or gene expression patterns. 
GOLPH performs three non-iterative stages. First, it detects primary QTL and creates 
modules of all the genes that link to each locus. The second stage detects secondary loci and 
represents these as a decision tree, or regulatory program, and the third stage reassigns genes 
to iQTL modules based on the regulatory programs defined in stage 2.  Stages 1 and 2 include 
only genes with standard deviation > 0.25 and stage 3 expands to all genes in the data.  
At the heart of GOLPH is the modularity assumption. Stated simply, due to the modular 
organization of the regulatory network, true QTLs are likely to influence the expression of many 
genes. It is widely accepted that the cell’s regulatory network has evolved to be modular, 
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reflecting common biological processes and pathways sharing regulatory mechanisms168. Indeed, 
it has been shown that the deletion of a single regulator alters the gene expression of hundreds of 
genes: Transcription factors170,175, signaling molecules176 and chromatin modifiers177.  Moreover, 
it has been shown that most transcription factors directly bind hundreds of genes178. Therefore, if 
gene deletion alters the expression of hundreds of genes, it is reasonable to expect that other 
genetic changes which alter a regulator’s function or abundance should also have significant 
influence on many transcripts.   
Stage	  1	  
Stage 1 is similar to classic 
linkage methods that are based on 
non-parametric permutation 
testing15,179. Each gene is tested 
against each locus and significant 
associations are reported. After 
associating genotypes to genes, I 
cluster nearby small linkage peaks 
and merge them with the largest 
dominant linkage peak along the 
chromosome (Figure II-7).  
To detect significant gene-
locus pairs, GOLPH uses Welch's 
t-test180 splitting the segregants 
into two groups based on their genotype (BY or RM). Welch's t-test is an adaptation of the 
Student's t-test intended for use with two samples that may have unequal variances. This is 
similar to regression commonly used for association testing because the segregant data is binary; 
a gene can only be inherited from a BY or RM strain.    
GOLPH evaluates the significance of each gene-locus pair via two tests: the parametric p-
value of the Welch t-test and non-parametric permutation testing. For each gene 1000 random 
 
Figure III-7 - Merging close loci 
(a) The top panel shows the linkage signal before unifying signals 
from nearby markers. The signal creates broad hills, rather than 
sharp peaks. The x axis represents the location of the locus, each 
of the bold lines below the axis represents a yeast chromosome (I 
to XVI).  The y axis represents the number of genes linked to 
each locus.   (b) The bottom panel shows a much cleaner linkage 
map with sharper peaks after unification step. 
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permutations of segregant label were used, randomly assigning each gene expression profile to 
the genotype of another segregant. This way both gene expression and genotype hold their 
natural structure, but are independent of one another. All 526 markers for all 1000 random 
permutations were scored, generating a null distribution of Welch’s t-test p-value for each gene. A 
gene is linked to a locus if its Welch p-value is better than 0.05 and permutation based p-value is 
better than 10-5 (p-value of 0.001 after Bonferroni correction for 526 markers).   
Genes linked to one marker are also likely to have linkage signals in neighboring markers 
due to similarities between proximal markers (Figure II-7a). To pinpoint the most likely marker, I 
merge small peaks with proximal larger peaks. Based on modularity, the assumption is that if a 
nearby marker linked to a large number of genes, it is more likely to involve a causal factor than 
one that links to only a few genes. For each marker I construct a gene set including all the genes 
that link to that marker. I remove genes from small gene sets and move them to larger nearby loci 
based on the ratio between the size of the linked sets and the delta p-value of the linkage score. I 
run the algorithm several times, each time handling a different order of linkage peaks to get a 
stable linkage map. After removing modules that have fewer than five genes, 44 loci remain, each 
linked to at least five genes (Figure II-7b and Table II-1). Only two adjacent loci remain in the final 
map, each linked to a different set of genes.   
 
Table III-1 - Module Growth 
Locus # genes linked 
after stage 1) 
# of genes linked after all 
stage, out of 1733 genes 
# genes linked after all 
stage out of all genes 
M15_170945_180961 604 990 2128 
M14_449639_449639 166 402 1088 
M12_659357_674651 92 302 697 
M2_533262_555787 47 128 292 
M11_247944_247956 36 172 273 
M3_100213_105042 31 101 173 
M16_511400_523450 26 216 390 
M13_46070_69122 24 82 181 
M8_111679_111690 23 67 209 
M5_420595_430931 22 76 123 
M14_486861_486861 20 368 1018 
M1_41483_42639 20 130 210 
M2_310928_310928 19 154 282 
M13_261719_286122 16 40 110 
M9_139462_141014 15 40 63 
M5_109310_117705 14 63 114 
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M12_677957_697260 12 190 407 
M4_246738_262796 12 17 31 
M15_838599_850119 11 20 39 
M9_214482_254745 11 130 221 
M7_98231_117900 10 9 17 
M4_555043_555043 10 13 20 
M15_515917_546197 9 9 26 
M11_388373_397458 9 10 11 
M10_163850_185319 9 9 14 
M8_185012_188851 9 17 32 
M13_404546_404546 8 40 66 
M12_423789_423789 8 10 16 
M11_566015_566015 8 50 113 
M10_472146_503466 8 11 27 
M7_402833_415585 8 22 45 
M4_1418647_1418647 8 21 67 
M4_114155_122293 8 76 147 
M2_562409_570229 8 132 321 
M14_220948_220948 7 7 22 
M12_92674_95639 7 16 30 
M7_1058947_1063841 7 43 108 
M4_1240155_1240245 7 6 10 
M2_352257_368060 7 82 171 
M15_968429_970605 6 5 7 
M7_916471_919654 6 39 93 
M4_935079_935079 6 8 17 
M2_328489_334016 6 146 311 
M2_87845_87845 6 2 2 
Lists the number of linkages to the 44 primary loci selected in stage 1, throughout the stages of the 
algorithm. The first column lists all loci of stage 1 and the number of genes linked. After merging of close loci 
and removal of modules with less than 5 genes, 44 modules remain. The second and third columns list the 
number of linked genes in stage 3. 
 
Stage	  2	  
In the second stage, GOLPH constructs iQTL modules by finding secondary loci that interact 
with the primary loci identified in stage one. This approach is similar to that of Storey et al.165, and 
they have demonstrated that this two-step approach outperforms the exhaustive 2D scan, which 
tests all pairs of loci. More power is gained by evaluating significantly fewer hypotheses. 
For each of the 44 modules identified in stage 1, segregants are partitioned into two sets 
based on whether they are BY or RM at the primary locus. For each gene in the module, (i.e., 
each gene linked to the primary locus), secondary linked loci are searched using the Welch 
permutation test as described for stage 1, based on a Welch's t-test p-value of 0.05 and a 
permutation p-value threshold of 10-4. This process is carried out independently for segregants 
	  
 44	  
that have the BY or RM allele at the primary locus. Each detected secondary linkage creates an 
iQTL represented as a decision tree. The resulting tree can have secondary splits on the BY 
(right) side, the RM (left) side or both.  
As in stage 1, close loci link to overlapping sets of genes. To pinpoint iQTL peaks and remove 
redundant iQTL modules based on neighboring loci, I use a different approach from the one used 
in stage 1. For each chromosome, I create a graph where each chromosomal marker is 
represented as a node. An edge exists between two nodes if there is a gene linked to both 
markers.  I collapse each fully connected clique (a subgraph of nodes fully connected to each 
other by edges) into the single marker with the most linkages in that clique, resulting in fewer loci 
with more genes linked per locus to each other. I use the resulting markers to construct the iQTL 
modules, their regulation trees and the set of linked genes. After removing modules that have 
fewer than five genes, we obtain 91 iQTL modules. 
Stage	  3	  
In this stage iQTL modules are expended based on the modularity assumption. Using the 
regulatory programs found with a stringent statistical threshold in stage 2, genes are reassigned 
to modules using false discovery rate (FDR181) on the permutation based p-values. In loose 
formalism, one can view stage 2 of the algorithm as constructing a “prior” on iQTL, assigning a 
higher “prior probability” for iQTL that have strong linkage to at least 5 expression traits. Stage 3 
recalculates linkage allowing this “prior” to weigh in (this is not technically a prior, as the data 
itself is used to construct it), leading to the inclusion of many additional genes in each iQTL 
module. 
Each regulation tree is examined, and all 4338 genes are evaluated for each tree, involving 
two independent tests, depending on the structure of the tree.  A gene has to pass both tests to 
be included in a module. 
• If a tree has only one secondary-split (Figures I-2,5), both the major locus and the 
secondary locus are tested.  
• If a tree has two secondary splits, both secondary splits are tested, and the primary locus 
is used only to partition the segregants.  
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Using permutations, a p-value distribution was independently generated for each of the two 
tests above.  An FDR threshold is determined from the observed p-value and a final gene set that 
passes an FDR threshold of at least 0.01 on both tests was chosen. Hence the threshold is 
adaptive to the number of genes and the strength of linkage signal for each locus, so a large 
number of weak signals that point to the same locus increase the significance. As a result, a 
larger number of genes are added to the modules (Table I-1). In the case of two sided modules 
and in contrast to stage 2, a gene does not need to link to the primary locus to be tested for an 
iQTL module. It is possible for a gene to join a module without significant linkage to the primary 
locus as clear separation of expression patterns occurs only in the secondary split.   
Modules sharing the same primary locus are often found to have overlapping gene sets, but 
one has an allele-specific interaction on the BY side, and the other has one on the RM side. In 
many cases, a regulatory program with these two sub-splits was not created in stage 2 due to the 
rigorous cutoff and the use of fewer genes. A unified regulatory program is now created, and the 
overlapping genes are removed from their single-sided modules. The new expanded regulatory 
programs are now tested again for linkages using the method in stage 3.  
Expression	  Patterns	  
Linkage for modules is performed independently for each gene ignoring coexpression. 
Although no restriction on correlation of expression is forced by GOLPH, expression between 
genes in each module does correlate, and in most cases the majority of the genes in the module 
are captured by a small number of expression patterns (see Figures I-3,5). Typically, when more 
than one expression pattern exists in an iQTL module, the patterns always reversed, or mirrored. 
While one group of genes is up-regulated in one pattern, the other group is down-regulated, and 
vice-versa.   
 
Statistical	  Validation	  	  
To test the credibility of our algorithm I performed a number of randomization tests to ensure 




The dataset was randomized by permuting the labeling of the segregants in the gene 
expression data. Both gene expression and genotype datasets remain intact, preserving the 
modularity and co-expression in the gene expression matrix as well as the genomic organization 
of the genotype data. The difference is that the gene expression of a strain does not match the 
genotype and therefore any linkage is spurious. This is equivalent to the randomization used to 
evaluate Welch's t-test, except that here it is treat it as the “input data” for GOLPH.  
I ran stage 1 on several permutated datasets and found only a small number (2-3) of small 
linkage peaks. This is compared to the original dataset in which many linkages including sets as 
large as 604 genes were detected. Stage 2 did not find any single iQTL with 5 or more genes. 
Therefore I conclude that GOLPH’s iQTLs are robust and represent true biological signal.  
Randomized	  iQTL	  
Another concern is that by lowering the threshold, stage 3, which reassigns genes to pre-
defined iQTL, might add many spurious linkages. To test my assumption that only true interacting 
loci will result in a large module (many genes) in stage 3, I randomized the pairs of iQTL given as 
input to stage 3 (Figure II-8). Randomizations were performed in two ways: 
• Double random: 1000 random pairs of loci out of the available 526, where both the 
primary and secondary loci were selected at random, as well as a random determination 
of the BY or RM allele for the secondary split.  
• Secondary random: 1000 random pairs of loci, where the primary locus is randomly 
chosen out of the 44 true primary loci and the secondary split is chosen at random from 
all 526 markers, as well as a random determination of the BY or RM allele for the 




Figure II-8 shows us that large iQTL modules do not form with random loci pairs, but rather 
with true interacting pairs. It is also 
evident why a requirement for at least 
five genes in the iQTL was used before 
applying the expansion: many random 
iQTL have a few genes linked to them, 
but rarely do random pairs have 5 or 
more genes. Among the 1000 
randomized secondary loci, only 218 
have more than one gene linked to 
them. 20 out of these 218 programs 
were identified by GOLPH from the 
original data, explaining linkages for 
185 genes. Taking this into account, 
we found only 144 genes linked to the 
rest 198 modules by chance. 
Taking these results together, I conclude that the iQTL chosen in stage 2 are statistically and 
biologically meaningful. 
Validation	  using	  other	  data	  sources	  
The biological relevance of each iQTL module was evaluated using gene set enrichment 
analysis from a number of other genomic data sets and databases. GO categories with more than 
5 genes were used to evaluate the functional coherence of modules. I compiled a number of 
resources to generate gene sets associating regulators and their targets. These include ChIP 
binding data for transcription factors182 and chromatin modifying factors183,184, gene expression 
data from deletion mutants17,185 and putative transcription factor binding sites (TFBS) from the 
Fraenkel lab web site http://fraenkel.mit.edu/yeast_map_2006/ (The TFBS map with sequences 
conserved in at least two other yeast species and matched with a ChIP binding event was used). 
 
Figure III-8 - Results of Randomized iQTLs 
Randomized allele pairs.  The resulting module sizes 
(number of genes) in the x axis and number of modules for 
each size (out of 1000 random iQTLs) in the y axis.  (a) 
represents the 1000 double random iQTL and (b) represents 
1000 secondary random iQTL. (c) shows the results of the 
real data.   
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Hypergeometric enrichments were calculated for all modules against all gene sets and carried out 
an FDR correction considering values of Pcorrected < 0.005 to be significant. 
Definition	  of	  Interaction	  Types	  
Let X be the primary locus and Y, Z be secondary loci. GOLPH’s model can be written as 
expression y=baseline+aX+αbY+(1-α)cZ, α=1 for X=BY and α=0 for X=RM. 
Using the resulting model I define 4 interaction types. While the categorization is defined 
algorithmically and is based on the module structure identified by GOLPH, the resulting 
categories exhibit distinct characteristics.  
Allele specific: Modules with only one secondary locus, linking to only one allele of the 
primary locus. In allele specific modules, the secondary locus is not significant for the other allele 
of the primary locus. This splits into two additional categories based on the primary allele, RM 
(Figure II-5a orange) and BY (Figure II-5a brown).  A gene-locus pair (G,L) is considered allele 
specific if G resides in an allele specific module, with L being its secondary locus. I note that if G 
is included in a module that is two-sided for L, it is excluded from any allele specific module 
involving L as a secondary locus. This definition does not formally test that an independent 
contribution of L to G’s expression is 0; nevertheless, Figure II-5b demonstrates that c is small 
and that c<<b for the case of BY allele specific and likewise b is small and b << c for RM allele 
specific. 
Double Allele specific: Modules with two different secondary loci regulating each allele of the 
primary locus. Neither secondary locus links to the other side (Figure II-5a green). 
Additive:  Modules with the same secondary locus significant for both alleles of the primary 
locus (Figure II-5a dark blue). Additionally, F-test was used as described in163 to test for 
synergistic interaction - whether the expression is better described as y~AX+BY or 
y~AX+BY+CXY.  For additive modules, C is insignificant or b≈c in our model’s formalism. An 
example of such a module is given in Figure II-4a.  
Synergistic: Modules with the same secondary locus significant for both alleles of the primary 
locus (Figure II-5a light blue) that are best represented as y~AX+BY+CXY, i.e., C is a significant 
term in the F-test.  In the model’s formalism this means that b and c are significantly different and 
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can at times be even opposing in their effect. An example of such an opposing influence is given 
in Figure II-4b.  
 
Fifty non-allele specific 
modules were identified by 
GOLPH, with a total of 562 genes 
creating 151 gene expression 
patterns. 31 patterns in 18 
modules were found to have a 
significant interaction term, 
passing a p-value threshold of 
0.05 in the F-Test (Table I-2).  
Five out of the 31 synergistic 
programs show reverse effect of 
the second regulator. In these 
cases, the second regulator has 
one effect on the segregants with 
a RM allele of the major regulator, 
either over or under expression, 
while showing the reverse effect 
on the BY segregants (Figure II-
4b, Table II-2).  
Comparison	  to	  previous	  studies	  
Previous studies by Storey et al.165 developed an algorithm to detect interacting QTL using a 
stepwise algorithm. While both methods use a stepwise approach to identify secondary linkage, 
there are three key differences between GOLPH and these previous studies: modularity, allele-
specificity and "one gene-one program" assumption.  
Table III-2 – eQTL reverse interactions 
Primary Locus Secondary Locus # Genes 
M15_170945_180961 M7_167587_192140 1 
M15_170945_180961 M4_161196_165032 1 
M15_170945_180961 M10_89097_96376 1 
M15_170945_180961 M9_190794_205191 1 
M15_170945_180961 M4_85846_106892 2 
M15_170945_180961 M4_85846_106892 1 
M15_170945_180961 M4_85846_106892 1 
M15_170945_180961 M12_92674_95639 1 
M15_170945_180961 M10_472146_503466 1 
M15_170945_180961 M10_472146_503466 6 
M15_170945_180961 M9_21454_21455 1 
M15_170945_180961 M9_21454_21455 26 
M15_170945_180961 M9_21454_21455 1 
M15_170945_180961 M9_21454_21455 3 
M15_170945_180961 M16_84943_104423 3 
M15_170945_180961 M12_450041_508029 1 
M15_170945_180961 M12_450041_508029 1 
M15_170945_180961 M6_70818_75460 1 
M15_170945_180961 M6_70818_75460 3 
M15_170945_180961 M6_70818_75460 12 
M15_170945_180961 M3_100213_105042 3 
M14_449639_449639 M12_642137_644136 1 
M14_449639_449639 M1_51324_52943 1 
M14_449639_449639 M1_51324_52943 2 
M14_449639_449639 M1_51324_52943 4 
M12_659357_674651 M15_802724_819015 1 
M12_659357_674651 M5_492125_504717 3 
M12_659357_674651 M5_492125_504717 2 
M12_659357_674651 M1_41483_42639 1 
M2_533262_555787 M13_33501_33681 2 
M2_533262_555787 M13_33501_33681 1 
31 modules that were identified as synergistic using F-test. 




At the heart of GOLPH is our “modularity assumption" and I apply this assumption in a number 
of points during the algorithm. Stage 1 uses the assumption of modularity to unite adjacent 
markers which show linkage to overlapping sets of genes. Stage 2 only considers significant 
modules with 5 or more genes, and stage 3 uses modularity to reassign a higher “prior 
probability” to iQTL detected in stage 2. GOLPH uses the modularity assumption to lower the 
threshold of stage 3 by calculating FDR on sets of genes. The largest gain in GOLPH linkages 
(red bars in Figure II-2a) is due to this application of modularity in stage 3.  
Allele-­‐Specificity	  
GOLPH tests the secondary locus for each primary allele independently and can detect two 
different secondary alleles. The mathematical model assumed by Storey et al. can be written as:  
y~aX+bY+cXY, whereas GOLPH’s model can be written as y~ aX+αbY+(1-α)cZ. The second and 
third genotypes (Y and Z) only affect the expression level when the primary locus (X) has a 
specific allele, hence the term "allele-specific iQTL." 
"One	  Gene-­‐One	  Program"	  
The above-mentioned studies looked for the single best primary linkage for each gene in the 
first step, and then used this best linkage to find a single best secondary linkage. My approach is 
not based on the assumption that only the best linkage found is true, but rather all linkages that 
pass the defined significance thresholds are considered to be true. This approach allows me to 
find more than two QTL for one gene. Figure II-2b demonstrates the number of linkages achieved 
for each gene and these match the theoretical studies by Brem and Kruglyak163 on the expected 
number of influences for each gene.   
 
As a consequence of these differences the linkages resulting from each of the two methods 
are different and complementary to each other. In total, GOLPH identifies many more linkage 
pairs (and single linkages) than the method of Storey et al.  Many allele specific and opposing 
interactions are detected only by GOLPH; moreover in stage 3 many genes are added that do not 
pass significance by Storey’s FDR.  The largest overlap in the detected linkages between the two 
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methods is in the interactions we characterized as additive. Nevertheless, Storey’s method 
detects many additional additive linkage pairs that are missed by GOLPH. GOLPH removes from 
consideration all iQTLs involving fewer than 5 genes linking to that pair (motivated by our tests on 
randomized data) and for an individual gene versus a locus pair, the FDR implemented by Storey 






The emergence of new technological advances in high throughput genotyping and sequencing 
has enabled large scale characterization of genetic variation at high resolution. However, novel 
computational approaches are needed to detect causal sequence variants and model how 
genotype influences phenotype. A first step is to characterize the landscape of genetic 
interactions between naturally occurring variants and to elucidate how multiple loci combine to 
affect phenotype.  
Applying GOLPH to yeast detected between two to ten linkages for each of 2745 genes, 
providing a first expansive view on the architecture of multi-locus traits and the genetic 
interactions between them. A remarkable finding is a large-scale occurrence of allele-specific 
interactions, indicating that the landscape of multi-locus traits is predominantly non-additive. A 
likely mechanism for allele-specific interactions stems from the observation that genetic variation 
can mimic the response to environmental change. Thus different biological states occur not only 
in response to the external environment but also as a result of intrinsic genetic variation.  
Genetic variation in both coding and regulatory regions of transcription factors can lead to 
responses that alter cellular state (e.g. HAP1, HAP4). More intriguing, such large scale 
transcriptional responses are not only caused by variation in classical transcriptional regulators, 
but also due to polymorphism in metabolic enzymes, regulators of translation and molecular 
chaperones (e.g. LEU2, MKT1, TCM62). These demonstrate that genetic variation in a single 
gene may trigger a cascade of events, leading to an alternative cellular state, by predisposing the 
cell towards shutdown or activation of pathways. In this way the molecular network can be 
considered an intricate web of interacting factors in which dynamic entities may rewire their 
connectivity in response to perturbations in the environment and as a result of intrinsic genetic 
variation.  
The prevalence of complex, non-additive gene-gene interactions is likely to play a large role in 
human and disease- related genetics and offers clues as to why recent association studies 
involving over tens of thousands of individuals have only accounted for a very small fraction of the 
heritable variation observed 159. I believe that state changes driven by intrinsic genetic variation 
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and the resulting allele specific interactions are likely common in human and disease associated 
genetics. In multi-cellular organisms, genetic variation can lead not only to an altered cellular 
state, but can propagate to changes at the level of the entire organism. Detecting such allele-
specific association in human is significantly more challenging as the genome is two orders of 
magnitude larger than yeast and the population structure is more complex. 
This work also demonstrates the value of using gene expression as a proxy between genotype 
and phenotype. Contrary to previous association studies, I used clusters of genes and not single 
genes as the phenotypes. Aggregating genes in clusters proved to enhance the power of the 
study by two fold – First, clusters of genes cancel the noise in the data, allowing for more 
accurate association; Second, post-analysis on the cluster genes allow linking the loci to 
molecular functions, greatly enhancing the biological interpretation and value of linkage analysis. 
Others have shown that gene expression can also identify the casual gene within the loci186, 





Chapter	  III -­‐	   An	   Integrated	   Approach	   to	   Uncover	  
Drivers	  of	  Cancer	  
This work was done in collaboration with Dr. Uri-David Akavia and was published under Akavia, 
Litvin et al.12 
Introduction	  
Large-scale initiatives to map chromosomal aberrations, mutations and gene expression have 
revealed a highly complex assortment of genetic and transcriptional changes within individual 
tumors. For example, copy number aberrations (CNAs) occur frequently in cancer due to genomic 
instability. Although multiple new genes have been implicated in cancer through sequencing and 
CNA analysis103, these studies have also revealed enormous diversity in genomic aberrations 
among individuals. Each tumor is unique and typically harbors a large number of genetic lesions, 
of which only a few drive proliferation and metastasis. Thus, identifying driving mutations (genetic 
changes that promote cancer progression) and distinguishing them from passengers (those with 
no selective advantage) has emerged as a major challenge in the genomic characterization of 
cancer. 
The most widely used approaches are based on the frequency an aberration occurs: if a 
mutation provides a fitness advantage in a given tumor type, its persistence will be favored and it 
is likely to be found in multiple tumors. For example, GISTIC identifies regions of the genome that 
are aberrant more often than would be expected by chance, and has been used to analyze a 
number of cancers25,187,188. However, there are limitations to analytical approaches based on CNA 
data alone: CNA regions are typically large and contain many genes, most of which are 
passengers that are indistinguishable in copy number from the drivers. CNA data has statistical 
power to detect only the most frequently recurring drivers above the large number of unrelated 
chromosomal aberrations that are typical in cancer. Finally, these approaches rarely elucidate the 
functional importance or physiological impact of the genetic alteration on the tumor. These 
limitations highlight the need for new approaches that can integrate additional data to identify 
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drivers of cancer. Gene expression is readily available for many tumors, but how best to combine 
it with information on CNA is not obvious. 
Here we use gene expression as a phenotype, and associate it with CNA. We postulate that 
driving mutations coincide with a “genomic footprint” in the form of a gene expression signature. 
We developed an algorithm that integrates chromosomal copy number and gene expression data 
to find these signatures and identify likely driver genes located in regions that are amplified or 
deleted in tumors. Each potential driver gene is altered in some, but not all tumors and, when 
altered, is considered likely to play a contributing role in tumorgenesis. Unique to our approach, 
each driver is associated with a gene module, which is assumed to be altered by the driver. We 
sometimes gain insight into the likely role of a candidate driver, based on the annotation of the 
genes in the associated module.  
We demonstrate the utility of our method using a dataset187 that includes paired 
measurements of gene expression and copy number from 62 melanoma samples. Our analysis 
correctly identified known drivers of melanoma and connected them to many of their targets and 
biological functions. In addition, it predicted novel melanoma tumor dependencies, two of which, 
TBC1D16 and RAB27A, were confirmed experimentally. Both of these genes are involved in the 
regulation of vesicular trafficking, which highlights this process as important for proliferation in 
melanoma. 
Our results show that gene expression reflects cellular state and can be used to support 
algorithms that require information regarding pathway activity and phenotypic outcome. By using 
gene expression we are able to identify phenotypes and correlate them with locus aberrations. 
Moreover, we found that many of the phenotypes, and therefore the influence of a driver 
mutation, are context-specific – present only in a context of another mutation. These results 
emphasize the critical information gene expression provide over the frequency of a mutation 
regarding the impact of the mutation, as many driver mutations are present in only a fraction of 




CONEXIC	  –	  a	  computational	  framework	  
We define a “driving mutation” to be a genetic alteration that provides the tumor cell with a 
growth advantage during carcinogenesis or tumor progression98. We reasoned that driving 
mutations might leave a genomic ‘footprint’ that can assist in distinguishing between driver and 
passenger mutations based on the following assumptions:  
1. A driving mutation should occur in multiple tumors more often than would be expected by 
chance (Figure III-1A). 
2. A driving mutation may be associated (correlated) with the expression of a group of 
genes that form a ‘module’ (Figure III-1B). 
3. Copy Number Aberrations often influence the expression of genes in the module via 
changes in expression of the driver (Figure III-1C). 
 
Figure III-1 - The assumptions underlying CONEXIC 
For all heat maps, each row represents a gene and each column represents a tumor sample. A. The same 
chromosome in different tumors, orange represents amplified regions. The box shows regions amplified in 
multiple tumors. B. An idealized signature in which the target genes are up-regulated (red) when the DNA 
encoding the driver is amplified (orange). C. A driver may be overexpressed due to amplification of the DNA 
encoding it, or due to the action of other factors. The target genes correlate with driver gene expression 
(middle row), rather than driver copy number (top row). D. Data representing amplified region on 
chromosome 17. Heat maps of expression for 10/24 genes in the region that passed initial expression 
filtering. Samples are ordered according to amplification status of the region (Orange amplified, Blue 
deleted). These genes are identical in their amplification status and while gene expression is correlated with 
amplification status to some degree, the expression of each gene is unique. It is these differences that 




Driving mutations are frequently associated with the abnormal regulation of processes such as 
proliferation, differentiation, motility and invasion. Given that many cancer phenotypes are 
reflected in coordinated differences in the expression of multiple genes (a module)189,190, a driving 
mutation might be associated with a characteristic gene expression signature or other phenotypic 
output representing a group of genes whose expression is modulated by the driver. Additionally, 
CNAs do not typically alter the coding sequence of the driver and so are expected to influence 
cellular phenotype via changes in the driver’s expression. In consequence, changes in expression 
of the driver are important and so approaches that measure association between the expression 
of a candidate driver (as opposed to its copy number) and that of the genes in the corresponding 
module are likely to promote the identification of drivers. 
Gene expression is particularly useful for identifying candidate drivers within large amplified or 
deleted regions of a chromosome: whereas genes located in a region of genomic copy gain/loss 
are indistinguishable in copy number, expression permits the ranking of genes based on how well 
they correspond with the phenotype (Figure III-1D). CNA data aids in determining the direction of 
influence, which cannot be derived based on correlation in gene expression alone. This permits 
an unbiased approach for identifying candidate drivers from any functional family, beyond 
transcription factors or signaling proteins. 
A	  Bayesian	  Network	  Based	  Algorithm	  to	  Identify	  Driver	  Genes	  
We developed a computational algorithm, COpy Number and EXpression In Cancer 
(CONEXIC), that integrates matched copy number (amplifications and deletions) and gene 
expression data from tumor samples to identify driving mutations and the processes they 
influence. CONEXIC is inspired by Module Networks169, but has been augmented by a number of 
critical modifications that make it suitable for identifying drivers (see Computational Methods). 
CONEXIC uses a score-guided search to identify the combination of modulators that best 
explains the behavior of a gene expression module across tumor samples and searches for those 
with the highest score within the amplified or deleted region (see Computational Methods). 
The resulting output is a ranked list of high scoring modulators that both correlate with 
differences in gene expression modules across samples and are located in amplified or deleted 
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regions in a significant number of these samples. The fact that the modulators are amplified or 
deleted indicates that they are likely to control the expression of the genes in the corresponding 
modules (see Figure III-3). Since the modulators are amplified or deleted in a significant number 
of tumors, it is reasonable to assume that expression of the modulator (altered by copy number) 
contributes a fitness advantage to the tumor. Therefore, the modulators likely include genes 




CONEXIC is a data driven algorithm that takes matched copy number and gene expression 
data from tumors as input and combines these to identify driving aberrations and associate these 
with the genes they modulate. CONEXIC is based on a Bayesian scoring function that evaluates 
each candidate driver, or ‘modulator’. The score measures how well a modulator (or combination 
of modulators) predicts the behavior of a gene expression module across tumor samples. 
CONEXIC identifies the most likely drivers by searching for the highest scoring modulators in a 
 
Figure III-2 - Overview of the CONEXIC learning algorithm 
1. Selection of candidate driver genes (modulators). The same chromosome is represented in different 
tumors and orange represents amplified regions. The box shows a region amplified in multiple tumors, 
considered significantly amplified. Multiple genes reside in this region, represented as shaded boxes along 
two strands of DNA. Only the purple box represents a driver gene, whereas the gray boxes represent 
passenger genes and these are indistinguishable based on copy number alone. All genes located in 
significantly amplified or deleted regions are selected as candidate driver genes. 
2. Single Modulator step. Modules of genes are each associated with the best possible candidate driver, 
based on gene expression of the gene and the candidate driver. The heat-map represents a good 
association where both copy number of the modulator influences the expression of the modulator and the 
expression of the modulator corresponds to the expression of the genes in the module. Random re-
sampling with replacement is used to generate perturbations on the initial dataset and this step is repeated 
across datasets (bootstrapping). The histogram represents the number of runs (datasets) in which each 
selected modulator appears, the final run is performed with candidate drivers chosen for 90% of the runs 
(dotted red box). 3. Network Learning step. Using the set of Single Modulator of modules as a starting 
point, the algorithm refines the selected modulators and modules, now allowing for more than one 
modulator associated with each module. Bootstrapping is used similarly to the Single Modulator step, with 
the distinction being that modulators must be selected in 40% of the runs 
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stepwise manner (Figure III-2) that seeks to improve the Bayesian score. 
The resulting output is a set of predicted modulators that map within an amplified or deleted 
region. Each is associated with a module, a set of genes whose expression is likely altered by 
changes in expression of the modulator. In some cases, a module is associated with multiple 
modulators that form a regulatory program.  
The tool is available from http://www.c2b2.columbia.edu/danapeerlab/html/software.html  
 
Regulation	  programs	  
We adopted the concept of the regulation program from Segal et al.169. Formally, the 
regulatory program is a conditional probability distribution for the module gene expression, 
conditioned on the gene expression of the modulators. A regulation program of a module M 
specifies a set of contexts and the expected expression values for each context. A context is 
determined by the expression of a small set of modulators that influence M’s expression. This set 
of contexts is organized as a regression tree composed of two basic building blocks: decision 
nodes and leaf nodes. Each decision node corresponds to a modulator and a query on its value 
(for example, "is MITF >= threshold”). Each decision node has two child nodes: the right child 
node is chosen when the answer to the corresponding query is true; the left node is chosen when 
it is false. For each sample, one begins at the root node and continues down the tree in a path 
according to the answers to the queries in that particular sample until a leaf node is reached. 
Each leaf encodes a probability distribution representing how the module’s genes are expected to 
behave in that sample. The expression of genes in M in each context is modeled as a normal 
distribution; this distribution is encoded using a mean and variance stored at the corresponding 
leaf.  
Regression trees are particularly well suited for modeling driving mutations in cancer because 
(i) these can capture combinatorial and condition specific relations that frequently occur in cancer 
(e.g. both over-expression of EGFR and deletion of P16 are required) (ii) These can capture 
changes in both the mean and the variance of the module gene expression.  
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The	  CONEXIC	  algorithm	  
The CONEXIC learning algorithm consists of three key steps: 
1. Selection of candidate driver genes (Figure III-2A) 
2. Single Modulator step that creates an initial association between candidate drivers and 
gene modules (Figure III-2B) 
3. An iterative Network Learning step to improve on the initial model (Figure III-2C) 
 
CONEXIC searches for a model that can explain the variation in the gene expression across 
samples as a function of a small number of modulators. The search is driven by the optimization 
of a Bayesian scoring function. The search begins with an initial starting point and then proceeds 
in making stepwise changes that improve the score at each step.  
 
Selection	  of	  Candidate	  Drivers	  
Motivation: First, we want to identify regions of the DNA that are recurrently amplified/deleted 
in tumors and consider genes within or neighboring to those regions as candidate drivers. We 
expect that many of the driving mutations will be contained in this candidate list.  
Details: We applied the (GISTIC) algorithm25, using the JISTIC implementation available from 
http://www.c2b2.columbia.edu/danapeerlab/html/software.html104, to all 101 samples. To increase 
sensitivity, we used a q-value threshold of 0.3, compared to 0.25 previously used with this data 
187. Genes that overlap a significant aberrant region are chosen as candidate driver genes. To 
capture aberrations in regulatory regions, for each aberrant region, the closest non-overlapping 
genes on each side are also chosen as candidate drivers, if their distance from the edge of the 
region is less than 100Kb.  
Result: This resulted in 27 amplified regions containing 513 peak genes and 23 deleted 
regions with 384 peak genes (Table III-1). In subsequent steps, we aim to identify which of these 
897 candidates are likely drivers.  
Expression Filtering: We now integrate copy number and gene expression data, which is 
available for 62 tumors.  As an initial filter, we require candidate drivers to be differentially 
	  
 62	  
expressed across the different tumor samples. This removes genes that are expressed at a 
constant level across all tumors and not influenced by their copy number. Additionally, this 
removes genes that are not expressed, and are therefore unlikely to be drivers. Our final set of 
candidate drivers included 428 genes in significantly amplified or deleted regions, whose gene 
expression varied with standard deviation greater than 0.25. 
Single	  Modulator	  step	  	  
Motivation: The Single Modulator step constructs an initial model, which focuses the 
subsequent search on variation in gene expression that can be explained by drivers encoded in 
CNAs (as opposed to variation due to other types of aberrations such as coding mutations). The 
Single Modulator step (Figure III-2B), establishes an initial pairing between candidate drivers and 
gene expression modules by associating each target gene with the single driver gene that fits it 
best (based on corresponding gene expression profiles). As a result, each gene is clustered into 
a module consisting of those genes for which the same driver gene was found to be the best fit 
and the module is associated with that candidate driver.  
Details: To aid the identification of a good starting model, the Single Modulator step considers 
a smaller search space and more conservative set of candidate drivers, only those whose gene 
expression is significantly altered by either their amplification or deletion status. Candidates are 
filtered using a Welch t-test (p-value < 0.05), comparing amplified versus normal or deleted 
versus normal - 347 candidate drivers pass this test. Amplification or deletion status of a gene in 
a specific sample is determined using the average copy-number value for all SNP markers inside 
the gene; if the gene contains no SNP markers we take the copy-number value for the single 
closest SNP marker. Using the same thresholds as in 187, if the average value of the SNP 
markers around a gene is above 0.3, the gene is marked as amplified, if the average value is 
below -0.3,it is marked as deleted. 
For each candidate driver gene, we use the gene expression values of the amplified/deleted 
samples to guide the choice of threshold, and consider the gene expression of the 
amplified/deleted samples to represent appropriate high/low expression levels. We use k-means 
clustering, using k=2 and the normal and amplified/deleted samples as the two initial clusters to fit 
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two normal distributions. The boundary between the two clusters is the selected expression 
threshold level for this driver gene. The expression of each target gene is split into two sets: those 
in the tumor samples in which the driver's expression is below the threshold, and those in the 
tumor samples in which the driver's expression is above the threshold. The NormalGamma 
scoring function is used to compute the quality of this split, thus measuring a target gene's fit with 
a candidate driver.  
After the score is computed for all pair-wise combinations of candidate drivers and target 
genes, each gene is assigned to the single highest scoring candidate driver. Permutation testing 
is used to verify the statistical significance of association between driver and gene. Driver gene 
expression is randomly permuted 10,000 times, conserving the composition of values, but 
rendering the order random and independent of the target gene. Each of these permutations is 
scored, creating a null distribution to compare with the unpermuted order; thus providing a p-
value for the association between gene and candidate driver. If this p-value < .001, we associate 
between gene and candidate driver, declaring the candidate driver a modulator of its associated 
gene. Care must be taken to avoid spurious associations due to the dense correlation structure of 
genes encoded in the same aberrant region, as it is easy to obtain associations between all 
candidate drivers in a region with the same target gene. Thus, it is important to find only the 
single best association between a gene and its modulator.  
We established a number of additional criteria to ensure the robustness of our results; these 
criteria were guided by results on randomly permuted data. First, we require that each modulator 
be chosen by at least 20 genes. If some of the modules have less than 20 members, we break up 
the smallest module and reassign its genes to the next best scoring modulator, repeating until all 
modules have at least 20 members. Second, we apply non-parametric bootstrapping and repeat 
this procedure 100 times, generating variations on the dataset using random re-sampling with 
replacement. This ensures that the association is not an artifact of the specific set of samples and 
is robust across different subsets of the original data. We select candidate drivers that were 
selected in at least 90% of the runs.  
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We then make one final run of the Single Modulator step, using this filtered set of 130 
candidate driver genes. The selected set of modulators all reside in significantly aberrant regions 
and their gene expression best corresponds with at least 20 genes. The statistical significance of 
this association is ensured both by permutation testing and non-parametric bootstrap.  
Result: Single Modulator step identified 78 modulators that explain the behavior of 4018 
genes. Each of the 78 modulators is associated with a module containing at least 20 genes. 
These will be refined in subsequent steps.  
Network	  Learning	  step	  
Motivation: The Network Learning step (Figure III-2C) uses the modules generated by the 
Single Modulator step as a starting point and uses an iterative approach to improve the score of 
the modules and their regulatory programs. The Network Learning step is based on the Module 
Networks algorithm169,174 with a few critical improvements, designed to remove spurious 
association, described below.  
Details: The algorithm iteratively alternates between two tasks: (i) learning the regulation 
program for each module; (ii) and re-assigning each gene into the module that best models its 
behavior. The score improves at each iteration and these terminate if fewer than 10% of the 
target genes have been re-assigned to a different module during the gene re-assignment step. 
Given a set of modules, we learn a regulatory program for each module. We recursively learn 
the regulatory program by choosing, at each point, the candidate driver that best splits the gene 
expression of the module genes into two distinct behaviors. All candidate drivers and potential 
split values are evaluated and the driver-split combination that achieves the highest improvement 
in score is selected. Only if the score improvement is greater than a pre-defined penalty, the split 
is selected. Unlike Single Modulator, all 428 candidate drivers are considered and each candidate 
driver is not limited to a single split threshold; rather the optimal threshold is chosen to maximize 
the score. While multiple thresholds are possible across the different regulatory programs, the 
score includes a penalty on the number of different split values, thus limiting the number selected. 
The tree is recursively grown from the root to its leaves. At each new split, the driver gene that 
provides the best improvement in score is chosen; permutation testing (as in the Single Modulator 
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step) is used to ensure the statistical significance of the split; and the outlier-removal test 
(described below) is used to ensure the modulator was not selected due to outliers in the data. 
For each new split, linear influence of the modulator on each side of the split is tested (as 
described below), and if linear influence is found further sub-splits on this side of the split are 
forbidden. The process terminates when no query that improves the score and passes these two 
tests can be found, allowing for up to a total of five splits in each regulatory program.  
In addition to permutation testing, the regulatory-program learning process includes two 
additional statistical tests, designed to remove spurious splits. (i) To ensure that modulators were 
not selected due to outliers in the data, splits are subjected to a outlier-removal test, as follows: 
for each candidate split, we remove the highest 4% of expression values in the side that has 
higher mean expression, and re-calculate the score improvement with the remaining 96% of the 
data. We reject the split if the score improvement is less than 0.6 times the score improvement 
with the entire data. We perform a similar test removing the lowest 4% of expression values in the 
side that has lower mean expression. The resulting splits are robust to outliers in the data. 
(ii) Some of the modulators have a linear influence on the target gene expression and their 
values are enough to explain the variation in the expression of the target genes without additional 
splits. In most cases, such influence is only on one side of the split, e.g. target gene expression of 
one leaf is linearly correlated with the modulator expression, while the expression of the other leaf 
is not. Our goal is to remove additional splits when the modulator is correlated across all samples 
and retain splits in cases the correlation is one sided. Correlation alone is not sufficiently sensitive 
to distinguish between a strong correlation that is limited to one side of the split, versus a weaker 
correlation across all samples. To make this distinction, for each new split, and for each side of 
that split, we calculate the Pearson correlation and regression slope between the expression 
values of the modulator and of the members of the module. First, we ask whether the modulator 
is correlated with the module, and require a Pearson correlation coefficient > 0.6 for at least one 
of the leaves. Next, we evaluate whether the slope on both sides of the split is similar, requiring 
that the slope in the leaf with higher correlation and the slope of the combined data (on both 
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leaves) be within a ratio of 0.7 to1.4. If both criteria hold, we forbid any further sub-splits on the 
correlated side.  
Given the inferred regulation programs, we determine the module whose associated 
regulation program best predicts each gene's behavior. Specifically, we iterate over all genes, 
one at a time, and move each gene into the module that provides the highest improvement in the 
score. This step is guaranteed to improve the score, or leave it the same (if the gene is not 
moved). We repeat this reassignment process for all genes three times, at every iteration. 
Similarly to the Single Modulator step we boost robustness using non-parametric bootstrap. 
The iterative learning algorithm is run 100 times. We then filter the set of candidate driver genes, 
leaving only genes that appeared in at least one regulatory program in at least 40% of the runs. 
65 modulators pass this threshold and continue to the next step. We then make one final run of 
the Network Learning algorithm, using this filtered set of candidate driver genes. 
Results: This resulted in the identification of 64 modulators that explain the behavior of 7869 
genes.  We compared the models at the beginning versus at the end of the Network Learning 
step and found the end model superior by a number of measures: 
1. The final model can explain the behavior of 7869 genes, relative to only 4018 at the end 
of Single Modulator (starting model).  
2. The test log-likelihood is significantly higher for the final model, relative to the initial 
model, in a leave-one-out cross validation (see Figure III-2D and robustness section 
below). 
3. TBC1D16 is a good example of the need for the more aggressive search performed by 
network learning. It was the 2nd highest scoring modulator at the end of network learning 
and empirically validated. Due to its more limited search, Single Modulator did not select 
TBC1D16 at all.  
Model	  refinement	  
The candidate drivers used for the regulatory programs include only genes residing in CNA 
regions, which are expected to explain only part of the global changes in gene expression. 
Observed changes in gene expression can also result from additional factors, such as somatic 
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mutations that are not included in our data. While the algorithm attempts to assign all genes to 
modules, some genes expression is not influenced by any CNA based driver. Therefore, it is 
important to remove genes that can’t be explained by any regulatory program, or more formally, 
no program significantly improves the gene’s likelihood. For each gene, we calculate the 
difference between the likelihood of its data using its assigned regulatory program and the 
likelihood of its data without any regulatory program. For each module, we calculate the 
distribution of these delta likelihoods; those genes for which the delta likelihood is two standard 
deviations or more below the mean are removed from the module. These genes can’t be 
explained by any regulatory program and will not be members of any module. A final iteration of 
learning the regulation program is executed after these genes are removed.  
Score	  function	  
We use a Bayesian scoring approach that maximizes the overall joint probability of both the 
data and of the model structure. Let D represent the data and S represent the structure of the 
network, then the scoring function is expressed as . Where 
the first term is the likelihood of the data for a given model (in the Bayesian approach we 
integrate over all possible model parameters) and the second term is the prior on the structure for 
which we use a penalty score on model complexity.  
Following the Module Networks approach169 we use Normal Gamma distribution for our 
likelihood function. Normal Gamma gives a higher score to data with lower variance and hence 
finds splits that create two different contexts that represent two distinct behaviors (normal 
distributions). The Normal Gamma score is described below: 
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Leaf is a vector of gene expression values contained in the leaf and α,λ and β are parameters. 
A split is scored by comparing the score of the split data to the score without the split, along with 
a penalty for the split.  
 
Our penalty function is comprised of two parts. Following Module Networks 169, we use a 
complexity prior that penalized the number of leaves in each regulation program, using the 
exponential distribution over total number of leaves. Denoting the regulatory program as T and L 
as number of leaves, . Following genetic Module Networks 174, in addition to a 
penalty specific to each regulation program, we have a network wide penalty function that 
penalizes the total number of modulators. The prior takes the form of a power-law distribution on 
the number of modulators. This prior encourages the algorithm to select a sparse number of 
modulators, which is particularly important in this application, whose main purpose is to identify a 
small set of potential drivers. Full details are available in174. 
The scoring function has 5 parameters, α and λ for the Normal Gamma distribution and β, x 
and y for the complexity prior. These were selected using 10-fold cross validation and the 




Parameter	  Selection	  and	  Robustness	  	  
Selection	  of	  Candidate	  Drivers	  
Selection of candidate drivers requires determining a q-value threshold for GISTIC, the higher 
the threshold, the more candidate regions and genes will be selected, 0.25 is typically used as a 
threshold for determining the final list of significant regions 25,187,188. Within CONEXIC, GISTIC is 
used to only generate a pool of candidate genes for further selection, so we used the more 
permissive threshold of 0.3. It is likely that there are additional drivers even beyond a threshold of 
0.3, but too many candidate modulators burden CONEXIC both computationally and statistically. 
Therefore, we selected a threshold of 0.3 and correctly identified CCNB2 and RAB27A as drivers 
in region below the 0.25 threshold, demonstrating increased sensitivity.  
Single	  Modulator	  step	  	  
The Single Modulator requires a confidence threshold for non-parametric bootstrap. We 
selected 90, meaning that we only selected modulators chosen in more than 90% of the bootstrap 
runs. Before removing modules containing fewer than 20 genes the median single modulator run 
included 295 modulators. After removing small modules, a median of 202 modulators still 
remained. Following bootstrap with a threshold of 90% only 78 remained. 
Why did we choose 90? In a histogram representing the number of modulators at each 
confidence threshold (Figure III-3A) we observe that below 90 the distribution of modulators at 
each confidence level flattens and becomes uniform. It is important to note that this threshold 
does not define a filter, but rather only a starting point for Network Learning, which reconsiders all 
428 candidate drivers. Indeed, 10 modulators that are not selected at this stage are included in 
the final model, including TBC1D16 and ZPF106.  
CONEXIC achieves similar results across a broad range of thresholds and the final results 
bear significant similarity, even in a comparison between using 80 versus 95 as a threshold. 
Using 80 as a threshold results in 60 modulators and using 95 as a threshold results in 57 
modulators, the overlap between them is 45 modulators. The final model using 80 as a threshold 
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is much closer to our final model, with complete overlap in all the modulators discussed in this 
chapter.  
Network	  Learning	  step:	  
While the model resulting from Network Learning is higher scoring than the model resulting 
from Single Modulator, the former has more parameters and hence over-fitting is a concern. To 
evaluate whether the learned models can be generalized to unseen data, we compared the 
models derived from Single Modulator versus Network Learning using leave-one-out cross 
validation. For each sample (tumor), the two models were learned using the 61 other samples. 
 
Figure III-3 - Robustness analysis 
A. Histogram representing confidence values for bootstrap of Single Modulator. B. Histogram representing 
confidence values for bootstrap of Network Learning. C. Histogram representing confidence values for 
bootstrap of Network Learning, where the data has been randomly permuted. These values represent 
spurious modulators and none passed a confidence threshold of 35. 
D. Test likelihood for each sample in leave-one-out cross-validation. Each column is matched for the same 
sample, where green and blue stars represent test likelihood for single modulator and test likelihood for 
final CONEXIC model, respectively. The full model significantly outperforms Single Modulator on test data.  
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We calculated the test log-likelihood of the held out ‘test’ sample for each of the models. In 
essence, we are testing how well the model “predicts” a new sample. The likelihood of the held 
out sample was consistently better in the Network Learning model, for almost all of the 62 
samples (Figure III-3D).  
Network learning reconsiders all candidate drivers, so bootstrap is needed for this step, for the 
same reason it is needed in Single Modulator. Here, a clear threshold cannot readily be 
determined from a histogram representing the number of modulators at each confidence 
threshold (Figure III-3B). Instead, we used a similar histogram generated from the same data, 
only randomly permuted to determine a confidence threshold that is beyond spurious 
associations. Observing the histogram in Figure III-3C we see there are no spurious associations 
above 35, so we selected 40 as our threshold.  
A concern in this domain is its dense correlation structure; candidate drivers residing in the 
same region are all correlated to the region’s copy number and among themselves. Bootstrapping 
has a pivotal role in dealing with the spurious correlations that can arise: if a candidate driver 
corresponds to a module only through its correlation to its own copy number, other candidates in 
the region are equally likely to be selected and will not hold pass bootstrapping. Only when the 
candidate driver provides a substantially better score than its neighboring candidates in the 
region does the association hold. A threshold of 40 is more than enough to serve this role, as 
most regions have at least 5 genes, typically dozens.  
This threshold largely determines the final output and changes in it directly add or remove 
modulators from the final model. The result is a relatively short, ranked list of putative drivers, 
however discretion must still be applied. The ranking is informative; the top 10 are more reliable 
than those ranked 50 to 60. Additional filters can be applied to evaluate this list, such as whether 
it replicates in other datasets or whether it associates with a module annotated for cancer related 
processes. Our goal was generating a list of modulators that have a signal above spurious noise 




Comparison	  to	  other	  methods	  
Comparison	  to	  Module	  Networks	  
CONEXIC uses an algorithm similar to Module Networks169 as its key statistical engine. 
Module Networks is based on two principles: (i) influences and interactions between proteins 
often generate statistical dependencies in gene expression and (ii) testing dependencies on 
entire modules of genes enables statistical discovery that is undetectable when considering each 
gene in isolation. Module Networks was designed to infer regulatory models of transcription 
factors and their upstream signaling proteins. Module Networks handles the ambiguity between 
correlation and influence using prior knowledge: Taking a precompiled list of transcription factors 
and signaling proteins it assumes: ‘If a protein that has a known role in transcriptional regulation 
and is correlated (or anti-correlated) with the expression of genes in a module, it is likely to 
regulate the genes in that module.’ Module Networks was applied to a yeast dataset with 173 
samples, to build a regulatory model over 2355 genes169. 
CONEXIC has a fundamentally different goal: the identification of drivers of cancer. In this 
application, the primary role of the module is to provide support for a gene as a driver, the 
‘network interpretation’ is secondary. We apply CONEXIC to a human cancer dataset with 62 
samples, to build a model over 7869 genes involving influences that go beyond direct 
transcriptional cascades. CONEXIC is based on a different set of assumptions. It assumes that 
perturbations originate in the DNA and this provides the direction of influence (Figure III-3A). The 
set of candidate modulators includes all genes contained within frequently amplified and deleted 
regions of any functional class and thus extends beyond transcriptional regulation. It aims to 
capture modulation of expression in response to altered cell physiology (Figure III-3B). 
Aberrations in the DNA lead to perturbations which provide a rich source of variation that can be 
used to help uncover molecular influences in the cell. Numerous adaptations were made to the 
Module Networks algorithm to make it more suitable for this application.  
We provided the Module Networks algorithm, as originally implemented169 with the same 
candidate driver set (GISTIC output) used by CONEXIC. The resulting model includes 347 
modulators, which are a large fraction of the 428 candidates that pass expression filtering and is 
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of limited use as a selective method for identifying drivers. Additionally, only one of the empirically 
confirmed MITF targets (as defined by Hoek (Hoek et al., 2008) was associated with MITF, in 
contrast to the 45 identified by CONEXIC. The Single Modulator step was used to derive modules 
for initialization of Module Networks, as opposed to clustering initialization. Starting from the 
Single Modulator (with bootstrap) defined modules, the final output included 109 modulators, and 
MITF was associated with 46 of its experimentally derived targets (both numbers are median 
values across 100 runs). We conclude that the Single Modulator initialization method is critical for 
CONEXIC’s success in associating a modulator to genes it influences. It focuses the learning on 
changes in expression altered by CNA, as opposed to those altered via other mechanisms (e.g. 
coding mutations in the ERK pathway).  
The output from running Module Networks with bootstrap, using a candidate set defined by 
GISTIC and initialized using Single Modulator, yields results similar to those of CONEXIC. Each 
of the additional refinements: permutation testing, outlier removal, removal of linear splits and 
gene removal provide smaller improvements to the final results. For example, the removal of 
linear splits only removes 21 out of 489 splits in the model. Nevertheless, each of these steps 
improves the model, as assessed by leave-one-out likelihood tests.  
Integration	  of	  CNA	  with	  gene	  expression	  	  
Methods based on copy number information alone, e.g. GISTIC25,188 are typically limited to 
detecting large regions containing multiple genes, such that the driver cannot be readily identified 
among them. Applied to this melanoma dataset, GISTIC (with q-value of 0.25) finds multiple 
regions containing 588 genes187, the drivers and passengers indistinguishable. While GISTIC is a 
valuable method to filter a genome of ~23,000 genes and derive a set of hundreds of candidate 
drivers, additional data types are required to narrow this list down further.  
A number of different approaches integrate CNA and gene expression by identifying genes 
with significant correlations between DNA copy number and gene expression. Lin et al.187 applied 
the approach to this data and predicted KLF6 and CUL2 as putative drivers. Recently Huh et 
al.191 KLF6 was validated as a driver in melanoma. MITF CNA is poorly correlated with its gene 
expression and hence not identified with this approach. 
	  
 74	  
SLAMS192 bears some conceptual similarity to CONEXIC, but there are critical differences. 
SLAMS requires an initial signature that is used to divide the samples into classes and runs SAM 
to find the copy number that best separates the classes. The algorithm then finds a gene (or 
multiple genes) in the selected region, where the expression of the gene is a good predictor of the 
expression signature. In contrast to SLAMS, CONEXIC does not require a pre-defined expression 
signature, but identifies one or more signatures de novo. To test SLAMS on the melanoma 
dataset, we used the MITF targets identified by Hoek193 as a signature.  SLAMS identified the 
copy number of 1444 genes as significant, ranking MITF as 75th. In contrast, CONEXIC correctly 
identified MITF as the top ranked gene, associated MITF with its targets de-novo and predicted 
many additional drivers. 
Witten et al.194 described a method based on applying penalized canonical correlation analysis 
(CCA) to the cross product matrix of gene expression and CNA data, identifying the regions and 
correlated genes in a single step. We applied the method to the melanoma dataset using the 
same steps and parameters as those used in the original paper. This method identified 7980 
genes as significant, including almost all the genes influenced by CNA, but did not distinguish the 
drivers among them. 
 
Methods	  that	  integrate	  CNAs	  with	  other	  data	  types	  	  
In addition to expression, other data types have been used with CNA to help identify drivers. 
GRAIL195 prioritizes genes within GISTIC regions based on prior knowledge and known gene 
annotation. GRAIL identified MCL1 (using 3000 samples across multiple cancers), but failed to 
find MITF or KLF661.  
Another approach, NetBox196, uses a curated human protein-protein interaction database as 
an additional source of information. It constructs protein-protein interaction networks from genes 
within recurrently aberrant regions and defines drivers as hubs in these networks. Applied to the 
Lin melanoma dataset NetBox did not find any significant networks (lowest p-value 0.15). Even 
considering networks of low significance, NetBox did not identify MITF, KLF6 or any other known 
melanoma oncogene/tumor suppressor. Both GRAIL and NetBox are strongly based on prior 
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knowledge and annotations. While they present a powerful approach for identifying oncogenes in 
new contexts (e.g. MCL1 which has not yet been verified in melanoma), they only predict drivers 
among well annotated genes. The advantage of assaying copy number, gene expression, 
sequencing and other technologies genome-wide is that the data are comprehensive and 






Results	  –	  CONEXIC	  in	  melanoma	  	  
We applied the CONEXIC algorithm to paired gene expression and CNA data from 62 cultured 
(long and short term) melanomas187. A list of frequently altered loci was generated  
using copy number data available for 101 melanoma samples by applying a modified version104 of 
 
Figure III-4 - Top 30 modulators 
Gene names are color-coded based on the role of the gene in cancer, 10 genes have been previously 
identified as oncogenes or tumor suppressors (peach), of these 3 in melanoma (brown). Column 3 
represents chromosomal location, where orange represents amplification and blue represents deletion. 
These genes were identified within regions containing multiple genes, the number of genes in each 
aberrant region is listed in column 4. Column 5 lists the p-value for modulator validation in independent 
data. p-values are shown for the Johansson dataset, unless the modulator was missing from this 
dataset, and then p-value from the Hoek dataset is shown. 
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GISTIC25 (see Table III-1). Next, we integrated copy number and gene expression data (available 
for 62 tumors) to identify the most likely drivers within those loci (see Computational methods). 
Statistical power is gained by integrating all data, and by combining statistical tests on thousands 
of genes to support the selected modulators. This resulted in the identification of 64 modulators 
that explain the behavior of 7869 genes. We consider the top 30 scoring modulators, presented in 
Figure III-4, as likely drivers. 
Table III-1 - List of aberrant regions 
Amplifications Deletions 
Chr. Start End #Genes Chr
. 
Start End #Genes 
1 147226092 150596000 55 5 58445032 58683084 1 
3 70107048 70229264 1 5 59075480 59432304 1 
3 120500072 120923376 12 5 112049568 11210581
6 
1 
3 129929104 130624856 16 6 162494042 16363721
3 
2 
3 139476272 139507824 4 8 6333250 9359366 28 
3 139674960 141259840 15 9 21999960 22009732 2 
3 173931152 174312880 3 10 89436437 89908984 3 
3 175468448 175633120 1 11 111213008 11196167
2 
17 
3 192266400 199124224 52 13 19867988 96252808 203 
5 11347004 14472551 3 14 38302632 38988776 7 
6 3859295 5698904 9 14 45505796 46786096 2 
6 57103452 57277264 5 14 102319430 10381078
9 
19 
7 139232720 140249792 10 15 39444436 39948236 13 
8 121760777 128993129 31 15 40049072 40114644 4 
1
1 
68953208 69754234 8 15 40603172 40933120 7 
1
2 
18722300 19574988 5 15 41605345 43473384 30 
1
2 
24388521 32822550 45 16 52162032 52621120 3 
1
2 
67491552 67636136 3 16 77264113 78880878 2 
1
5 
53109188 58337128 33 16 87889112 87959104 2 
1
5 
87547925 89038234 23 18 62719491 76117153 33 
1
7 





47893352 49179608 16 7 12105143 13052351 2 
2
2 
39399572 40948612 36 17 74741058 77061186 24 
    20 49142876 50443163 4 
    10 2552329 4073842 3 
    14 55290464 55652536 2 
    14 57178720 57588888 2 
This table specifies the significant regions of copy number gain (A) and copy number loss (B) and the 





Figure III-5 - Associating modulators to genes 
A. Three scenarios could explain a correlation between a candidate driver (gene A) and its target (gene B): 
A could influence B, B influence A, or both could be regulated by a common third mechanism. The 
availability of both gene expression and chromosomal copy number data allows us to establish the likely 
direction of influence. If the expression of gene A is correlated with its DNA copy number, and the copy 
number is altered in a large number of tumors, it is likely that the copy number alteration results in a change 
in expression of A in these tumors. So the model in which A influences the expression of B and other 
correlated genes is the most likely. In this way, examination of both copy number and gene expression in a 
single integrated computational framework facilitates identification of candidate drivers. B. Modulator 
influence on a module can go beyond direct transcriptional cascades involving transcription factors or 
signaling proteins and their targets. Genetic alteration of any gene (e.g., a metabolic enzyme) can alter cell 
physiology, which is sensed by the cell and subsequently leads to a transcriptional response through a 
cascade of indirect influences and mechanisms. While modules are typically enriched for genes influenced 
by the modulator, they also contain genes that are coexpressed with the modulator ('joint modulator'). Both 
types are helpful for annotating the module and determining the functional role of the modulator. C. The 
TNF module. The modulators include TRAF3 and MITF, where high TRAF3 and low MITF are required for 
upregulation of the genes in the module. The annotation for each gene is represented in a color-coded 
matrix. Blue and orange squares represent literature-based annotation; green and brown are from GO. 
LitVAN associated the genes in this module with TNF and the inflammatory response. 
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Many	  modulators	  are	  involved	  in	  pathways	  related	  to	  melanoma	  	  
The top 30 modulators (likely drivers) include 10 known oncogenes and tumor suppressors 
(Figure III-4). In many cases, CONEXIC chose the cancer related gene out of a large aberrant 
region containing many genes. For example, DIXDC1, a gene known to be involved in the 
induction of colon cancer197, was selected among 17 genes in an aberrant region. CCNB2, a cell 
cycle regulator, was selected from a large amplified region containing 33 genes. The modulators 
span diverse functional classes including: signal transducers (TRAF3), transcription factors 
(KLF6), translation factors (EIF5) and genes involved in vesicular trafficking (RAB27A). 
Performing a comprehensive literature search for all genes is tedious and time consuming, so 
we developed an automated procedure, LitVAn - Literature Vector Analysis, that searches for 
over-represented terms in papers associated with genes in a gene set. LitVAn uses a manually 
curated database (NCBI Gene) to connect genes with terms from the complete text of more than 
70,000 published scientific articles (see LitVAn). LitVAN found a number of over represented 
terms (Figure III-11) among the top 30 modulators, including ‘PI3K’ and ‘MAPK’, which are known 
to be activated in melanoma, ’cyclin’, representing proliferation which is common in all cancers 
and ‘RAB’. Rabs regulate vesicular trafficking, a process not previously implicated in melanoma19.  
The	  association	  between	  a	  modulator	  and	  the	  genes	  in	  a	  module	  	  
Beyond generating a list of likely drivers (modulators), the CONEXIC output includes groups of 
genes that are associated with each modulator (modules). We tested how reproducible the 
modulators and their associated modules are using gene expression data from two other 
melanoma cohorts with 45198 and 63199 samples (see Comparison to other methods). We found 
that 51/64 (80%) of the selected modulators are conserved across datasets in a statistically 
significant manner. Modules (statistically associated genes) are likely enriched with genes whose 
expression is biologically affected by the modulator (Figure III-5). In consequence, the processes 
and pathways represented by genes in a module can help us to gain insight into how an 




Annotation of data-derived sets of genes is typically carried out based on gene set enrichment 
using Gene Ontology (GO) annotation. Although this approach is useful, there are modules for 
which GO annotation does not capture the known biology. For example, the 'TNF module' is 
enriched with the GO terms 'developmental process' and 'cell differentiation' (q-value=0.0014 and 
0.004 respectively). We used LitVAn to carry out a systematic literature search and found 11/20 
genes in the module related to the TNF pathway, inflammation or both (Figure III-5C), although 
only 2 of these genes were annotated for these processes in GO. TRAF3, the modulator chosen 
by CONEXIC, is known to regulate the NF-kappa-B pathway200, a major downstream target of 
TNF. Although TRAF3 has not been previously implicated in melanoma, the importance of the 
NF-kappa-B pathway in melanoma is well supported. 
A	  known	  driver,	  MITF,	  is	  correctly	  associated	  with	  target	  genes	  	  
CONEXIC identified microphthalmia-associated transcription factor (MITF) as the highest 
scoring modulator. MITF is a master 
regulator of melanocyte 
development, function and 
survival119,201 and the over-
expression of MITF is known to have 
an adverse effect on patient 
survival103. 
To test the association between 
modulator and module, we obtained 
an experimentally derived list of 
MITF targets 193 and asked whether 
the modules identified by CONEXIC 
associate MITF with its known 
targets. The MITF associated modules contained 45/80 previously identified targets (p-value < 
10-45) supporting a match between the transcription factor (TF) and its known targets. However, a 
few targets (TBC1D16, ZFP106 and RAB27A) are both associated with MITF and are themselves 
 
Figure III-6 - MITF expression correlates with expression of 
the genes in the associated module 
A. Each row represents the gene expression of one of 78 MITF 
targets identified by Hoek 193; the tumor samples are split into 
two groups based on the copy number of MITF (Welch t-test p-
value=0.04) B. The rows represent the same genes, in the same 
order as in A, but here the tumor samples are split into a group 
of samples that express MITF at high (n=46) or low levels 
(n=16) Welch t-test p-value=0.0001).  
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modulators of additional modules. CONEXIC limits each gene to a single module, so association 
with an MITF target would preclude association with MITF. If we permit indirect association to 
MITF through the modules of these additional modulators, CONEXIC correctly identifies 76 of the 
80 targets identified by Hoek et al. (p-value<10-78). Similar target sets are not available for any 
other modulator, precluding a more rigorous evaluation of our other predictions. 
 
MITF	  expression	  correlates	  with	  targets	  better	  than	  copy	  number	  
Expression of MITF correlates with the expression of its targets better than MITF copy 
number, though both correlations are statistically significant (p-value of 0.0001 versus 0.04, 
Figure III-6). This relationship is unidirectional: MITF is significantly over-expressed when its DNA 
is amplified (p-value 0.0004), but over-expressed MITF does not always correspond with MITF 
amplification. We find that MITF is less correlated with its copy number (rank 294th) than most 
 
Figure III-7 - MITF associated Modules 
A. MITF up-regulated module. This module contains genes that were associated with MITF and 
correlate with its expression. The genes are listed with gene symbol and Entrez Gene ID and they 
are enriched for Vesicular Trafficking and Melanogenesis. B. MITF down-regulated Module. This 
module contains genes that were associated with MITF and anti-correlate with its expression. The 




other genes in aberrant regions and more than half of the tumors that over-express MITF do not 
have a CNA that spans the MITF gene. Comparison of MITF target expression between samples 
with and without MITF amplification did not show an effect of DNA amplification on expression of 
the targets (see Computational methods). 
MITF	  correctly	  annotated	  with	  its	  known	  role	  in	  melanoma	  
We used LitVAN to identify the biological processes and pathways represented in each 
module associated with MITF. The module containing the genes most significantly up-regulated 
by MITF (Figure III-7A) is significantly enriched for the terms 'melanosome' and 'pigment granule' 
(q-value= 10-6 for each). It includes targets involved in proliferation such as CDK2, consistent with 
the observation that MITF can promote proliferation via lineage specific regulation of CDK2202. 
The module containing genes most strongly inhibited by MITF (Figure III-7B) has a metastatic 
signature strongly associated with invasion, angiogenesis, the extracellular matrix and NF-kappa-
B signaling. These modules and their annotation suggest that MITF serves as a developmental 
switch between two types of melanoma, where high MITF expression promotes proliferation and 
low MITF expression promotes invasion. Thus our automated, computationally derived findings 
dissect a complex response and accurately recapitulate the known literature, including the 
experimental characterization of MITF193. 
The detailed match between the CONEXIC output and empirically derived knowledge of the 
role of known modulators in melanoma provides confidence in CONEXIC’s predictions for 
modulators that are not well characterized. 
Identification	  of	  TBC1D16	  as	  a	  tumor	  dependency	  in	  melanoma	  
The second highest scoring modulator identified by CONEXIC is TBC1D16, a Rab GTPase-
activating protein of unknown biological function. Rabs are small monomeric GTPases, involved 
in membrane transport and trafficking. TBC1D16 is well conserved and although its targets are 
not known, a close paralog, TBC1D15, regulates RAB7A (also selected as a modulator, Figure 
III-4)203. We used a module associated with TBC1D16 to infer its potential role in melanoma 
(Figure III-8A), and discovered that diverse biological processes are represented by genes in the 
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module and that more than half are annotated for processes such as melanogenesis, vesicular 
trafficking and survival/proliferation. This suggests that TBC1D16 plays a role in cell survival and 
proliferation. 
TBC1D16 is an uncharacterized gene located in an amplified region that contains 23 other 
genes, including CBX4, which is known to play a role in cancer204. Expression of TBC1D16 is not 
highly correlated with TBC1D16 copy number, compared to other genes in the region (ranked 7th 
out of 24) or to all candidate drivers (252th out of 428). Nevertheless, TBC1D16 is the top scoring 
gene in the region and the 2nd highest scoring modulator, so it was selected for experimental 
verification. 
 
Figure III-8 - TBC1D16 is necessary for melanoma growth 
A. A module associated with TBC1D16 and RAB27A, the genes in the module are involved in 
melanogenesis, survival/proliferation, lysosome and protein trafficking. B. Representative growth curves for 
each of the 4 STCs infected with TBC1D16 shRNA, each curve represents 3 technical replicates. RT-PCR 
was used to confirm that the reduction in the amount of the TBC1D16 transcript was similar for all of the 
STCs (Figure III-9). C. Change in growth over time, relative to the number of cells plated, averaged over all 
replicates (see experimental methods). Mean over 3 biological replicates X 3 technical replicates for each 
STC, see Figure III-9. D. Growth inhibition at 8 days is directly proportional to the amount of the TBC1D16 




The module exhibits a dose-response relationship between TBC1D16 expression and the 
expression of genes in the module such that higher expression of TBC1D16 is correlated with 
higher expression of genes in the module (correlation coefficient 0.76). These results suggest that 
knockdown of TBC1D16 expression in tumors that have high levels of TBC1D16 will lead to a 
reduction in proliferation. 
 
TBC1D16	  is	  required	  for	  proliferation	  
To test whether TBC1D16 is required for proliferation of melanoma cultures we carried out a 
knockdown experiment. We 
selected two STCs with high 
levels of TBC1D16, WM1960 
(16-fold greater expression than 
WM1346, DNA not amplified) 
and WM1976 (34-fold greater 
expression, amplified DNA) and 
control STCs, WM262 and 
WM1346 that express TBC1D16 
at a lower level. We used two 
shRNAs to knock down 
TBC1D16 expression in each of 
the four STCs and measured 
growth over 8 days (see 
experimental methods). RT-
PCR was used to confirm that 
the reduction in the amount of 
the TBC1D16 transcript was 
similar for all of the STCs 
(Figure III-7). Knockdown of TBC1D16 expression reduced cell growth in WM1960 and WM1976 
 
Figure III-9 - TBC1D16 mRNA knockdown and growth effects 
A. RT-PCR levels of TBC1D16 mRNA after shRNA knockdown for 
each of the 4 STCs tested. The reduction in the amount of the 
TBC1D16 transcript was similar in all of the STCs, where each bar 
represents data from 3 biological replicates. B. Representative growth 
curves for each of the 4 STCs tested with TBC1D16 knockdown with 
the hairpin sh1490, each curve represents 3 technical replicates. C. 
Growth inhibition at 8 days is directly proportional to the amount of the 
TBC1D16 transcript and is independent of TBC1D16 copy number. 




to 16% and 40%, respectively, relative to controls infected with GFP shRNA in the same STCs 
(Figures III-6B, C and D). This result is specific for cultures with high levels of TBC1D16, as the 
controls, WM262 and WM1346, grow at similar rates to cultures infected with shGFP (75%-90%). 
As predicted, growth inhibition at day 8 is proportional to the amount of the TBC1D16 transcript 
and is independent of TBC1D16 copy number (Figures III-8C and D). Taken together, these 
results support CONEXIC’s prediction that TBC1D16 is required for proliferation in melanomas 
that over express the gene. 
	  
 86	  
RAB27A	  identified	  and	  experimentally	  confirmed	  as	  a	  tumor	  dependency	  
The TBC1D16 module contains a second modulator, RAB27A, also known to be involved in 
vesicular trafficking (Figure III-8A). RAB27A functions, with RAB7A, to control melanosome 
transport and secretion. RAB7A localizes to early melanosomes, while RAB27A is found in 
mature melanosomes 205. CONEXIC 
selected both RAB27A and RAB7A as 
modulators. 
RAB27A is in an amplified region that 
did not pass the standard GISTIC q-
value threshold for significance and 
expression of the gene is not highly 
correlated with RAB27A copy number, 
compared to other candidate drivers 
(323th out of 428). Nevertheless, 
CONEXIC identified it as the top-scoring 
modulator out of the 33 genes in this 
region, and ranked it 8th out of 64 
modulators and it was therefore selected 
for empirical assessment. 
To test the prediction that RAB27A is 
important for proliferation in tumors with 
high levels of RAB27A, we tested the 
effect of shRNA knockdown of the 
RAB27A transcript on proliferation. We 
chose two STCs in which the gene is 
highly expressed WM1385 (28-fold greater expression compared with A375, DNA amplified) and 
WM1960 (38-fold greater expression, DNA not amplified) and two controls that express RAB27A 
 
Figure III-10 - RAB27A is necessary for melanoma 
growth 
A. Representative growth curves for each of the 4 STCs 
infected with RAB27A shRNA, each curve represents 3 
technical replicates. RT-PCR was used to confirm that the 
reduction in the amount of the RAB27A transcript was 
similar in all of the STCs (Figure III-11). B. Change in 
growth over time, relative to the number of cells plated, 
averaged over all replicates. Knockdown of RAB27A 
expression in cells that express this gene at high levels 
reduces proliferation. Data averaged over all replicates for 
each STC, see Figure III-11 C. Growth inhibition at 6 days is 
dependent on the amount of the RAB27A transcript and is 
independent of RAB27A copy number. 
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at a lower level (A375 and WM1930). Western blots show that expression of RAB27A correlates 
with expression of the cognate gene in these cultures (data not shown). 
Knockdown of RAB27A expression using shRNA was similar for all cultures (Figure III-9), but 
only reduced cell growth significantly in the STCs that overexpress RAB27A (18% or 35% in 
WM1385 or WM1960 
relative to the same 
cultures infected with GFP 
shRNA). RAB27A shRNA 
had less impact (growth 
rates of 65-80%) in the 
control STCs that have low 
RAB27A (Figures III-10A 
and B). Growth inhibition at 
6 days is correlated with 
the amount of the RAB27A 
transcript and is 
independent of RAB27A 
copy number (Figures III-
10B and C). Taken 
together, these results 
support CONEXIC’s 
prediction that RAB27A is 
a tumor dependency in 
melanomas that 
overexpress RAB27A. 
RAB27A	  affects	  the	  expression	  of	  genes	  in	  associated	  modules	  
To test whether RAB27A affects the expression of genes in associated modules, as predicted 
by CONEXIC, we carried out microarray profiling after knockdown of RAB27A in the test STCs 
 
Figure III-11 - RAB27A mRNA knockdown and growth effects 
A. RT-PCR levels of RAB27A mRNA after shRNA knockdown for each of 
the 4 STCs tested. The reduction in the amount of the RAB27A transcript 
was similar in all of the STCs, where each bar represents data from 3 
biological replicates. B. Representative growth curves for each of the 4 
STCs tested with RAB27A knockdown with sh477, each curve represents 3 
technical replicates. C. Growth inhibition at 6 days is dependent on the 
amount of the RAB27A transcript and is independent of RAB27A copy 
number. Data averaged over all replicates for each STC. 
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(WM1385, WM1960). We compared the expression profile after RAB27A knockdown to a control 
profile generated by infecting the same STC with GFP shRNA. We used Gene Set Enrichment 
Analysis (GSEA)206 to test whether each of the 3 modules associated with RAB27A are enriched 
with genes that are differentially expressed (DEG) after knockdown (see Experimental Methods). 
We found that all 3 RAB27A associated modules are significantly enriched for genes affected by 
RAB27A (p-values < 10-5 for all 3 modules, see Figure III-12C), and that these modules 
responded in the direction predicted by CONEXIC. 
These results support our computational prediction that the expression of RAB27A affects the 
expression of the genes in the associated modules. We note that RAB27A functions as vesicular 
trafficking protein, suggesting that it influences gene expression through an unknown, and likely 
indirect, mechanism. We used LitVAN to identify the biological processes and pathways 
represented among the DEGs. Cell cycle related terms are significant among the down-regulated 
genes, which might be expected given the reduced growth after RAB27A knockdown. In addition, 
we found that genes annotated for the Erk pathway are up-regulated (including MYC, FOSL1 and 
DUSP6). We used GSEA to measure enrichment of an experimentally derived set of genes that 
respond to MEK inhibition in melanoma130. The resulting p-value < 10-5 suggests that ERK 
signaling is altered after RAB27A knockdown in these STCs. 
TBC1D16	  influences	  the	  expression	  of	  genes	  in	  associated	  modules	  
We carried out microarray profiling after knockdown of TBC1D16 to evaluate whether 
expression of TBC1D16 affects the expression of genes in the 4 modules associated with it. We 
used two shRNAs to knock down TBC1D16 in the test STCs (WM1960, WM1976) and compared 
the gene expression to controls infected with GFP shRNA (in the same STCs). GSEA analysis 
established that all 4 modules are significantly enriched for genes affected by differences in 
TBC1D16 expression (p-values < 10-5, 0.0002, 0.008 and 0.009 respectively, see Figure III-12). 
Two modules responded to TBC1D16 knockdown in the direction predicted by CONEXIC. In 
addition, GSEA analysis ranked genes in the TBC1D16 module (Module25) highest out of 177 
(based on the GSEA p-value), demonstrating that the genes in this module are the most highly 
differentially expressed genes in the data set. 
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The function of TBC1D16 is unknown, but it is predicted to be involved in vesicular trafficking. 
In our knockdown analysis LitVAN annotated the up-regulated genes with terms related to 
vesicular trafficking. These include RAB3C, RAB7A, CHMP1B, RAB18, SNX16, COPB1 and 
CAV1. However, it is not clear how TBC1D16 affects gene expression or how changes in 
expression impact vesicular trafficking. 
 
Figure III-12 - Results of knockdown microarrays for RAB27A and TBC1D16 
A. To the left is one of the modules associated with RAB27A and to the right data generated following 
knockdown (KD) of RAB27A for the same genes in the STCs indicated (pink and blue). The expression of 
genes in the module goes down relative to shGFP as predicted, KD expression heatmap shows Z-scores 
(see Experimental Methods) showing that these are some of the most differentially expressed genes (DEGs) 
in the genome. B. To the left is one of the modules associated with TBC1D16 and to the right data 
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generated following KD of TBC1D16 in the STCs indicated. The expression of genes in the module goes up 
relative to shGFP, as predicted. The test STCs (blue) and control STCs (pink) respond differently 
demonstrating the importance of context (TBC1D16 over-expression status) in determining the response. C. 
GSEA p-value and ranking (relative to 177 CONEXIC modules) for RAB27A and TBC1D16 associated 
modules. GSEA was calculated using the median of 4 profiles (2 cell lines X 2 hairpins) on the test STCs. 
Significant p-values indicate that knockdown of RAB27A and TBC1D16 each affect the subset of genes 
predicted by CONEXIC (note that 10-5 is the smallest p-value possible given that 100,000 permutations are 
used). The color of the module name represents the predicted direction of response to knockdown (red and 
green represent up and down regulated, respectively). The arrow represents the observed response to 





Data	  and	  Processing	  
We used copy number data for 101 melanoma samples generated by Lin et al.187. The SNP 
locations were translated from HG17 to HG18 using the UCSC liftOver application207. Gene 
expression was available for 62 of these samples using HT-HGU133A Affymetrix chip, which 
measures the expression of 12725 genes187. We removed probe sets whose standard deviation 
was smaller than 0.25 on a log2 scale, resulting in 12,101 probe sets measuring 8,243 unique 
genes. We merged probe sets for genes if these agreed and removed inconsistent genes, 
resulting in a final set of 7,981 genes. Expression values were normalized to mean of zero and a 
standard deviation of one for each gene.  
Experimental	  Methods	  
Melanoma short-term cultures (STCs) derived from metastatic foci187 were cultured in RPMI 
medium (MediaTech) supplemented with 10% fetal bovine serum (Gemini). A375 melanoma cell 
line and 293T virus packaging cells were cultured in DMEM medium (MediaTech) with 10% fetal 
bovine serum. All cells were maintained in 100 units/mL penicillin, 100 µg/ml streptomycin at 
37°C under 5% CO2.  
Knockdown was carried out by infection with lentivirus using RNAi sequences designed by the 
RNAi Consortium. shRNA lentivirus were prepared according to TRC protocols 
(http://www.broadinstitute.org/rnai/trc), with minor modifications. Cell proliferation assays, RT-
PCR, microarrays and immunoblotting were carried out using standard techniques. Primer 
sequences and detailed methods can be found in Supplementary Experimental Procedures. 
All primary data are available at the Gene Expression Omnibus (GSE23884). 
shRNA	  
shRNA knockdown sequences for TBC1D16 and RAB27A were those designed by the RNAi 
Consortium (TRC): 
shRAB27A_865 (TRCN0000005296): CGGATCAGTTAAGTGAAGAAA 
shRAB27A_477 (TRCN0000005298): CAGGAGAGGTTTCGTAGCTTA 
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shTBC1D16_302 (TRCN0000061889): CCTGTGCTTGTACATGGAGAA 
shTBC1D16_1490 (TRCN0000061891): GCGAAAGGAGTACTCTGAGAT 
The negative control was 
shGFP: GCAAGCTGACCCTGAAGTTCA 
 
The shRNA lentiviruses were produced according to TRC protocols 
(http://www.broadinstitute.org/rnai/trc). Briefly, 2x106 293T cells were seeded in 100 mm plates, 
and at 24 hours were co-transfected with 3 µg of pLKO.1-shRNA, 2.7 µg of Δ8.9, and 0.3 µg of 
VSV-G vectors using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s 
instructions. At 48h post-transfection, viral supernatant was collected, passed through a 0.45 µm 
filter (Nalgene), and stored in small aliquots in -80°C until use. To reduce nonspecific viral 
cytotoxicity, each viral supernatant was titrated: Target cells were seeded in 6-well plates (1x105 - 
2x105/ well), and at 24h post-seeding, were infected with dilutions (1:5, 1:10, 1:20, 1:40, 1:100, 
1:200) of each lentivirus preparation. Infections were carried out in duplicate, in 2 ml medium/ well 
containing 6 µg/ml polybrene for 6h. 48h post-infection, puromycin was added to one set of 
infected cells, leaving the remaining set unselected. Cells were washed with PBS, trypsinized, 
and collected for counting using a Vi-Cell XR Cell Viability Analyzer (Beckman Coulter) after 3-4 
days of selection. For each virus, the ratio of cells surviving in media with puromycin versus 
media without puromycin was determined for each dilution. Titers that yielded approximately 50% 
survival were used for subsequent infections. 
To perform knockdown experiments, target cells (1.2x106 - 3x106) were plated the day before 
infection to obtain 30-40% confluence at the time of infection. Cells were then incubated with 
virus at the dilution established above, the virus-containing media was removed and fresh media 
was added. The next day, puromycin was added to select for infected cells (WM1960 and 
WM1385 at 2 µg/ml; WM1346, WM1976, WM1930, WM262 and A375 at 1 µg/ml). After selection, 
cells were plated for proliferation assays or used for RT-PCR or immunoblotting. 
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Cell	  proliferation	  assays	  
Cultures with stable expression of each shRNA construct were seeded in triplicate (technical 
replicates) in 12-well plates at 1x104 - 5x104 cells/ well in 1ml of medium. Cells were washed with 
PBS, trypsinized and counted using a Vi-Cell XR Cell Viability Analyzer (Beckman Coulter) or 
Coulter particle counter (Beckman Coulter) at the times indicated.  
Quantitative	  reverse	  transcription-­‐PCR	  analysis	  
Total RNA was harvested using the RNeasy Mini Kit (Qiagen), and cDNA prepared with the 
SuperScript III First-Strand Synthesis Supermix Kit (Invitrogen) according to the manufacturers’ 
recommendations. All real-time PCRs were performed in triplicate using PCR SYBR Green 
Master Mix (Applied Biosystems) on an ABI 7300 (Applied Biosystems). The data were 
normalized to TBP. Gene-specific primer sequences follow: 
TBP  
 forward: 5’- CCACTCACAGACTCTCACAAC-3’ 
reverse: 5’- CTGCGGTACAATCCCAGAACT-3’ 
RAB27A  
 forward: 5’- GAAACTGGATAAGCCAGCTACAG-3’ 
reverse: 5’- ATATTTCTCTGCGAGTGCTATGG-3’ 
TBC1D16_114 
  forward: 5’- CTACTCCAAGAACAATGTCTGCG-3’ 
 reverse: 5’- GCCTCTGGATGCGAGAGTTG-3’ 
TBC1D16_1211   
forward: 5’- CGCCCCCGATAAGACATGC-3’ 
 reverse: 5’- CCTTCCGCAGCTTGTACTC-3’ 
TBC1D16_1752   
forward: 5’- GATGAGTCAGACACCTTC-3’ 
 reverse: 5’- GGTACAGCAGTTGTTTCT-3’ 
 
Microarray	  analysis	  
Total RNA was harvested using the RNeasy Mini Kit (Qiagen). The Affymetrix GeneChip 
Human Gene 1.0 ST Arrays were used for gene expression profiling, performed by the Dana 
Farber Cancer Institute facility according to the manufacturer's protocols.  
Immunoblot	  analysis	  
Western blotting was carried out using standard methods on cell lysates, normalized for total 
protein. Primary antibodies used were RAB27A (Santa Cruz, 1:500), TBC1D16 (Novus 
Biologicals, 1:500), β-actin (Sigma-Aldrich, 1:12,000) or α-tubulin (Cell Signaling Technology, 
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1:1,000). Secondary antibodies were anti-rabbit or anti-mouse IgG, HRP-linked; Cell Signaling 
Technology, 1:1,000 dilution). The signal was detected using SuperSignal West Pico or West 






LitVAn - Literature Vector Analysis - is an automatic literature-based analysis tool for inference 
of gene module functionality. The basic principle is similar to other gene set enrichment methods, 
identifying over-represented terms associated with a subset of genes.  
We use the NCBI database, which associates each gene with manually curated papers. Our 
corpus contains around 70,000 full-text papers. The algorithm is based on TF*IDF score, which 
gives a higher score to words which are overrepresented in a subset of documents relative to the 
full corpus. Inverse Document Frequency (IDF), gives each “term” (a word) a score based on the 
portion of documents it appears in, with high scores for low coverage. Term Frequency (TF), is 
calculated for a subset of documents rather than the entire set, and is a direct count for the 
number of times the term appears in the subset. For each set of genes (a module), we count the 
term frequency in papers associated with these genes and compare this count to the null 
distribution, using a TF*IDF score208.  
The TF*IDF score takes the “bag of words” approach, ignoring the order of which the words 
appear and their location in the text (headers, legends, etc.). The documents are first processed 
by a semantic stemming algorithm, which converts words to their most basic form in order to treat 
different forms of the same word equally. The IDF score is calculated once for the entire 
compendium and stored, and the TF score is calculated for each module separately, using all the 
papers linked to genes in the module. To avoid biasing the module score with terms related to 
only one gene that has many papers associated with it, we use a “Leave-One-Out” score. With 
this approach, for each term we indentify the gene that contributes the most to it, and remove its 
contribution from the TF score of that term. Although TF is generally defined as a linear score, our 
tests show clear advantage of using a log2 scale.  
To evaluate the significance of the TF*IDF score, we generate an expected score based on 
random modules. Sets of genes in different sizes, varying from 5 to several hundred genes, were 
randomly selected and their best LitVAn result was used to determine the expected score 
(calculated using a linear regression between the top TF*IDF score and the number of papers 
associated with the random module). Based on the randomized scores, the 95% confidence 
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intervals of the linear regression were used to determine the threshold of significance for a given 
number of papers. 
The output of LitVAn is a ranked list of terms with an indication of their significance level, as 
well as a map linking the genes, significant terms and papers that contribute to the score. An 
online version of LitVAn is available at http://litvan.bio.columbia.edu.  
 
Figure III-13 – A graph output from LitVAn 
LitVAn was used to analyze literature trends in the 30 selected modulators appearing in Figure III-4, the top 
four most significant terms: 'MAPK', 'PI3K', 'cyclin' and 'RAB'. The figure represents the graphic output of 
LitVAn, where significant terms (red circles) are associated (graph edge) with multiple genes in the query 
(yellow dots). An edge with a green dot represents a publication that significantly associates between the 
gene and the term in itself (typically through repeated use of the term throughout the paper) and the 
interactive version includes a link to the PubMed abstract. Only the top 5 most significant papers for each 







We have demonstrated that combining tumor gene expression and copy number data into a 
single framework increases our ability to identify likely drivers in cancer and the processes 
affected by them. Gene expression allows us to distinguish between multiple genes in an 
amplified or deleted region (many of which are indistinguishable based on copy number) and to 
identify those that are likely to be drivers. The combination of data types allows us to identify 
regions that would be overlooked using methods based on DNA copy number alone. 
Expression	  of	  a	  driver,	  not	  its	  copy	  number,	  drives	  phenotype	  
The novelty of our method and the key to its success is our modeling paradigm: the 
expression of a driver should correspond with the expression of genes in an associated module. 
Examination of MITF and its targets supports our assumptions. Expression of MITF best 
correlates with the expression of its targets, but MITF overexpression does not always 
correspond with MITF amplification. A change in DNA copy number is only one of many ways that 
gene expression can be altered. For example, MITF expression can be upregulated via signaling 
from the Ras/Raf (oncogenic BRAF occurs frequently in melanoma)209 and Frizzled/Wnt 
pathways 19. 
Most methods for identifying drivers within aberrant regions focus on genes whose expression 
is well correlated with the copy number of the cognate DNA 187,210. The expression of many of the 
predicted drivers we identify is poorly correlated with their copy number, relative to other genes in 
the region and to all other candidate drivers MITF (294th), TBC1D16 (252th) and RAB27A (323th). 
We believe the discrepancies between CNA and expression arise because there are multiple 
ways to up or down-regulate a gene. For example, TBC1D16 and RAB27A were both identified 
as transcriptional targets of MITF 193,211, and are therefore up-regulated when MITF is over-
expressed. Moreover, we postulate that many drivers are less correlated with their copy number 
than passengers due to selective pressure; if there is a fitness advantage to up or down regulate 
expression, the tumor will find a mechanism to do so. 
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Association	  between	  modulator	  and	  module	  
A key feature of our approach is that CONEXIC goes beyond identifying drivers. By 
associating candidate drivers with gene modules and annotating them using information from the 
literature, CONEXIC provides insight into the physiological roles of drivers and associated genes. 
We used LitVAn to find biological processes and pathways overrepresented in each module and 
to associate drivers with functions, accurately identifying targets of MITF and annotating the 
functions of known drivers (MITF, CCBN2 and TRAF3). 
The results of microarray profiling following knockdown further support the association 
between modulator and module and confirm our ability to identify genes affected by TBC1D16 
and RAB27A. We successfully connected genes involved in vesicular trafficking to their effects on 
gene expression, likely through a cascade of indirect influences. In addition to profiling the STCs 
that highly express each of these genes (test STCs), we also profiled two lower expressing STCs 
(control STCs), in which the effect of knockdown is less detrimental to growth. For TBC1D16, 
there is substantial overlap in the DEGs in the test STCs (p-value < 10-22), but not in the DEGs 
between control and test STCs (p-value > 0.76). This reflects the complexity of the transformed 
state and demonstrates that genetic context has a fundamental impact on the effect of a 
perturbation. 
TBC1D16	  and	  RAB27A	  dependency	  is	  context-­‐specific	  	  
We tested two drivers predicted by CONEXIC with knockdown experiments, and showed that 
tumors that express either TBC1D16 or RAB27A at high levels are dependent on the 
corresponding gene for growth. Our results demonstrate that these dependencies are determined 
by expression of the gene (in both cases), rather than DNA amplification status, further 
supporting the assumptions underlying our approach. Thus, we not only identify tumor 
dependencies, but also the context in which these genes are crucial for proliferation.  
Our approach is unbiased with respect to protein function and does not incorporate prior 




Of the top 30 drivers selected by CONEXIC, three genes (TBC1D16, RAB27A and RAB7A) 
are known to be involved in vesicular trafficking 203,205. All of these genes are amplified (DNA) and 
highly expressed (RNA) in multiple melanomas. There is increasing evidence that genes 
controlling trafficking play a role in melanoma. Germline variation in GOLgi PHosphoprotein 3 
(GOLPH3), a gene involved in vesicular trafficking, is associated with multiple cancers212. Our 
data identifies two novel dependencies that are encoded in somatic CNAs, demonstrates the 
dependency of melanoma on TBC1D16 and RAB27A expression for proliferation and highlights 
the potential role of vesicular trafficking in this malignancy. 
Beyond	  Melanoma	  
The challenge of finding candidate drivers is considerable: tumors are heterogeneous, the 
data are noisy and highly correlated and there are a large number of possible combinations of 
drivers and genes in modules. Our approach is successful because it couples simple modeling 
assumptions with powerful computational search techniques and rigorous statistical evaluation of 
the results at each step. 
The principles underlying CONEXIC can be applied to any tumor cohort containing matched 
data for copy number aberrations and gene expression. The principle of associating any type of 
mutation (e.g., epigenetic alterations, coding sequence) with gene expression signatures or other 
phenotypic outputs that differ among samples will be of increasing importance as sequence and 
epigenetic data accumulates. Not only does this help to distinguish between driving and 
passenger mutations, but the genes in the associated module can also provide insight into the 
role of the driver. This approach can be used to identify the genetic aberrations responsible for 
tumorigenesis and to find those that relate to any other measurable phenotype, such as the 
resistance of tumors to drugs.  
We anticipate our approach of combining gene expression and genetic lesions will make an 
important contribution towards a basic mechanistic understanding of cancer and in revealing 
associations of clinical significance. Cancer is a heterogeneous disease in which we are only just 
beginning to appreciate the importance of genetic background and the myriad ways in which the 
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cellular machinery can be redirected towards the transformed state. Methods that begin to dissect 







Chapter	  IV -­‐	   A	   system	   analysis	   identifies	   synergy	  
between	   MEK	   inhibition	   and	   interferonα/β 	   in	  
melanoma	  
Introduction	  
Other and I have previously shown that cancer is a heterogeneous disease, both in genotype 
and phenotype, with each tumor harboring hundreds of mutations. In this work I focus on the 
transcriptional and phenotypic response to targeted therapy. New drugs target frequent driver 
mutations, such as HER2 in breast cancer and BRAF-V600 in melanoma127,213, but studies show 
dramatic variation in the response to these drugs, both in vitro and in the clinic127,214,215. The 
molecular mechanisms that underlie this phenotypic heterogeneity, however, are still not well 
understood.  
The phenotypic variability in response to inhibition of a specific pathway suggests that either 
the downstream targets of the pathway vary between different tumors, or that alternative 
oncogenic pathways protect the cells. A better understanding of the interactions and 
dependencies between pathways, and how these differ between tumors, may explain the 
variability in response to treatment. The ability to infer dependencies and interactions between 
pathways is significantly enhanced by measuring the response following perturbation47,216. 
Perturbation, whether inhibition or activation of different components of the pathway, breaks 
correlated patterns into cause and effect, and can reveal crosstalk between pathways. Post-
perturbation data can therefore assist in the identification of cell-line-to-cell-line differences that 
underlie the phenotypic variance in response pathway inhibition.  
Here, I focus on the phenotypic variance following MAPK pathway inhibition in melanoma. 
Seventy percent of melanoma tumors harbor an oncogenic mutation in the MAPK pathway217, 
and drugs targeting the pathway have been recently approved with observed clinical success127. 
However, responses to MAPK pathway inhibitors, both of patients and in vitro, vary 
dramatically127,214. We use post-perturbation gene expression data to reveal cell-line-to-cell-line 
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differences in interactions between the MAPK pathway and other pathways, in an effort to 
elucidate the origins of phenotypic variance. 
To characterize the differences related to the MAPK pathway between tumors that could 
underlie phenotypic variance, I developed computational tools that analyze pre- and post- 
perturbation gene expression data. I applied them to gene expression data from a panel of 14 
melanoma cell lines treated with PD325901, a MEK inhibitor used to inhibit the MAPK pathway. 
My results show that although all cell lines harbor an oncogenic activation of the MAPK pathway, 
a vast majority of MAPK pathway targets are context-specific - under the influence of the pathway 
only in a subset of tumors. Importantly, these differences are not seen in cell lines at steady state, 
and are only revealed upon perturbation.  
My computational methods found that the interferon pathway is either on or off in different cell 
lines, and identified an interaction between the interferon and the MAPK pathways. This 
interaction suggested synergy between two unrelated therapies for melanoma – Type-I Interferon 
(IFNα/β) and MEK inhibitor. I validated these findings experimentally and demonstrated that 
IFNα/β enhances the cytotoxic effect of MEK inhibition, but does so only in cell lines with low 
basal activity of the interferon pathway. However, cell lines with high basal activity are resistant to 
both MEK inhibition and its combination with IFNα/β.  
I also found that a deletion of the interferon locus, next to p16, is correlated with basal 
activation of the interferon pathway and with treatment sensitivity. However, I found that the 
reason for the resistance in cell lines with high pathway activity is not due to differences in the 
interferon response, but rather due to a failure in the caspase pathway activation. Taken together, 
these data suggest that the interferon pathway plays an important role in melanoma cell survival, 
and can be used both to predict response of MAPK inhibition, and to enhance the efficacy of 
these inhibitors.  
My results demonstrate that inhibition of key oncogenic pathways leads to substantially 
different transcriptional programs in different cell lines. Such differences should be considered 
when evaluating the phenotypic and clinical consequences of oncogene-inhibition therapy. 
Moreover, we show that a better understanding of the interactions and activity state of different 
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pathways would enable clinicians to tailor new and unexpected drug combinations to individual 






Cell lines and tumors harboring MAPK-activating mutations respond differently to inhibition of 
the pathway 42. To characterize the targets and interactions of the MAPK pathway, I chose a 
panel of 14 genetically diverse melanoma cell lines. This panel represents the spectrum of 
genetic aberrations in melanoma, including cell lines with NRAS or BRAF mutations, 
amplifications in MITF - a known oncogenic transcription factor in melanoma - and cell lines with 
AKT activation caused by PTEN deletion (figure IV-1A).  
 
Figure IV-1 - Heterogeneity in response to MEK inhibition in melanoma 
I used a MEK inhibitor, and not the clinically used BRAF inhibitor, to compare the response of BRAF-mut 
and NRAS-mut cell lines. A. BRAF, NRAS, PTEN and MITF status show the genetic diversity of our 14 cell 
line panel. B. MEK inhibition reveals transcriptional targets of MEK (right), undetectable in steady-state 
conditions (left). These genes are only regulated by MEK in high MITF cell lines. In this and other heat-map 
figures, columns are samples, and rows are genes. Red-Black-Green represent pre-treatment levels 
comparing between cell lines, and Orange-White-Blue show expression fold change 8 hours after treatment 
(both in log2 scale). C. 3 gene clusters demonstrating the extent of context-specificity of MAPK targets. The 
genes in the left and middle clusters are only regulated in a subset of cell lines, while the genes in the right 
cluster are up- or down-regulated in different cell lines. Cell line order and genes are different in each 
cluster. As an example, we highlighted A375 (brown) and Colo829 (green) to demonstrate the 
heterogeneity in response.  D. Number of differentially expressed genes as a function of fold change and 
number of cell lines. Arbitrarily choosing the cutoff is poised to mislabel hundreds of genes. 
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To compare the transcriptional and phenotypic response to MAPK pathway inhibition of both 
NRAS-mut and BRAF-mut cell lines I used a MEK inhibitor (PD325901, 50nM) that fully inhibits 
the pathway in all cell lines, and not the more clinically used BRAF inhibitor which works on 
BRAF-mut cells only (for a comparison of BRAF and MEK inhibitors see materials and methods).  
I first characterized the cell lines’ cytotoxic and cytostatic responses to MEK inhibition, in each 
of the 14 cell lines included in our panel. The cell lines display a wide range of phenotypic 
responses to MEK inhibition, including full or partial cell cycle arrest, and a range of cytotoxic 
responses, from complete resistance to high sensitivity (figure IV-2). Notably, and contrary to 
previously published results 42,45, I found that key genetic aberrations common in melanoma, 
including MITF and PTEN status, and MAPK mutation type, fail to explain and predict the 
cytotoxic and cytostatic responses.  
 
Figure IV-2 - Phenotypic Heterogeneity 
B. Growth curves of untreated (blue) and MEK-inhibited (green) cells showing dramatically different 
responses. Cells were plated in 6-well plates, with 50K cells per well with 2mL of growth media. Treated with 
DMSO (vehicle) or PD901 after 24h and counted every 24 hours. C. Cytotoxic response to MEK inhibition, 
assessed by percentage of cells in SubG1 72 hours after treatment with DMSO (blue) or PD901 (red). 
Genotype, MITF and pSTAT3 status listed at the bottom. The 3 cell lines with low STAT3 activation show the 
strongest cytotoxic response (right-most bars). 
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Heterogeneity	  in	  transcriptional	  response	  to	  MAPK	  inhibition	  
I hypothesized that differences in the interactions and downstream targets of the MAPK 
pathway underlie the observed phenotypic variability in response to MAPK inhibition. To 
characterize MAPK targets and crosstalk with additional pathways, I measured both pre- and 
post- MEK inhibition gene expression profiles. I used gene expression 8 hours following MEK 
inhibition to capture the peak of MEK inhibition before a known feedback loop reactivates the 
pathway 130. 
My data demonstrate that perturbations reveal heterogeneity between tumors that is not 
observable in steady state expression. For example, a set of genes that display no correlation 
with respect to mRNA expression levels before pathway inhibition becomes strongly correlated 
following MEK inhibition (figure IV-1B). Moreover, the data show that some genes, including 
CDK2 and DUSP23, are either up- or down- regulated by MEK inhibition in different cell lines 
(figure IV-1C). In fact, most genes are regulated by MAPK in only a subset of the cell lines we 
tested. For example, only 18 genes change by >2 fold in all 14 cell lines, but 936 genes pass this 
threshold in 4 or more cell lines (figure IV-1D). I term those genes context-specific targets, as 
they are under the control of MAPK in only a subset of cell lines. These context-specific targets 
include, among many others, DUSP1 and DUSP2, members of phosphatases that regulate 
MAPK pathway activity. These genes may play an important role in feedback, but have been 
overlooked because their expression level changes only in a subset of cell lines (figure IV-3).  
Notably, no two cell lines present 
the same transcriptional response to 
MEK inhibition, demonstrated by the 
large variability in gene expression 
changes (Figure IV-1C). These 
results are consistent with the idea 
that the MAPK pathway controls different genes in different contexts and suggest that the 
interactions of the MAPK pathway vary between cell lines. I postulated that the transcriptional 
response to MEK inhibition can be used to infer the interactions between MAPK and other 
 
Figure IV-3 - DUSPs are context specific targets 
DUSP1 and DUSP2 are context-specific targets of the MAPK 




pathways, and how these differ between cell lines. Therefore, I developed a method to identify 
targets in a subset of tumors, and not only targets shared by all tumors.  
 
Figure IV-4 - Tippi – a method to identify context-specific transcriptional targets. 
A. Tippi – Target Identification using Pre- and Post-Inhibition data. Changes in expression following MEK 
inhibition are proportional to the pre-treatment expression levels. B. Four targets identified by Tippi, including 
the known target DUSP6. Each dot represents the expression level of a gene in one cell line, x-axis shows the 
pre-treatment levels, and y-axis is the fold change after MEK inhibition. Tippi identified 793 genes that exhibit 
such behavior (see figure IV-5). C. Tippi’s underlying model – I. mRNA expression level of target gene is 
similar in all tumors’ precursor cells. II. Oncogenic pathway is activated to different degree in different tumors, 
leading to different target gene expression levels. III. Pathway inhibition brings gene expression to its original 
pre-oncogenic level. Tippi uses the correlation between pre- and post- inhibition expression levels to identify 
downstream targets, and is independent of the extent of fold change and the number of cell lines in which the 
gene is under the control of MAPK.  
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Target	  Identification	  using	  Pre-­‐	  and	  Post-­‐Inhibition	  data	  
I developed a method – Tippi (Target Identification using Pre- and Post-Inhibition data) - to 
identify context-specific transcriptional targets. Tippi identifies targets with strong anti-correlation 
between their steady state expression and fold change levels across cell lines (Figure IV-4A). 
Several known downstream genes of MAPK, such as DUSP6 and IL10, exhibit such pattern 
(figure IV-4B). Overall, Tippi identifies 793 genes as MAPK targets using two independent 
biological replicates, of which only 5 were previously known.  
Tippi is not a threshold-based method. The approach is based on the assumption that the 
degree of MAPK pathway activation varies between cell lines, leading to different basal gene 
expression levels in different cell lines. However, after pathway inhibition, the expression of a 
given gene returns to its pre-activation level, and the extent of change is proportional to the 
degree of the activation (Figure IV-4C). Therefore, Tippi is independent of fold change thresholds 
and has no restriction on number of cell lines in which a gene’s expression is altered. 
Tippi’s advantages allow it to identify hundreds of context-specific targets of MAPK that are 
missed by threshold-based methods. For example, EGF, CTLA4 and PIK3CB, that were shown to 
play important roles in melanoma 218,219, have a relatively low expression change in a subset of 
cell lines. Hence, they are missed by typical threshold-based methods, but identified by Tippi 
(figure IV-5). Out of the 793 genes identified by Tippi, only 5 show large changes in their 
expression level across all 14 cell-lines and were therefore previously identified as MAPK target 
by threshold-based methods 130. The other 788 targets either change only in a subset of cell lines, 
or change to a lesser extent (full algorithmic details under computational methods).  
 
Figure IV-5 – Context-Specific targets 
CTLA4, EGF and PIK3C2B, among many other genes, are context-specific targets 
identified by Tippi. 
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Importantly, Tippi only identifies genes consistent with its assumptions – similar basal 
expression levels before oncogenic activation and short mRNA half-life of the target. Hence Tippi 
is not comprehensive; rather, it supplements other methods to detect transcriptional targets. 
 
Figure IV-6 - COSPER identifies COntext-SPEcific Regulation 
A. HEY1, a target identified by Tippi, exhibits a context-specific behavior - regulated by MAPK in only a 
subset of cell lines (blue dots). MEK inhibition doesn’t affect its expression in the other group of cells (red), 
and its basal expression is lower in these cell lines. B. A cartoon of context-specific regulation exhibited by 
HEY1. ERK up-regulates a set of targets in high-MITF cell lines only, while it has no effect in low-MITF lines 
(upper panel). Therefore, the genes are only affected by MEK inhibition of ERK in high-MITF lines (lower 
panel). C. COSPER identifies gene clusters with context-specific regulation. This cluster contains HEY1, 
and its genes are controlled by MAPK only in cell lines with MITF-M expression. Heat-map on the left shows 
expression levels before pathway inhibition, and heat-map on the right shows fold change after MEK 
inhibition. MITF expression, which is not part of this cluster, is in the top row. Part of the cluster is shown 
(full cluster in IV-8A). D. A second cluster identified by COSPER. Its genes are overexpressed in low-MITF 
cell lines, and are down-regulated only in these cells after MEK inhibition. MITF expression is in the top row. 
Part of the cluster is shown (full cluster in IV-8B). E. MITF protein levels in all 14 cell lines. A2058 (green 
rectangle) is the only low mRNA-MITF cell line that expresses the MITF-M isoform. 
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Tippi	  identifies	  prevalent	  context-­‐specific	  regulation	  of	  MAPK	  targets	  
Roughly half of the targets captured by Tippi are under the control of MAPK in only a subset of 
cell lines. For example, HEY1, a transcriptional repressor in the notch pathway (figure IV-6A), has 
high expression levels before inhibition in one group of cell lines, which decrease after inhibition. 
In the second group, the basal levels of HEY1 are lower and do not change after MEK inhibition.  
Therefore, HEY1 is under MAPK control in a subset of samples, i.e. its regulation is context-
specific.    
Further evaluation of HEY1’s regulation shows that it is under MAPK control only in cell lines 
with relatively high basal expression levels of MITF. MITF is a lineage-specific oncogenic 
transcription factor 12,103,220, and is regulated by MAPK, as its expression levels increase after 
MEK inhibition (figure IV-7A,B). Other genes, including a number of known MITF targets 193, also 
exhibit such behavior (figure IV-6B); they are highly expressed in MITF-high cell lines, and 
repressed in these lines after MEK inhibition (figure IV-6C).  
The patterns of regulation are not restricted to HEY1’s pattern, depicted in figure 3B. For 
example, another group of genes, some of which are known MITF targets 193, exhibit a different 
behavior - they are highly expressed in high MITF cell lines, but they are upregulated in these 
same cell lines after MEK inhibition (figure IV-7C). Among context-specific MAPK targets, both 
the context (grouping of the cell lines that are influenced by MAPK), as well as the pattern of this 
regulation varies. 
COSPER	  identifies	  a	  large	  number	  of	  MAPK	  targets	  in	  melanoma	  	  
I reasoned that context-specific targets provide increased resolution about the differences in 
MAPK pathway dependencies and interactions between cell lines. To identify these context-
specific targets, I developed a computational framework – COSPER (Context-SPEcific 
Regulation) – that detects clusters of genes that respond to MEK inhibition in similar, coordinated 
fashion, in subsets of samples.  In each cluster, the cell lines are divided into two groups, or 
contexts, and the genes behave differently in each context, both before and after pathway 
inhibition (figure IV-6B, full algorithmic details under experimental methods).  
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Overall, COSPER identified 70 context-specific clusters with 5 genes or more, and assigned 
1024 genes to clusters (genes are allowed to belong to more than one cluster), of which 244 
genes were also identified by Tippi. Notably, none of the clusters correlate with the oncogenic 
activation of MAPK (BRAF or NRAS), or with the cells’ PTEN status. Moreover, I also explicitly 
tested for genes correlated with these aberrations, but no genes were found to be significantly 
associated with these mutations (see computational methods). Instead, I believe that these 
clusters represent context-specific crosstalk and regulation involving additional pathways and 
processes.  
 
Different	  MITF	  isoforms	  give	  rise	  to	  distinct	  regulatory	  programs	  
Fifteen clusters discovered by COSPER, containing 401 genes in total, associate with MITF. 
The clusters either have a perfect correlation with MITF expression, such as the cluster in figure 
IV-6D (MITF-expression cluster), or have 1-2 cell lines “switch sides” - they behave similarly to 
cell lines with the opposite MITF status (figure IV-6C and IV-8A).  
 
Figure IV-7 – MITF is regulated by MAPK in a context-specific way 
A. MITF mRNA expression levels before (x-axis) and after (y-axis) MEK inhibition. Steady state and fold 
change levels are negatively correlated. B. Levels of MITF protein isoforms in 12 cell lines, before and 8 
hours after MEK inhibition. Each isoform is regulated to different degrees in the different cell lines. Strong 
(S) and Weak (W) film exposures are shown. C. Another pattern of context-specific regulation identified by 
COSPER (see figure IV-6C for comparison). The genes in this cluster show high basal expression in high 
MITF cell lines, and are up-regulated only in these cell lines after MEK inhibition. 
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Steady state expression levels alone are not sufficient for detection of context-specific targets. 
For example, 2244 genes are correlated with MITF before treatment, but only ~20% exhibit MITF-
dependent behavior following MEK inhibition. Only by combining both pre- and post-inhibition 
data, was I able to focus our search and identify context-specific targets of MAPK.  
I focused on two clusters identified by COSPER. We postulated that clusters with imperfect 
correlation to MITF levels represent different isoforms of MITF. One cluster is associated with 
MITF mRNA expression (figure IV-6D and IV-8B), while the other is associated with the 
abundance of the MITF-M protein isoform (figure IV-6C). A2058 is the only cell line with low 
mRNA expression that expresses the MITF-M isoform. In melanoma, MITF has at least 4 different 
protein isoforms 221, as shown by a Western blot (figure IV-6E).  
The different functional activities of the genes in the two clusters show that different MITF 
isoforms regulate different processes. The promoters for genes in the MITF-M cluster are highly 
enriched for the MITF binding site (CACATG) 119 (pvalue=10-3 compared with 0.7 for genes in 
MITF-expression, see computational methods). However, the MITF-expression cluster, but not 
the MITF-M cluster, is enriched for the GO annotation “melanocyte differentiation” (qvalue=10-4), 
suggesting that another isoform of MITF is responsible for cellular differentiation.  
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These clusters suggest that different combinations of MITF isoforms expressed in each tumor 
define various MITF states and distinct regulatory programs. Each of these isoforms presumably 
regulates a different set of genes and processes that are being influenced by MAPK to different 
degrees (figure IV-7B). These combinations and interactions create a vastly more complicated 
regulatory network than has been previously appreciated103, and still remains to be fully 
elucidated.  
Growth	  under	  MEK	  inhibition	  correlates	  with	  STAT3	  and	  non-­‐canonical	  NF-­‐kB	  
The phenotypic response to MEK inhibition varies significantly between cell lines. While MITF 
levels were previously found to correlate with response to MEK inhibition in melanoma 45, data 
show that, albeit correlated, not all six MITF-high cell lines are sensitive to inhibition. Specifically, 
only 3 out of 6 MITF-high cell lines show strong growth arrest and cytotoxic responses following 
treatment (figure IV-2A,B). I used COSPER to find pathways that can better predict response to 
MAPK inhibition.  
 
Figure IV-8 – MITF clusters 




COSPER identified one cluster that separates the 3 cell lines with the strongest growth 
inhibition from the other 11 cell lines (figure IV-9A and IV-10A). This cluster’s genes can be used 
to identify potential upstream pathways that control their expression. Gene set enrichment 
analysis associates the genes with cytokine-cytokine receptor pathway (qvalue<10-3), and with 
miR-19 and miR-17 (qvalue<10-3). Both gene sets are associated with STAT3 222,223. Additionally, 
the cluster also includes several genes associated with the NF-kB pathway (qvalue<10-3).  
These predictions 
were confirmed by 
measuring STAT3 and 
NF-κB activity in the cell 
lines. Levels of 
pSTAT3-Y705, an 
indicator for STAT3 
activity, and nuclear 
localization of two non-
canonical NF-κB 
proteins, RelB and p50, 
but not the canonical 
NF-κB proteins, match 
the cluster’s contexts 
(figure IV-9B-C, IV-
10B). Sensitive cell 
lines present low activity 
of both pathways. It has 
been previously 
reported that activation of p50 predicts worse clinical outcome 224. Taken together, it is possible 
that activation of these pathways gives cells partial protection from the cytotoxic and cytostatic 
effects of MEK inhibition, and targeting those pathways can be beneficial for patients.  
 
Figure IV-9 - STAT3 and non-canonical NF-κB basal activity levels predict 
growth phenotype 
A. COSPER cluster correlated with growth rate under MEK inhibition. Growth 
rate shown in the top row, yellow represents the ratio between the number of 
cells after 4 days of treatment with number of cells before treatment. 3 Cell lines 
(left), with low gene expression levels in cluster genes, are more sensitive to 
MEK inhibition. The cluster is enriched for STAT3- and NF-κB- related 
annotations. B. pSTAT3-Y705 levels are correlated with the cluster, as predicted 
by COSPER. The 3 highly sensitive cell lines (in red) have low pSTAT3. C. 
Sensitive cell lines (in red) have lower RelB and P50 activity, but not of other NF-
κB proteins (figure IV-10B). NF-κB activity was assessed by nuclear localization 
(right panels). D. STAT3 is directly regulated by MAPK. MEK inhibition 




Western blots confirmed COSPER’s prediction regarding network state and showed that NF-
κB and STAT3 are either on or off in different cell-lines. However, COSPER also predicts a direct 
interaction between MAPK and those pathways, as the post-inhibition expression data indicate 
that expression of NF-κB and STAT3 targets are altered following MEK inhibition. I therefore 
tested whether STAT3 and NF-κB themselves are also regulated by MAPK, and found that 
STAT3 activity, but not NF-κB 
activity, is regulated by MAPK, 
as pSTAT3 levels increase 
following MEK inhibition (figures 
IV-9D and IV-10C).  
Using the MITF and 
STAT3/NF-κB examples, I 
showed that COSPER infers 
both network state and 
interactions between pathways. 
However, when running 
COSPER on steady-state data 
alone, the resulting clusters are 
much larger, less specific, and 
therefore less informative than 
the clusters resulting from using 
both datasets (see 
computational methods). 
Therefore, post-inhibition mRNA 
expression data plays a critical 
role in identifying the state and 
interactions of the pathways, 
and how they are associated with phenotypic response. Although only 14 cell lines were used, 
 
Figure IV-10 - NF-kB regulation 
A. Full cluster shown in figure IV-9A. The cluster is enriched for STAT3 
and NF-kB targets, and displays several regulation patterns. B. 
Canonical NF-kB genes – NFkB and BCL3, are not correlated with 
growth phenotype (sensitive lines shown in red). C. MEK inhibition does 
not lead to an upregulation in P50 and RelB activity (nuclear 
localization) and expression levels. Increase in pSTAT3 levels shown 




COSPER was able to identify these two pathways and rule out associations, such as MITF levels, 
made using much larger control-only panels 45.  
Both	  low-­‐	  and	  high-­‐pSTAT1	  cell	  lines	  are	  resistant	  to	  interferon	  
After successfully using COSPER to identify the growth inhibition phenotype, I looked for 
additional clusters that might predict response to treatment. I identified a small cluster correlated 
with basal activity of the Type I interferon pathway. Since interferon (IFN) is one of the few 
approved drugs for metastatic melanoma, I decided to focus on this cluster.  
This cluster contains several known interferon stimulated genes, IRF7, IRF9, CCL5 and IFI44L 
(figure IV-11A), and splits the cell lines into two groups; the first contains 3 cell lines with an up-
regulation of interferon response genes, while cell lines in the second context express these 
genes at lower levels. Notably, the cell lines with up-regulation of the STAT1-interferon response 
genes are not the same 3 cell lines with low activity of STAT3 and NF-κB. Levels of pSTAT1-
Y701, an indicator of the interferon-STAT1 activity levels 225, confirmed that the high basal 
expression levels of the pathway targets correspond with high signaling activity of the pathway 
(figure IV-11B). 
High basal activity of the STAT1-interferon pathway has been previously shown to be 
necessary, but not sufficient, for IFNa/b-induced apoptosis 226. To test this claim, 3 low- and 3 
high-pSTAT1 cell lines were treated IFNβ and apoptosis levels were assessed by TUNEL. All 
low-pSTAT1 and 2 high-pSTAT1 cell lines were resistant to the cytotoxic effects of IFNb, and one 
high-pSTAT1 cell line was marginally sensitive (figure IV-11D). Both IFNα and IFNβ were tested, 
and as previously shown 227, IFNβ led to a greater apoptotic response than IFNα (figure IV-12A); 
thus, IFNβ was chosen for further analysis. My results confirmed the previous findings that 




MEK	  inhibition	  and	  IFNβ 	  treatment	  act	  synergistically	  to	  increase	  apoptosis	  
The expression data indicate that MEK inhibition leads to an up-regulation of the IFNα/β 
pathway. Analysis of protein levels by Western blot demonstrates an increase in pSTAT1 levels 
after MEK inhibition, confirming a crosstalk between MAPK and STAT1 (figure IV-11c). Because 
interferon activity was shown to be required for IFN-induced death, I hypothesized that IFN might 
synergize with MEK inhibition to increase apoptosis.  
First, the cytotoxic effect of MEK inhibition on both high- and low-pSTAT1 cell lines was 
assessed. I found that high-pSTAT1 cell lines are mostly resistant to inhibition of the pathway, 
 
Figure IV-11 - IFNβ  enhances cytotoxic response of MEK inhibition in low-pSTAT1 cell lines 
A. COSPER identified a cluster containing several known interferon targets marked in red. Three cell lines 
have high expression, and MEK inhibition upregulates the pathway in the other 11 cell lines. B. pSTAT1-
Y701, a marker for interferon-STAT1 pathway activity, is correlated with the gene expression and shows 
high basal activation level in the 3 high cell lines (blue). C. MEK inhibition leads to up-regulation of pSTAT1 
in all cell lines. D. High interferon pathway activity is necessary, but not sufficient, for IFN-induced death. 
Only one out of 3 high-pSTAT1 cell lines respond to IFNβ (red), using TUNEL staining as a marker for 
apoptosis 72 hours after IFNβ treatment. I used IFNβ, and not IFNα, due to its higher efficacy (see figure 
IV-12A). E. MEK inhibition induces death in low-pSTAT1 cell lines only (green). IFNβ and MEK inhibition in 
low pSTAT1 cell lines synergize to increase apoptosis levels (purple). High pSTAT1 cell lines show only 
mild response to the MEK inhibitor and its combination with IFBβ (right). IFNβ alone and untreated cells 
(red and blue respectively) have almost no cytotoxic response. 
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while low-pSTAT1 cells are sensitive (figure IV-11e). Notably, both groups contain NRAS and 
BRAF mutant cell lines, and cell lines with high and low MITF expression, although both MITF-low 
cell lines and NRAS mutant cell lines have been previously reported to be less sensitive to MAPK 
pathway inhibition 45,126. Moreover, the results also show that the cytotoxic response of MEK 
inhibition is independent of its cytostatic response. For example, SkMel133, one of the only cell 
lines that continue to grow rapidly under MEK inhibition (figure IV-12B), has relatively high 
apoptosis levels under MEK inhibition. 
I then examined the cytotoxic effect of the combination of MEK inhibition and IFNβ. While 
IFNβ as a single agent has no cytotoxic effect on low-pSTAT1 cell lines, it notably enhances the 
cytotoxic response of MEK inhibition, increasing TUNEL-positive cells by almost two-fold (figure 
IV-11E, IV-12B). While low-pSTAT1 cell lines show a 
strong sensitivity to the combination of MEK inhibition and 
IFNb treatment, high-pSTAT1 cell-lines have consistently 
low apoptosis levels (figure IV-11E). Moreover, these cell 
lines seem to be resistant to the cytotoxic effects of both 
MEK inhibition alone and the dual treatment.  
 
Figure IV-12 – Effects of IFN 
treatment 
A. Dose-dependent response to IFNα 
and β. The cytotoxicity of IFN was 
assessed in high pSTAT1 cell line, 48 
hours after treatment using SubG1 
percentage. IFNα has a weaker 
cytotoxic effect than IFNβ, and both 
show dose-dependent effects. 
1000Units/mL of IFNβ was used for all 
experiments in this manuscript. B. 
Growth curves of 2 low- (top) and 2 
high- (bottom) pSTAT1 cell lines with 
MEK inhibition, IFNβ or both.  
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Transcriptional	  response	  to	  IFN	  is	  similar	  in	  all	  cell	  lines	  
My data demonstrated that basal activation level of the 
interferon pathway predicts the cytotoxic response to MEK 
inhibition, and to its combination with IFNα/β. We 
hypothesized that differences in the response of the 
interferon pathway in high- and low-pSTAT1 cell lines to 
IFN contribute to this phenotype. I therefore characterized 
the signaling and transcriptional responses to IFNβ and 
MEK inhibition, aiming to identify the components that 
contribute to the lack of cytotoxic response in high-
pSTAT1 cell lines, and to the synergistic effect of IFNβ and 
MEK inhibition.  
Western blots show that activation of STAT1 by IFNβ is 
identical, in both timing and extent, when comparing a low-
pSTAT1 cell line to a high-pSTAT1 cell line (figure IV-14A). 
IFNβ treatment quickly elevates pSTAT1 levels in both cell 
lines. Additionally, both cell lines activate the interferon 
transcription program, as assessed by levels of Interferon 
Response Factor 1 (IRF1) 228. Moreover, inhibition of MEK 
does not alter the timing or extent of the IFNβ response 
(figure IV-14A).  
To search for more global regulatory differences in the interferon response, I measured gene 
expression levels 8 hours after treatment with PD325901, IFNβ or their combination in three low- 
and three high-pSTAT1 cell lines. All cell lines show a dramatic increase (up to 100 fold) in the 
expression of interferon targets following IFNβ treatment, confirming that the interferon response 
pathway is present and active in both contexts (figure IV-13A). Furthermore, no significant 
differences in the transcriptional response following IFNβ treatment between the low- and high-
 
Figure IV-13  - Transcriptional 
response to IFNβ  
22 genes with the highest fold change 
following IFNβ treatment. The 
transcriptional response is similar in all 
cell lines, both with low- and high- basal 
activation of the pathway. Notably, the 
fold change of several genes reaches 
100 fold, just 8 hours after treatment. 
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pSTAT1 cells become apparent after 8 hours of treatment. Additionally, MEK inhibition does not 
alter the IFNβ response, and does not synergize with interferon to induce transcription of any 
other genes (see materials and methods).  
 
These data indicate that the differences in the phenotypic response are not due to the basal 
activation level of the interferon pathway. The results show that the immediate transcriptional 
response to IFNβ is not different between high- and low- pSTAT1 cell lines, and therefore fails to 
explain the synergistic effect of MEK inhibition and IFNβ, and the lack of cytotoxic response in 
high pSTAT1 cell-lines.  
 
Figure IV-14 - Elucidating the synergistic response of IFNβ  and MEKi 
A. Response to IFNβ, as measured by pSTAT1 and IRF levels, are similar in both high- and low- pSTAT1 cell 
lines MEK inhibition doesn’t alter the response (for transcriptional response see figure IV-13). Notably, basal 
activity level of the pathway in high-pSTAT1 cell lines is much lower than the induction in pathway activity 
after IFNβ treatment. B. MEKi activates the intrinsic apoptotic pathway by cytochrome C release from the 
mitochondria, approx. 36 hours after treatment. IFNβ enhances the response in all cell lines, including the 
high-pSTAT1 resistant cell lines. C. Caspase 7 and 9, but not Caspase 3 (figure IV-15), are cleaved and 
activated following MEK inhibition in low pSTAT1 cell lines only. IFNβ enhances MEKi’s effect, but fails to 
activate the pathway by itself. Both caspases are not cleaved in high-pSTAT1 cell lines, explaining their 
resistance to treatment.  
	  
 121	  
High-­‐pSTAT1	  cell	  lines	  fail	  to	  activate	  the	  caspase	  pathway	  
As the transcriptional response to IFNβ fails to explain the differences in the cytotoxic 
response between low- and high-pSTAT1 cell lines, I characterized the apoptotic pathway 
directly.  
The intrinsic apoptotic pathway is initiated by the release of cytochrome C (CytoC) from the 
mitochondria, which together with Apaf-1, cleaves and activates initiator and executioner 
caspases 229. I found that inhibition of MEK is sufficient to induce release of CytoC in all cell lines. 
Furthermore, co-treatment with IFNβ synergizes with MEK inhibition and increases cytoplasmic 
CytoC levels (figure IV-14B). However, although MEK inhibition initiates the intrinsic pathway in 
high-pSTAT1 cell lines, and this response is enhanced by IFN, these cell lines fail to undergo 
apoptosis. 
CytoC release leads to apoptosis by activation of 
the caspase pathway. I found that caspase 9, an 
initiator caspase, and caspase 7, an executioner 
caspase, but not caspase 3, are cleaved following the 
release of CytoC by MEK inhibition (figure IV-14C and 
IV-15) in low-pSTAT1 cell lines only. Combinatorial 
treatment leads to a stronger and faster activation of 
these two caspases, but IFNβ treatment alone does not activate the caspase pathway (figure IV-
14C). Importantly, caspases 9 and 7 are not cleaved in high-pSTAT1 cell lines, although CytoC is 
released. This lack of activation explains their cytotoxic resistance to both MEK inhibition and its 
combination with IFN. 
 
Deletion	  of	  interferon	  locus	  correlates	  with	  cytotoxic	  response	  
I showed that basal activity of the interferon pathway predicts the cytotoxic response to MEK 
inhibition and its combination with IFNα/β. Therefore, I sought to identify genetic lesions that 
could be responsible for the differential basal activation of this pathway. 
 
Figure IV-15 – Caspase 3 
Caspase 3, an initiator, is not activated by 




Using The Cancer Genome Atlas (TCGA) melanoma dataset, I associated STAT1 pathway 
activity levels with genetic aberrations. To infer pathway activity, we used the genes in the STAT1 
cluster identified by COSPER, which reflect pSTAT1 levels, as demonstrated by Western blot 
(figure IV-11A,B). Those genes are also a highly correlated in the TCGA patient derived dataset 
(figure IV-16A), which allows me to infer pSTAT1 activity in the TCGA tumors. This extended 
patient-derived dataset enables a genome-wide search for loci whose copy number levels are 
associated with STAT1 activity (see materials and methods). 
The copy number aberration most associated with the STAT1 gene signature is a deletion of 
the interferon locus (qvalue=10-4), located in chromosome 9p22. The locus contains a cluster of 
26 interferon genes (figure IV-16B). Deletion of the locus corresponds to low basal activity of the 
interferon pathway. My cell line panel confirms this association - most cell lines with low pathway 
activity have 0 or 1 copies of the 9p22 locus, while all cell lines with high activity have 2 or 3 
copies (figure IV-16C, materials and methods).  
Interestingly, the interferon gene cluster on locus 9p22 is only 0.5Mbs downstream of p16 
(CDKN2A) (figure IV-16B), a known tumor suppressor gene deleted in roughly 60% of melanoma 
tumors 230. Deletion of both p16 and the interferon locus was previously reported 231, but as 
research focused on the role p16 in cancer, deletion of the interferon locus was viewed as a 
passenger mutation. However, copy number data show that both events are independent, and 
cell lines can lose both copies of p16 but retain both copies of interferon locus. Taken together, 
these results suggest that deletion of the interferon locus has important consequences on cellular 




High	  basal	  pSTAT1	  activity	  is	  caused	  by	  an	  autocrine	  loop	  
Copy number data show that cell lines with low basal activity of the interferon pathway have 
fewer copies, on average, of the interferon genes. IFNβ treatment elevates pSTAT1 levels and its 
downstream targets to similar levels in all cell lines. I therefore hypothesized that the basal 
activation of STAT1 and interferon pathway in cell lines and tumors might be due to expression of 
the genes in the interferon locus, which act in an autocrine loop to activate the pathway.  
Conditioned-media experiments confirm this hypothesis. In these experiments, conditioned 
media from a high-pathway-activity cell line activates the interferon pathway in low pathway-
activity cell line (figure IV-16D). These results demonstrate that cytokines in the media, 
presumably IFN, lead to the high basal interferon pathway activity in cell lines without a deletion 
of the interferon locus. Moreover, several interferon genes, including IFNb, which is located in the 
 
Figure IV-16 - Deletion of interferon locus and IFN expression levels explain the two interferon-
pathway states and predicts drug response 
A. The interferon gene cluster identified by COSPER is highly correlated in the TCGA melanoma expression 
data set. This allows me to infer pathway activity in the TCGA tumors and associate it with DNA aberrations. 
Genes above the yellow line were used for association with DNA copy number. B. The interferon locus 
contains 17 interferon genes, and is only 0.5Mb downstream of CDKN2A (p16), a known melanoma tumor 
suppressor. C. Interferon locus copy number is also correlated with pathway activity in our 14 cell line panel. 
p16 however, only 0.5Mb upstream, is not, suggesting that interferon deletion and p16 deletion are two 
independent events. SkMel200, a high-pSTAT1 cell line, was added for purposes of CNV analysis. D. 
Conditioned media experiment demonstrating that cytokines released to the media elevate pSTAT1 levels. 
Media taken from SkMel105, a high pSTAT1 cell line, quickly elevates pSTAT1 levels when applied to a low 
pSTAT1 cell line. Several IFN genes are upregulated in high-pSTAT1 cell lines (figure IV-14A). E. A cartoon 
depicting the two network states, before and after MEKi and IFN treatment. Inhibition of MEK leads to 
cytochrome C release in both cellular contexts, and IFN treatment enhances the response. However, caspase 
9 is cleaved and activated only in low pSTAT1 cell lines. 
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deleted locus, are correlated with pathway activity and overexpressed in high-pSTAT1 cell lines 
(figure IV-17). 
To summarize, my results show that cell lines with fewer copies of the interferon locus and 
without expression of the interferon genes 
are sensitive to the cytotoxic effects of MEK 
inhibition. Furthermore, IFNα/β enhances this 
cytotoxic response via an increase in CytoC 
release from the mitochondria. However, cell 
lines that retain both copies of the interferon 
locus and have high basal activity of the 
interferon pathway are resistant to MEK 
inhibition and its combination with IFNα/β. Although MEK inhibition initiates the apoptotic pathway 
in these cell lines, apoptosis is averted due to an impairment of the caspase activation 
mechanism. It is therefore possible that interferon pathway activity, interferon expression levels 
and/or interferon locus copy number can be used as a biomarker for treatment by MAPK pathway 
inhibition, and its combination with IFNα/β (figure IV-16E).  
  
 
Figure IV-17 – Expression of interferon genes 
IFN genes with a significant differential expression 
between low- and high- pSTAT1 cell lines. IFNA6, 
IFNA8 and IFNB1 are located in the interferon locus. 
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Materials	  and	  Methods	  
Cell	  Culture	  and	  drug	  treatment	  	  
Cell lines were obtained from N. Rosen (Memorial Sloan-Kettering Cancer Center), except for 
Colo829 and A2058 that were purchased from ATCC. All cell lines were maintained in RPMI 1640 
(Invitrogen 21870-092), supplemented with 2 mM glutamine, 50 units/mL penicillin, 50 units/mL 
streptomycin, and 10% FBS (Omega Scientific), and incubated at 37 °C in 5% CO2. 
Samples for protein and gene expression analysis were plated at 60-80% confluency and 
incubated for 20-24h. Then treated with PD0325901 (50nM), Interferon alpha (20000U/mL, R&D 
11100) or Interferon beta (1000U/mL, R&D 11415). Control samples were collected untreated at 
time of treatment.  
Protein	  levels	  
Samples for protein analysis were lysed using RIPA buffer. Protein concentration was 
assessed using BCA staining. Samples were then normalized to a fixed concentration and mixed 
with a 5x glycerol/SDS/DTT loading buffer. Lysates were run on gradient (4-12%) Bis-Tris gels.  
Cellular fractionation for nucleus isolation to assess NF-κB activity was performed using 
Subcellular Protein Fractionation Kit by Thermo-Fisher. 
Cytochrome	  C	  release	  
Protocol for Cytochrome C release is taken, as is, from Majewski et al 2004. It is brought here 
for convenience: 
Lysis buffer: 20 mM Hepes-KOH, [pH 7.5], 210 mM sucrose, and 70 mM mannitol; 1.5 mM 
MgCl2, 10 mM KCl2, protease inhibitor, and 1 mg digitonin/1mL lysis buffer. 
Cells are trypsinized, collected and spun down in 4C. They are then washed with PBS and 
spun down again. It is critical that cell pellets will be lysed immediately without freezing.  
Cells are gently suspended, without vortexing, in lysis buffer. Roughly double the cell pellet 
volume is used. They are incubated in 25C for 3-10min, depending all cell line. Spun down at 4C 
for 20 minutes at highest speed. Supernatant contains cytoplasmic fraction.  
Protein concentration was assessed using BCA.  
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Growth	  curves	  and	  Apoptosis	  levels	  
For growth curve measurement, 50K cells were plated in 6-well plates with 2mL of growth 
media. Cells were counted every 24h following treatment using a cell counter (Coulter Z1), in 
triplicates.  
Apoptosis was assessed by TUNEL staining. Cells were plated in 6-well plates at 200K 
cells/well. 24h after plating cells were treated with PD325901, and both floating and adherent 
cells were collected 72h after treatment. TUNEL was performed using Invitrogen BrdU TUNEL kit.  
Growth rate phenotype for the STAT3/NF-κB analysis was calculated by dividing number of 
cells after 4 days of treatment by the number in day 0.  
Gene	  expression	  and	  microarrays	  
Samples for microarrays were harvested 8h post treatment. RNA was extracted using a 
Qiagen RNeasy kit, and labeled using Agilent’s one-color labeling protocol. Labeled cRNA was 
hybridized to Agilent’s 8x60 human gene expression arrays. MEK inhibition and basal state 
expression levels were measured in biological duplicates. Data normalization is described in 
supplementary material. Genatomy was used for data visualization and enrichment analysis 158. 
I used Agilent’s 1M SurePrint CGH arrays to assess copy number. DNA was extracted using 
Qiagen’s DNeasy kit and labeled and hybridized according to Agilent’s protocol.  
All microarray data are available on GEO under accession number GSE51115. 
Microarray	  preprocessing	  
Agilent one-color human mRNA expression 8x60 arrays were used to assess expression 
levels. Biological duplicates of control and MEK inhibition (MEKi) samples were used (expect for 
Colo829 and SkMel28 that were added to the panel after the first batch). Samples for the IFNβ 
microarrays were collected 8h after treatment (with IFNβ, PD901 or both), and a single sample 
was used for each.  
Agilent’s software was used to assess raw signal intensity. Preprocessing of both the MEKi 
panel and the IFN experiment was similar. Each of the 3 batches were processed independently - 
MEKi panel 1, MEKi panel 2 and the IFN panel. 
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Preprocessing consists of 3 steps – probe filtering, data normalization and probe averaging.  
Probe	  filtering	  
Log2 values were used from this point on. Probes were filtered based on their values. Probes 
with low or high levels in more than 20% of samples were removed. This was done to remove 
noisy and saturated probes. The lower and upper thresholds were different in different batches, 
depending on labeling, hybridization and scan levels: 
 
Batch Lower threshold Upper threshold 
MEKi panel 1 6 16 
MEKi panel 2 7 18 
IFN panel 7 17.5 
 
Additionally, the Agilent probe flags were used to filter probes by a similar method: probes 
flagged in more than 20% of samples were removed. Flags that were used: will_above_bg, 
is_saturated, is_feat_non_uniform, is_feat_popn. 
A “rescue” step was used to return probes representing genes that no probe was left to 
represent them. Probes representing the same gene with a high correlation (Pearson >0.75) were 
rescued. Additionally, probes with high SD (>3) were also rescued. 
Data	  normalization	  
The 75th percentile of all samples was set to the average 75% by multiplying the values by a 
constant.  
Probes that measure the level of the same gene were averaged or filtered out.  
If the average Pearson correlation between all probes is > .75, probes are averaged. If it is 
lower, the probe with the lowest correlation is removed. Process repeats till probes are averaged 




Baseline expression levels are mean-normalized at the gene level. Fold change is calculated 
against the control (baseline expression) of the cell line. Data from the two MEKi panels are 
combined at this point by averaging the baseline expression and fold change data.  
 
TCGA	  data	  analysis	  
TCGA expression and CGH data were downloaded from the TCGA website. Genes for the 
STAT1 gene signature were a subset of COSPER’s STAT1 signature. All genes with a Pearson r2 
> 0.5 with at least 3 additional genes were included. Association with copy number was 
performed using Pearson correlation between the mean of the gene signature and copy number 
levels of each gene. Pearson’s pvalues were corrected by FDR 181.  
 
Comparison	  of	  BRAF	  and	  MEK	  inhibition	  -­‐	  PLX4720	  vs.	  PD901	  
I used PD901 to inhibit the MAPK pathway, and not the more clinically used PLX4032 BRAF-
V600E inhibitor to allow a direct comparison of BRAF and NRAS mutant cell lines. To ensure the 
short-term drug effects are similar, we compared the transcriptional response of MalMe3M, a 
BRAF-V600E cell line, following PD901 or PLX4032 treatment. I assessed expression fold 
change at 1 hour, 2, 4, and 8 hours following treatment using Illumina HumanHT-12 microarrays.  
Preprocessing	  
Illumina’s probe pvalues were used to filter out probes. Probes with p-value>0.05 in more than 
half of the samples were removed. Then microarrays were normalized according to their 75% 
percentile values. The 2 control array were averaged, and treated samples were compared to the 




MEKi and BRAFi are remarkably the same at all 
time points. Although some probes were noisy, 
resulting in minor difference between treatments, 
no gene had a difference greater than 0.5 fold (on 
a log2 scale) between treatments at all time points. 
Only 6 probes, out of 16000, had a difference of 
more than 1 fold at 8 hour time point (figure IV-18). 
None of them had such difference at 4 hours, 
suggesting that the difference arises from 
measurement noise.  
I conclude that there is no difference in the 
short-time transcriptional response between 
treatments in this cell lines. 
PD901	  and	  IFNβ	  microarray	  results	  
Data	  Preprocessing	  
Six cell lines were chosen for analysis. 3 are low-pSTAT1 – A375, SkMel133 and SkMel2, and 
3 high-pSTAT1 – SkMel105, SkMel39 and WM1361. They were treated with 50nM PD901, 
1000U/mL IFNβ or their combination. Samples were collected 8 hours after treatment, control 
samples were collected at 0h. RNA extraction, labeling and hybridization were conducted as 
described under methods. Agilent human 8x60 gene expression arrays were used.  
Raw data normalization and filtering were conducted as described above, with a low threshold 
of 7, and an upper threshold of 17.5.  
 
Figure IV-18 – Comparison of MEKi and 
BRAFi 
Comparison of MEK and BRAF inhibitors in a 
BRAF-V600E cell line shows an almost identical 
transcriptional response. Scatter plot shows fold 
change of all genes with a MEK inhibitor (x-axis) 
compared with a BRAF inhibitor (y-axis). Almost 
all genes fall directly on the diagonal. 
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IFN	  response	  in	  high-­‐	  vs.	  low-­‐	  pSTAT1	  cell	  lines	  
The IFN response includes dozens of genes with a dramatic induction in gene expression, of 
up to 500 fold, in all 6 cell lines (figure IV-13).  
There is, however, a difference in the extent of 
change in high- vs. low- pSTAT1 cell lines, that can 
be attributed to the different basal expression level 
of those genes. The maximum level of expression 
seems to be similar in all cell lines, but high 
pSTAT1 cell lines have a higher basal activity and 
therefore the fold change is lower.  
In order to compare the activation of the 
pathway between the two cell line groups, it is 
better to use the final expression level, i.e. the 
basal expression+fold change. However, such 
comparison reveals the expression of no genes is 
statistically significant different between high- and 
low-pSTAT1 cell lines (using t-test and FDR 
correction).  
I therefore determine that there is no difference 
in the response to IFNβ between high- and low-
pSTAT1 cell lines.  
Combinatorial	  treatment	  and	  synergy	  
To test whether the MEK inhibition and IFNβ synergize at the level of gene expression, I 
compared the fold change of the dual treatment with that of MEKi+IFNβ as single agents. Over 
all, those responses are very similar (figure IV-19). 
If no synergy exists, the values of Both-(MEKi+IFNβ) should be close to 0. Only one gene 
significantly deviates from 0 in all 6 cell lines. The gene is CCL4, and it is induced both by MEKi 
and IFNβ treatment as single agents, but a combinatorial treatment isn’t additive. 
 
Figure IV-19 – Transcriptional response isn’t 
synergistic  
Lack of synergistic and additive effects of MEK 
inhibition and IFNβ. Scatter plots show the fold 
change of all genes with a combination of MEK 
inhibition and IFN (x-axis) and the sum of fold 
changes with each treatment alone. Significant 
deviations from the diagonal represent 
synergism between drugs. Only one gene, 




I couldn’t identify any other genes that show a synergetic response in all 6 cell lines, or 
separately in low- or high-pSTAT1 lines (we defined synergy is the equation above >1 or <-1). 
Perturbation	  data	  allows	  better	  cluster	  identification	  
Combining pre- and post-inhibition data facilitates the identification of context-specific 
regulation and differential activation of pathways, while pre-inhibition data alone fall short due to 
lower specificity and much higher rate of false positive.  
For example, when running the first step of COSPER on pre-inhibition data alone, the STAT3-
NFkB cluster contains 766 genes, compared with 28 genes when using both datasets. While the 
smaller cluster is enriched for STAT3- and KFkB- related terms, the larger pre-inhibition-data 
cluster is enriched for general terms such as “extracellular region” and “plasma membrane”.  
The combination of pre- and post-inhibition data, therefore, provides specificity and limits the 







Tippi	  –	  Target	  Identification	  using	  Pre-­‐	  and	  Post-­‐Inhibition	  data	  
Tippi identifies target genes of a pathway (in this case MAPK) using gene expression data of 
pre- and post- perturbed cells. Most target identification methods are based on the fold change of 
a gene post-inhibition of the pathway, and require a gene to have a significant change in X or 
more samples. However, Tippi’s definition for a target is a gene with a negative correlation 
between the expression changes following a perturbation (i.e. pathway inhibition) and base line 
expression levels (steady state, pre-perturbation). 
Tippi scores genes using Pearson correlation and then uses permutation testing to assess the 
significance. Tippi uses the permutation p-value to construct the final target list.  To compute 
Pearson correlation, I use steady state levels correlated against the fold change of the gene 
across all cell lines. However, such score is prone to spurious associations due to outliers. To 
overcome this problem, I take a leave-one-out approach. In the leave-one-one process, I remove 
one sample at a time and calculate the Pearson r-value for a gene. The leave-one-out score, or 
the Tippi score, is the maximum r-value of the process.  
To assess the significance of the leave-one-out score and further filter false-positives, I use 
permutations. Samples are permuted in one of the datasets (steady state or fold change), and 
calculate the leave-one-out score. The process is repeated 1000 times, and the gene’s p-value is 
the number of permutations with a leave-one-out score better (lower) than the original (un-
permutated) score.  
I repeated the process for the two biological replicates independently. One datasets contains 
all 14 cell lines, and the other includes 12 of those (SkMel28 and Colo829 are not included). The 
final list includes all genes with a p-value<0.05 in both datasets. 1985 genes pass this threshold 
in the first batch, and 2012 pass it in the second batch. With an overlap of 793 genes 




COSPER	  -­‐	  Context-­‐Specific	  Regulation	  
COSPER – COntext  SPEcific Regulation – is designed to identify genes that are directly 
regulated by the MAPK pathway (or any other perturbed pathway) in only a subset of cell lines. It 
is based on the assumption that genes under the direct control of a pathway are correlated before 
pathway inhibition and show a correlated expression change after pathway inhibition. Since we 
are looking for genes under the control of the pathway in only a subset of cell lines, we expect 
expression changes in only these cell lines.  
COSPER uses pre-perturbation data to limit the search for genes under direct regulation of 
the perturbed pathway. After inhibition of a key signaling pathway such as MAPK, cellular events, 
such as metabolism, cell cycle and apoptosis, lead to expression changes of thousands of genes. 
Although the expression of those genes changes after MAPK inhibition, they are not directly 
regulated by MAPK. However, genes under the direct control of MAPK pathway depend on its 
activation levels both before and after inhibition of the pathway. For example, HEY1 (figure IV-6A) 
is under the control of MAPK in only a subset of cell lines. In HEY1 case, it is overexpressed by 
MAPK in cell lines with high MITF levels. Therefore, only in MITF-high cell lines, HEY1 
expression levels decrease after MEK inhibition. Both pre- and post-inhibition expression levels 
are needed in order to determine this relationship.  
COSPER is therefore designed to find genes with context-specific regulation patterns (figure 
IV-6B). It is consists of 3 major steps: 
1. Gene level – identify binary splits with high scores for both baseline expression and 
fold change and construct clusters. 
2. Merge related clusters – allows removal of spurious correlations and averaging the 
noise caused due to the small sample size.  
3. Add high scoring genes to the remaining clusters  
 






The algorithm is based on the NormalGamma score 169,232. The NormalGamma is a Bayesian 
score that takes variance, mean and number of data points into account. It gives a higher score to 
a data matrix with low variance.  
I use this score since we are looking to reduce the variance of the samples. COSPER 
searches for genes that behave similarly in a subset of samples. For example, I look for a subset 
of samples where a predefined set of genes is up-regulated, compared with the rest of the 
samples where the genes are not under pathway control. Mathematically, this problem can be 
viewed as a subset of samples where the data have a lower variance compared with the variance 
of all samples combined. The NormalGamma score is driven mainly by data variance and is thus 
suitable for our needs.  
 
The score: 
𝑁 = 𝑠𝑖𝑧𝑒 𝑑𝑎𝑡𝑎   
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The score used to assess the quality of the split is: 
NormalGamma (right samples)+ NormalGamma (left samples)- NormalGamma(all samples) 
Step	  1:	  Creating	  clusters	  
First, gene expression is normalized. Basal expression levels of each gene are set to have 
µ=0 and σ2=1. Fold change for each gene is standardized only (σ2=1). 
Next, clusters are built bottom-up – genes are assigned to “splits”, and a split with more than 
one gene assigned to it is considered a cluster. However, in order to filter out spurious 
associations I only consider clusters with 5 or more genes. All genes are tested across all valid 
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binary splits. A valid split assigns at least 2 samples to each sample group. The test is based on 
permutations and the NormalGamma score.  
A gene is assigned to a split if its NormalGamma scores (as defined in the previous section) in 
both the baseline expression and fold change are better than 99% of the split permutations 
(pvalue<0.01).Additionally, in order to keep the best split-gene pairs only, an additional threshold 
is used: 
NormalGamma (right)+ NormalGamma (left)- NormalGamma(all samples)>0 
To determine whether clusters with more than 5 genes can be constructed by chance, I 
permuted the samples in the fold change expression data and performed this step on the 
permutated data. No clusters with 5 or more genes were constructed.  Hence, the resulting 
clusters represent biological phenomenon.  
Step	  2:	  Merging	  clusters	  
A gene assigned to a split is very likely to be assigned to similar splits. A similar split might 
have one or more samples switching “sides” (figure IV-6C,D). Each split has 13 similar splits with 
a distance=1, where one sample has switched sides, and 91 splits with distance=2.  
The NormalGamma score is not strong enough to discriminate between the “true” split and 
neighboring splits, since the distribution of scores is very tight. However, I can assume that a 
gene is more likely to be assigned to the real biological split, and less likely to be associated with 
a split with a distance>0 from the real split. We also work under the assumption that a true 
biological “context” is likely to influence many genes, and therefore larger clusters are more 
biologically relevant.  
I use these two assumptions in order to identify the real gene-split associations and remove 
irrelevant clusters.  
The cluster merging algorithm is a iterative process. Each cycle identifies the largest cluster, 
its genes are removed from all its neighboring clusters, and the process iterates till no more 





The steps are: 
1. Each cluster is scored based on its overlap with its neighbors: 
𝑆𝑐𝑜𝑟𝑒 𝑐𝑙𝑢𝑠𝑡𝑒𝑟! = #(𝐺𝑒𝑛𝑒𝑠!"#$%&!! ∩ 𝐺𝑒𝑛𝑒𝑠!!"#$%!!)
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 we used d=2. 
2. We then choose the largest cluster, and remove its genes from all clusters with a 
distance<=d.  
To save computing time, only clusters that enter the algorithm with 5 or more genes are 
allowed to be selected.  
Step	  3:	  Adding	  genes	  to	  remaining	  clusters	  
In the last step, after filtering most clusters out, I allow genes from neighboring clusters to be 
added back to clusters. We found this step to be necessary due to the small sample size, the 
overall small distance between clusters, the relatively high noise of gene expression data, and the 
inability of the NormalGamma score to discriminate between similar splits.  
Genes belonging to clusters in a distance<=d of a specific cluster, and with a pvalue<0.01 are 
added to this cluster.  
 
MITF	  binding	  site	  analysis	  
To assess frequency of MITF binding site in gene promoters we used the motif CACATG, 
known to be a target sequence of MITF. Gene promoters were defined as 5000bp upstream of 
their transcription start site, or up to the closest upstream gene, whichever is shorter. For each 
gene, number of binding motif in its promoter sequence was noted.  
To assess the significance of number of motif occurrences, we used the binomial distribution. 
For each one of the two clusters, MITF-M and MITF-expression, we counted total number of motif 
occurrences in all the cluster genes. For simplicity, the expected probability of the motif to 
randomly appear in a DNA sequence is 2*1/46 (6 is the length of the motif, and 2 represent the 
two strands).  
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The pvalue of X occurrences is the probability of randomly observing X or more occurrences 
in a random sequence, or 1-BINOMIAL_CDF(X, N, p), where N is total sequence length and p is 
2/46.  
For MITF-M cluster, the total promoter sequence is 120735bp, with 83 motif occurrences (59 
expected). For MITF-expression cluster, the total promoter sequence is 183399bp, with 86 







Contemporary cancer drug development focuses on targeting recurring oncogenic events, 
such as gene amplification and overexpression (HER2) or activation (BRAF). This approach is 
based on the principle of oncogene addiction. However, the underlying assumption is that both 
the network structure and the downstream targets of the oncogenes are the same in all tumors. 
Taken further, drug combinations are also currently suggested based on the principle of similar 
network structure and pathway dependencies in tumors harboring a specific oncogenic mutation.  
However, my analysis of downstream targets of MAPK in MAPK-activated melanomas reveals 
tremendous differences in underlying network structure between tumors. Although I analyzed the 
transcriptional output of MEK inhibition only in melanoma cell lines with MAPK activating 
mutations (BRAF or NRAS), each cell line had a unique transcriptional signature. Moreover, a 
vast majority of downstream targets of the MAPK pathway are context-specific – under the control 
of the pathway in a subset of cell lines. I showed that these differences could predict the 
phenotypic heterogeneity observed in vitro. 
To detect context-specific targets using pre- and post-inhibition expression data, I developed 
and employed two algorithms, Tippi and COSPER. With Tippi I showed that the expression 
changes of hundreds of downstream genes following pathway inhibition are proportional to the 
expression levels at steady state. I then used COSPER’s clusters to identify the pathways that 
control the expression of the context-specific targets. For example, STAT3 and NF-kB were 
shown to have two activation states that influence MAPK targets. Moreover, I found that the 
activation states of these pathways are correlated with the growth rate under MEK inhibition. 
Tippi’s and COSPER’s results emphasize the importance of post-perturbation data. Even with 
a small sample size of only 14 cell lines, pre- and post- perturbation expression data empowers 
the discovery of dependencies and interactions between pathways. Larger datasets of pre- and 
post-inhibition expression data can help identify additional context-specific interactions, which are 
masked by the substantial influence of MITF status on gene expression in melanoma. Moreover, 
interactions between pathways can inform me about possible interactions between drugs. 
COSPER’s output provided me insights on a possible interaction between MEK inhibition and IFN 
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treatment, two approved treatments for melanoma. The experimental validation uncovered two 
key findings: first, IFNα/β enhances the cytotoxic response of MEK inhibition; second, cell lines 
with high basal activity of the interferon pathway exhibit much lower cytotoxicity under MEK 
inhibition. I was also able to identify that a deletion of the interferon locus is correlated with the 
basal activity level of the interferon pathway. However, my results indicate that the basal activity 
level is not the mechanism for the sensitivity and resistance to IFNα/β and MEK inhibition. 
Instead, I found that an impairment of the caspase activation mechanism leads to the cytotoxic 
resistance.  
I also demonstrated that MEK inhibition leads to, and IFNβ increases, the release of CytoC 
from the mitochondria in all cell lines, regardless of their interferon-pathway basal activity level. 
Following CytoC release, caspases 9 and 7 are activated only in cell lines with low interferon 
pathway activity. Cell lines with high basal pathway activity, however, do not cleave and activate 
caspase 9 following MEK inhibition, and apoptosis is averted. 
Interferon pathway activity was previously linked to drug response. Weichselbaum et al. 113 
have shown that breast tumors with high basal activity of the pathway are more resistant to 
chemotherapy and radiation. TCGA data show that a lower basal activity of the interferon 
pathway in breast cancer is associated with a deletion of IRF1, Interferon Response Factor 1, a 
necessary protein for interferon-induced death233.  Taken together, we postulate that constitutive 
exposure to IFN is adverse to cancer cells, and they overcome it by either deactivation of the 
interferon pathway, or by an impairment of the apoptotic pathway.  
My findings on IFNα/β and MEK inhibition could have important clinical implications. First, both 
IFNα/β and MEK/BRAF inhibition are approved treatments in melanoma, and a combination 
might be beneficial to patients. Moreover, this combination might specifically benefit NRAS 
melanoma patients, who are treated with low doses of the more toxic MEK inhibitors, compared 
with the BRAF-mutant specific drugs used in BRAF-patients. Second, the impairment in the 
caspase pathway might be clinically important in melanoma and other cancer types. Finally, it is 
possible that interferon pathway activity and/or the interferon locus can be used as a biomarker in 
cancer treatment.  
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The current paradigm in MAPK pathway inhibition aims at a complete blocking of pro-survival 
signaling. Suggested combinatorial treatments include combination of MAPK pathway inhibitors 
(such as RAF and MEK inhibitors 234), or combinations that prevent the feedback activation of 
RTKs 234. However, examination of the pathway interactions and analysis of transcriptional 
response following MEK inhibition identified a drug combination that takes a different approach. 
Instead of exerting all effort on shutting down MAPK signaling, I found that IFNβ, which works via 
a different signaling pathway, enhances the cytotoxicity of MEK inhibition. I believe that a 
COSPER-like analysis of pre- and post-perturbation data could reveal additional combinations of 
drugs that synergistically work on different pathways in other cancer types.  
To summarize, my work demonstrates that tumor networks are more complex and varied than 
previously appreciated, even within a subtype of cancer that shares key oncogenic mutations. 
Although only MAPK-activated melanoma cell lines were examined, these were found to be 
heterogeneous and immensely varied. Moreover, while all BRAF-mutant tumors are grouped 
together and treated similarly in the clinic, the targets and pathways regulated by BRAF in 
different cell lines are vastly different.  
The full scale of these differences is only revealed when examining a perturbed network, 
which highlights the importance of post-inhibition data, compared with steady-state data only. I 
believe that my research has only scratched the surface, and future studies with larger cohort 
size should be conducted, as my data demonstrate the value of system-wide perturbation 






Computational biology addresses a broad spectrum of questions and tasks, each of which 
uses different types of data, has different assumptions on the underlying model, and aims to 
answer different questions using different computational models.  
My work has touched several different tasks. I analyzed both yeast and cancer data using 
various data derived from various technologies – from high throughput genomic data, through 
growth curves and ELISA, to Westerns and qPCR. I addressed research problems and 
developed computational methods for association studies, driver identification and the underlying 
molecular mechanisms of resistance to drugs. My work spans various biological and 
computational fields, but I find that regardless of the organism I worked on and the biological 
problem I addressed, my research was guided by similar concepts.  
All my computational models account for context-specificity of the biological system. The 
computational methods were simple and had few assumptions about the underlying biology. And 
although I used high throughput and complex datasets, I attempted to investigate well-defined 
biological phenomena. The reasons I adhered to these guidelines are described in this 
discussion. 
Defining	  a	  phenotype	  
Addressing well-defined biological phenomena should be at the foundation of every research 
project, including computational modeling. In many cases, especially in the field of systems 
biology, a computational method is designed to identify features (genomic, genetic, etc.) that 
predict or explain a phenotype. A pivotal decision in project design is therefore the definition of 
the phenotype itself. Since many computational methods use a predictive model that assumes 
that one mechanism underlies the phenotype in all individuals, a good choice of phenotype would 
be one that is likely to be a result of one underlying mechanism.  
The project modeling the phenotypic heterogeneity of MAPK inhibition in melanoma 
exemplifies the importance of selecting an appropriate phenotype. There are several ways to 
assess the outcome of a treatment in an in vitro setting. The most popular phenotypes, including 
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IC50 and growth curves, are based on number of cells, i.e. the quantitative phenotype is based 
on the number of cells following a treatment compared to the number of cells before or with no 
treatment46. However, cell number following treatment is determined by several distinct cellular 
processes, including cell cycle and death. Each of these processes is likely to be controlled by a 
different underlying mechanism, or pathway. Computational methods designed to identifying one 
underlying mechanism for phenotypes that are a result of several underlying mechanisms, such 
as cell-number based phenotypes, are unlikely to find the true underlying mechanisms. 
In the case of drug sensitivity, especially in cases with small sample size, a better approach 
would be to model the various effects of the drug independently of others, e.g. cytotoxic, 
cytostatic, senescence. In my study I found that different cell lines respond in very different ways 
to MAPK inhibition. While some cell lines undergo apoptosis while continuing to proliferate, others 
fully arrest, but don’t die. Therefore, studies aimed to identify the mechanism for one such 
phenotype are more likely to succeed. It is of course possible that certain phenotypes, such as 
apoptosis, are a result of different molecular mechanisms in different individuals, and a good 
computational method should account for such heterogeneity.  
One	  phenotype	  –	  One	  mechanism?	  
Choosing an appropriate phenotype is only the first step in the design of a computational 
biology project. The selection of a mathematical method that best models the expected 
underlying mechanism is also crucial for the success of the project.  
In computational biology, the feature space (e.g. genes) is typically much larger than the 
sample space (e.g. cell lines), especially in genomics based studies. Therefore, the statistical 
burden of feature selection (e.g. identifying the features that best predict the phenotype) is very 
challenging. Under these conditions, the mathematical method has many possible solutions, and 
in order to create a robust method in conditions of vast uncertainty, the methods have to choose 
models that significantly simplify the problem. One of the most common techniques used to 
simplify the models is a linearity assumption, which predetermines the relationship between the 
features and the outcome, forcing it to be linear in nature45,46. The linearity assumption greatly 
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shrinks the solution space, allowing the method to be robust and consistent. However, if the true 
relationship is far from linear, the method can identify the wrong features.  
On top of the linearity itself, linear models also impose an extremely strong assumption on the 
feature’s influence on the phenotype – persistence. Simply put, persistence means that the same 
genomic feature exerts influence all individuals/cases. In such models, the phenotype is the 
combined result of all features in all individuals, even in cases in which a feature exerts no 
influence on the phenotype. Due to the small sample size typically used in these studies, 
persistence-based approaches are unlikely to identify the correct features, simply because the 
model’s assumptions are wrong. Although one mechanism can regulate a phenotype in all 
individuals, my research in several biological systems shows that this is the exception rather than 
the rule.  
To avoid making the linearity and persistence assumptions in the MAPK project, I decided to 
forgo predictive models altogether and instead model molecular interactions between the targeted 
pathway (MAPK) and other pathways. I hypothesized that by identifying pathways and processes 
that are under the control of MAPK, I will be able to learn about the molecular events that lead to 
the cytotoxic, cytostatic and other possible responses following MAPK inhibition. As the method is 
not aimed at predicting a phenotype, it doesn’t assume that one molecular mechanism underlies 
a phenotype in all cell lines, and allows for the discovery of context-specific mechanisms.  
Implications	  of	  Context-­‐Specificity	  and	  Heterogeneity	  
Context-specific models, in which a genomic or a genetic feature exerts influence on the 
phenotype only in the context of another feature, were a crucial part in my work. Unlike persistent 
models, context-specific models take heterogeneity of the underlying mechanism into account. 
This allows subsets of cases to be modeled independently of the others, which proved to be 
invaluable and necessary in the biological systems and questions I investigated.  
Both in drug screens and GWAS, in cancer and yeast, context-specific models were at the 
core of my methods. In GOLPH, context-specific interactions were 4 times more prevalent than 
linear interactions. In CONEXIC we showed that by accounting for context-specificity our model 
was able to identify drivers that were missed by other models. COSPER explicitly searches for 
	  
 144	  
context-specific interactions, and identified interactions that underlie resistance to treatment in 
melanoma. The context-specificity of the MAPK targets in melanoma also exemplified another 
key phenomenon – the heterogeneity of network structure.  
The predominance of network heterogeneity affects a broad range of tasks and tools in 
computation biology, from the design and application of computational methods, to the post-
analysis and interpretation of the results. In most of these tasks, researchers tend to ignore 
heterogeneity and draw broad and general conclusions based on private cases. For example, 
many in the field of systems biology, including myself, are inferring “the network” under a 
transcription factor or a signaling pathway using post-perturbation data. However, a quick 
literature review shows that in many cases, only one or two models/cell-lines are used235,236. In 
such cases, while the inferred network might be correct, it only reflects a network state in one cell 
line, under one experimental condition. As my MEK inhibition results have demonstrated, network 
downstream of MAPK is vastly different in different cell lines. Therefore, these results can’t be 
generalized to be the “global network” in all cell types or all living organisms. These misleading 
conclusions later hinder the analysis and interpretation of other computational results, by 
providing wrong lists of “targets” or “gene-sets” that are used for enrichment analysis of clustering 
results.   
In summary, biological systems present vast heterogeneity. The high variability between 
individuals, or contexts, requires careful design of the computational method, and even more so 
in the proper use of data from other systems and contexts to interpret the method’s results.  
The	  premise	  of	  computational	  biology	  
Biological systems are of vast complexity. High throughput technologies and statistical 
methods provide important tools in the analysis and understanding of these systems. However, 
because of the high complexity of the investigated systems, one has to practice extreme caution 
when interpreting results of computational models. 
Many of the questions addressed using computational methods in the field of systems biology 
are too complex, currently unsolvable and should not be naively approached with such tools. 
Theoretical research, of course, is necessary for the evolution of the field. For practical tasks, 
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however, computational methods must be carefully framed and applied only in situations where 
the mathematical models match the underlying biological mechanisms, and the data used are 
appropriate for the questions asked.  
Even after choosing appropriate questions, models and data, systems biology tools produce 
many false-positive results. Therefore, the outcome should not be used as the “true underlying 
biology”, but rather as hypothesis generation to direct and focus future research. For example, 
CONEXIC aimed at identifying CNV-driven oncogenes by using only CNV and expression data. 
By ignoring other critical factors such as mutations and epigenetic state, CONEXIC can’t explain 
all the variance in the data. However, the method fits all available data into a very limited 
conceptual model, inadvertently producing many false-positive predictions. In our research, we 
used CONEXIC’s output to identify two previously unknown drivers, RAB27A and TBC1D16. Our 
success in identifying those drivers by no means suggests that all other predictions made by 
CONEXIC are true. We merely used a computational method as a tool to guide and direct our 
research, and only after a careful examination of the results we were able to select those drivers.  
One might refer to this practice as “cherry-picking” - carefully selecting one true result to claim 
that the rest of output is also true. However, such claims should not, and were not, made. 
CONEXIC and other computational tools are of great value and strength, but they are not 
designed to find the entire underlying network. Computational modeling is a tool, not the goal. Its 
goal is to help researchers direct their efforts towards the more probable answer.  
 
To conclude, while computational tools are powerful and important in biology research, they 
should be carefully designed and applied, and their results should be interpreted in the scope in 





In this dissertation I presented 3 very different studies. Each of these studies examines new 
computational and conceptual approaches to answer burning biological questions. My work by no 
means provides a solution to any of these problems. If anything, it provides a glimpse into the 
landscape of the underlying biology, and explores the possible computational tools that can be 
used to model this landscape.  
 
GOLPH examined the landscape of genetic interactions in yeast and showed that a large 
percentage of expression variance can be explained with context-specific interactions. In 
collaboration with Kreimer and Pe’er20, I later expanded GOLPH to mammalian data. However, 
even with GOLPH’s context-specific interactions, most of the gene expression and phenotypic 
variance can’t be explained using genetic features alone. Future work will have to explore how 
additional features, such as epigenetic features, environmental cues and expression patterns, 
can be modeled and used in eQTL studies, and how each of these features influences and 
interacts with other features.   
 
CONEXIC was the first computational model to incorporate DNA features (copy number 
aberrations) with expression profiles to identify driver genes. CONEXIC, however, is the just the 
beginning and much more work has to be done in order to effectively identify drivers. The true 
underlying biology is far more complex, and other genetic aberrations contribute to tumorigenesis. 
Models that do not incorporate these features are unlikely to find all driver genes, and very likely 
to report many false-positives. Moreover, expression patterns alone, as demonstrated by 
COSPER, do not represent all the phenotypes regulated by driver genes. Functional assays, 
such as siRNA and drug screens, can supplement genomic data and support driver identification.  
 
Explaining the heterogeneous responses to drug treatments is probably the most critical and 
burning question in the cancer field. My research has just touched the field of drug sensitivity, and 
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used a very small dataset to do so. Larger datasets with additional data types can greatly 
enhance our ability to investigate the phenotypic heterogeneity.  
One of the greatest challenges I faced while analyzing the gene expression data was the lack 
of knowledge regarding targets of pathways and transcription factors (TFs). Although a target list 
for almost every TF is available in at least one study, my data show that targets are context-
specific, and genes are regulated by different transcription factors in different cell lines and cell 
types. A thoroughly collected database aimed at identifying TF targets in different contexts is, in 
my view, the single most important data that should be collected. Such database will transform 
the way expression data is analyzed, and will finally allow us to exploit the information hidden in 
large expression data cohorts.  
Conclusions	  
High throughput data are of great importance to biology research. Sequencing, gene 
expression, ChIP-seq and similar data types have transformed the way research is performed 
and significantly enhanced our abilities and knowledge. Statistics and computational modeling 
provide strong and necessary capabilities to analyze such enormous data sets.  
My results in three different projects provide a glimpse into the vast power of computational 
tools. With GOLPH I showed that non-linear interactions of genetic loci can explain part of the 
“missing heritability” of GWAS. In CONEXIC we demonstrated that combining data of different 
types greatly enhances the amount of information one can extract from high-throughput data. 
With COSPER I showed that a careful examination of transcriptional targets of an oncogenic 
pathway can help with the identification of resistance mechanisms in cancer.   
However, with computational biology, as with any other tool used by biologists, one has to 
properly select the tool to use, carefully design and collect its input and cautiously interpret its 
results. However, due to the complexity of computational methods, it is easy to improperly apply 
them and interpret their results, hindering their great strength and damaging their reputation.  
Only by combining knowledge and insights from both computational and experimental 
biologists we will be able to fully harness the strengths of high-throughput technologies and 
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